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Abstract  
 
Neurite size and morphology are key determinants of the functional 
properties of neurons. In this thesis, it is described for the first time the 
expression of APRIL (A Proliferation-Inducing Ligand, TNFSF13) in the nervous 
system. APRIL is a member of the tumour necrosis factor superfamily and one 
of its receptors BCMA (B-Cell Maturation Antigen, TNFRSF17) are co-
expressed in pyramidal neurons throughout the fetal and postnatal mouse 
hippocampus. The effect of APRIL on axon elongation is inhibited by the 
expression of a truncated BCMA receptor in the neurons, suggesting that 
BCMA mediates this effect. APRIL promotes rapid phosphorylation of ERK1/2, 
Akt and GSK-3β in cultured pyramidal neurons, and pharmacological inhibition 
of either MEK1/2 or PI3K, upstream activators of ERK1/2 and Akt/GSK-3β 
signalling, respectively, completely inhibits the axon growth-promoting action of 
APRIL. These findings reveal that APRIL selectively enhances axon growth 
from developing hippocampal pyramidal neurons by a mechanism that depends 
on BCMA and activation of ERK1/2 and Akt/GSK-3β signalling. 
 
In this thesis, it is also shown that GDF-5 (growth-differentiation factor 5), 
a member of the transforming growth factor-β superfamily with a well-
characterized role in limb morphogenesis, is a key regulator of the growth and 
elaboration of pyramidal neuron dendrites in the developing hippocampus. 
Pyramidal neurons co-express GDF-5 and its preferred receptors bone 
morphogenetic protein receptor-IB and bone morphogenetic protein receptor-II 
during development. In culture, GDF-5 substantially increased dendrite, but not 
axon, elongation from these neurons by a mechanism that depends activation 
of Smads1/5/8 and upregulation of the Hes5 transcription factor. In vivo, the 
apical and basal dendritic arbors of pyramidal neurons throughout the 
hippocampus were very markedly stunted in both homozygous and 
heterozygous Gdf-5 null mutants, indicating that dendrite size and complexity 
are exquisitely sensitive to the level of endogenous GDF-5 synthesis. 
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1.1. Hippocampus 
1.1.1. Early development and anatomical structure  
The central nervous system (CNS) develops from the neural tube. 
Shortly after closure, the neural tube becomes subdivided into the 
prosencephalon (forebrain), mesencephalon (midbrain), rhombencephalon 
(hindbrain) and spinal cord. As development proceeds, the prosenchephalon 
develops into the telencephalon and diencephalon1-4. By embryonic day (E) 
E10.5-E12.5, in the mouse, the neuroepithelium of the dorso-medial 
telencephalon invaginates to form two medial structures, the hippocampal 
primordia, that are mainly comprised of proliferating progenitor cells that will 
differentiate into the different cell types present in the mature hippocampal 
formation as development proceeds5-7. In 1990, Altman and Bayer injected 3H-
thymidine into the developing rat hippocampus at sequential, closely spaced 
time points to determine the origins of the different cell populations that make 
up the hippocampus, their routes of migration and their subsequent order of 
settling. They identified three components of the hippocampal primordial 
neuroepithelium: the ammonic neuroepithelium that will generate pyramidal 
cells, the primary dentate neuroepithelium that gives rise to granule cells and 
the fimbrial glioepithelium that will produce the glial cells of the fimbria4,8,9. 
 
In humans, the hippocampal formation is located in the medial portion of 
each temporal lobe of the cortex, whereas in rodents the hippocampus is an 
elongated, C-shaped structure, with hippocampi from each hemisphere leaning 
together at the top and spread apart at the base, with a septotemporal axis 
running from the septal nuclei rostrally ("septal pole") to the temporal cortex 
ventrocaudally ("temporal pole")10 (Fig.1). In both humans and rodents, the 
hippocampal formation consists of the following regions: dentate gyrus (DG), 
hippocampus, subiculum, presubiculum, parasubiculum and the entorhinal 
cortex (EC). The hippocampus itself is divided into three subdivisions: CA1, 
CA2 and CA3, which contain densely, packed pyramidal neurons and more 
loosely arranged interneurons. CA is an abbreviation of "Cornu Ammonis", a 
Latin designation for the shape of the hippocampus that resembles the ram’s 
horn of the Egyptian god, Amun. CA2 is a marginal region and is mainly a 
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transition between the CA1 and CA3 fields11. Pyramidal neurons in these latter 
two fields are morphologically and neurochemically distinct, although they are 
generated from the same precursor cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hippocampus location in the human and rodent brain.  
(A) Human brain showing the hippocampus (pink) attaching with the mamillary bodies (orange) 
through the fimbria-fornix. (B) Hippocampus (pink) location in the rodent brain. The images in A 
and B also show: the amygdala (green), bed nucleus of stria terminalis (BNST, blue), 
hypothalamus (yellow), main olfactory bulbs (MOB, purple), the nucleus accumbens (NuAc), 
ventral tegmental area (VTA), and the periaqueductal gray (PAG). In rodents (B), the olfactory 
bulbs are enlarged when compared to humans. Image B also shows the accessory olfactory 
bulbs (AOB, red)12. 
 
1.1.2. Hippocampal connections 
The basic circuit of the hippocampus involves the DG, CA3 and CA1 
areas establishing a tri-synaptic loop13. A major external input into the 
hippocampus is from the perforant pathway that comprises axons from layer II 
of the EC projecting to the DG granule cells. Perforant path axons innervate the 
outer and the middle third of granule cell dendritic trees. Granule cells of the DG 
project axons (mossy fibers) to pyramidal neurons within the CA3 area and 
these, in turn, project axons (Schaffer collaterals) to ipsilateral CA1 pyramidal 
neurons and contralateral CA3 and CA1 pyramidal cells through commissural 
connections. CA1 pyramidal neurons extend axons out of the hippocampus, 
which synapse in the subiculum and deep layers of the EC. This is the simplest 
synaptic circuit in the hippocampus, but there are several other pathways. For 
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instance, the CA1 area receives direct inputs from the CA3 subfield, EC layer III 
and the thalamus (the latter of which projects only to the terminal apical 
dendritic trees of CA1 pyramidal neurons). The hippocampal area is also 
innervated by commissural fibers from the contralateral hippocampus as well as 
receiving sub-cortical inputs from several different regions of the brain11,13 
(Fig.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Input and output pathways in the mouse hippocampus.   
The entorhinal cortex (EC) projects to the dentate gyrus (DG) via the Perforant fiber pathway. 
Granule cells of the DG project axons to CA3 neurons via the Mossy fiber pathway. In turn, CA3 
neurons provide input to CA1 neurons through the Schaffer collateral pathway. CA1 neurons 
project fibres out of the hippocampus to synapse in the subiculum (Sub) and EC. Additionally, 
the EC can also project directly to CA3, CA1 and Sub. The EC is the major output of the 
hippocampus. The diagram represents a coronal section of the adult mouse hippocampal 
formation14. 
 
 
The CA regions of the hippocampus are stratified into the following 
different layers: the alveus (mainly composed of myelinated hippocampal, 
subiculum and fimbria efferents); stratum oriens (the innermost layer contains 
the basal dendrites of pyramidal neurons); stratum pyramidale (contains the cell 
bodies of pyramidal neurons); stratum lucidum (only present in CA3 where 
mossy fibers terminate); stratum radiatum (contains the proximal apical 
dendrites of pyramidal neurons and receives commissural fibers input from the 
contralateral hippocampus); stratum lacunosum (area in CA1 and CA2 that 
receives myelinated Schaffer collateral input from CA3); stratum moleculare 
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(the most superficial layer in the hippocampus associated with distal apical 
dendrite terminal arborization and input of perforant pathway fibers from the 
EC). With the exception of the alveus, all CA field strata also contain the soma 
of interneurons4,11,15 (Fig.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Hippocampal formation.  
In this image the dentate gyrus (DG), CA3, CA2 and CA1 fields, the subiculum and 
presubiculum of the hippocampal formation are represented. Also represented, the different 
layers in the CA area and in the DG. The diagram represents a coronal section of the adult 
mouse hippocampal formation15. 
 
1.1.3. Hippocampal neurons  
 The mature hippocampus contains glial cells, pyramidal neurons, DG 
granule cells and interneurons, the latter of which represent less than 10% of 
the total number of hippocampal cells5,7. Whilst neurogenesis begins in the 
mouse hippocampal primordium at E10.5, the majority of cells present in this 
structure at E14.5 are still proliferating. In mice, CA3 pyramidal neurons are 
predominantly generated between E14 and E15 and CA1 pyramidal neurons 
between E15 and E165,6. The hippocampal regions are intrinsically determined 
early in neurogenesis and the initial specification of CA1 and CA3 neurons 
might begin as early as E10.5-E12.5. When isolated at this stage, telencephalic 
tissue can independently generate features of the patterned fields5. From E14.5 
to E18.5, pyramidal cells undergo radial migration from the ventricular zone to 
the hippocampal plate, the future pyramidal layer, via the intermediate zone9. 
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During this period, hippocampal neurons also start to undergo neurochemical 
and functional maturation, a process that extends into the postnatal period3,9. At 
the same time, afferents also extend into the hippocampus16,17. Entorhinal 
axons first enter the mouse hippocampus at E15. At E17, entorhinal fibers 
appear within the stratum lacunosum-moleculare and the first axons invading 
the outer molecular layer of DG are evident at E19. Commissural fibers begin to 
innervate the contralateral hippocampus at E18, targeting the stratum oriens 
and radiatum. From P2 onwards, commissural fibers are seen terminating in the 
inner zone of the molecular layer of the DG16,17.   
 
GABAergic interneurons in the hippocampus provide inhibitory input to 
control the activity of glutamatergic, excitatory pyramidal neurons and DG 
granule cells. GABAergic interneurons exert their inhibitory control on the 
activity of glutamatergic neurons through the activation of postsynaptic GABA 
receptors. Some interneurons also establish inhibitory synapses with other 
interneurons. Interneurons are generated in the developing hippocampus before 
pyramidal neurons and DG granule cells3,18,19. Most CA1 and CA3 GABAergic 
interneurons are generated between E12 and E13, whereas the majority of DG 
interneurons are born between E13 and E14. Whilst glutamatergic pyramidal 
neurons originate from the neuroepithelium in the ventricular zone of the dorsal 
telencephalon and migrate radially across the intermediate zone towards the 
hippocampal plate3, the origin and migration path of hippocampal GABAergic 
interneurons is still not certain. To date, the available evidence has suggested 
that a large number of GABAergic interneurons originate in the subpallium 
telencephalon, migrate tangentially, and populate several areas of the cortex, 
including the hippocampus18,19.   
 
In contrast to pyramidal neurons and interneurons, 85% of DG granule 
cells are born postnatally2,3,7,9. Most hippocampal glial cells are also generated 
postnatally from the same multipotent neuroepithelial progenitors that produce 
hippocampal neurons earlier in development. Astrocytes are generated first 
followed by oligodendrocytes20,21. 
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 Pyramidal neurons have a triangular soma and are polarized, with a 
single axon and multiple dendrites. The dendrites of mature hippocampal 
pyramidal neurons display numerous spines, small protrusions from the 
dendritic shaft, which increase the area available for synaptic contacts. The 
morphology and development of rat hippocampal pyramidal neurons has been 
well studied in several in vitro models. According to Dotti et al.22, the 
polarization of late embryonic rat hippocampal neurons in culture follows 5 well-
characterised stages (Fig.4). Shortly after the neurons are plated, it is possible 
to recognize lamelipodia around the cell bodies (Stage 1). Within 12 hours of 
culture, these lamelipodia give rise to minor processes or neurites (Stage 2). 
Over the following 12-24 hours, neurons undergo initial polarization, so that by 
1.5 days in vitro (DIVs) it is possible to distinguish the axon that has started to 
grow from one of the minor processes (Stage 3). By 4DIVs the remaining 
neurites start to develop into dendrites (Stage 4). The rate of axonal growth is 5 
to 10 times greater than the rate of dendritic growth. Subsequently, by 7DIVs, 
the neurons are mature and start to establish synaptic connections with their 
neighbouring neurons (Stage 5)22-25. 
         
 
 
Figure 4: The 5 stages of development of hippocampal neurons in vitro.  
Each stage corresponds to a number of days in culture22. 
 
Axons differ from dendrites morphologically and functionally, but they 
also diverge in their distribution of molecules and organelles. For example, 
polyribosomes and messenger RNA (mRNA) are largely excluded from the 
axon but are highly abundant within the somatodendritic compartment26. 
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Furthermore, axons and dendrites contrast in their distribution of the 
microtubule-associated proteins (MAP), tau (axonal) and MAP-2 
(somatodendritic). Microtubule orientation also differs between axons and 
dendrites. In axons, microtubules are uniformly oriented with their plus ends 
distal to the cell body, whereas microtubules are present in both polarity 
orientations in dendrites27,28. 
Actin filaments and microtubules are necessary to establish and maintain 
polarity in neurons by converting molecular signals into structural changes29. 
Axonal growth and, consequently the establishment of neuronal polarity, take 
place at the tip of the growing axon in a highly motile and specialized cellular 
compartment, the growth cone30. The axonal growth cone is composed of a 
central domain (C-domain), in which microtubules enter to polymerize and 
transport organelles and vesicles to the area, and a peripheral domain (P-
domain) that is highly dynamic and comprises actin filament-rich lamellipodia 
and filipodia. The C- and P-domains are separated by a transitional zone (T-
zone), where microtubules and the minus-ends of actin filaments interact, and it 
is the dynamic interplay among these structures that leads to neurite 
extention30,31.  
Traditionally, axons extend continuously following three stages that are 
influenced by environmental cues: protrusion, engorgement and consolidation 
(Fig.5). Barbed, fast growing plus-ends of actin filaments (F-actin), which are 
orientated towards the plasma membrane, continuously incorporate ATP-bound 
G-actin monomers. Newly incorporated actin monomers are effectively 
retrogradely transported along the actin filament, as further new monomers are 
added to the plus end, until they reach the minus-end of the actin filament 
where bound ATP is hydrolysed to ADP and they are released as monomers. 
ADP-bound G-actin monomers exchange ADP for ATP and are transported 
back to the plus end of the actin filament for further incorporation into F-actin. 
The result of this treadmilling is that actin filaments do not increase in net 
length, in a static growth cone32. During the protrusion phase, the P-domain of 
the growth cone contacts with a substrate leading to an increase in actin 
polymerization in the P-domain resulting in filipodial elongatation and foward 
movement of lamellipodia. At the same time there is a retrograde flow by which 
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the actin network and the adjacent membrane is pulled back. F-actin retrograde 
flow is driven both by contractility of the motor protein myosin II, and the ‘push’ 
from F-actin polymerization in the P domain. The myosin-dependent contraction 
together with the retrograde flow leads to a condensation of actin arcs and 
microtubules, in the C-domain, that suppresses actin polymerization and 
protrusion. 
This phenomenon leads to the second step of axon extention: 
engorgement. As a result of the retrograde flow, actin filaments disassemble in 
the T-zone and actin arcs reorient towards the growth direction originating a 
neurite shaft that is occupied by microtubules (which are guided by the T-zone 
actin arcs and C-domain actin bundles) and, subsequently, by vesicles and 
organelles forming the new axonal area33,34. Finally, consolidation occurs when 
the F-actin at the neck of the growth cone depolymerizes and the filopodia 
retract away from the area of new growth, promoting axon shaft 
consolidation30,32 (Fig.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Stages of Axon outgrowth. 
The axon outgrowth process occurs at the tip of the growth cone. After (a) encountering an 
attractive and adhesive substrate the growth cone progress by a sequence of three define 
stages (b) protrusion, (c) engorgement and (d) consolidation30. 
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Conversely, the future dendrites have static growth cones with a rigid 
actin cytoskeleton and less dynamic properties. As mention before, 
microtubules are present in both polarity orientations in dendrites. However, 
during stage 4 of development, in hippocampal neurons, minus-end distal 
microtubules in dendrites emerge first, and by stage 5 both microtubule 
orientations are equally abundant in proximal dendrites. In more distal 
dendrites, however, plus-end out microtubules dominate27. Studies suggest that 
motor proteins differentially organize the orientation of axonal and dendritic 
microtubules. For instance, the mitotic microtubule-based motor CHO135 and 
structural MAPs, such as MAP236 and MAP1A37 are enriched in dendrites and 
are implicated in dendritic differentiation and maintenance. Suppression of one 
of these genes leads to inhibition of dendritic differentiation and branching. The 
axonal exclusion or reduced levels of these proteins may also explain the 
reason why microtubules are only oriented in dendrites with a mixed polarity38.  
 
Specific microtubule associated proteins have been identified that influence 
axon specification and elongation. For example, collapsin response mediator 
protein-2 (CRMP-2) is preferentially associated with microtubules within axons, 
although it also binds tubulin dimers. The association of CRMP-2 with both 
tubulin dimers and polymers promotes rapid microtubule assembly and 
increases axonal length. Overexpression of CRMP-2 enhances axonal 
elongation from cultured hippocampal neurons, whereas expression of a mutant 
form of CRMP-2 reduces axonal length39. Regulators of actin cytoskeleton 
dynamics, in particular the Rho family of small GTPases comprising Rho, Rac, 
and Cdc42, have also been shown to play important roles in establishing neural 
polarity and neuronal morphology. For example, transgenic mice 
overexpressing a constitutively active mutant form of Rac1 display a significant 
reduction in the number of Purkinje cell axon terminals in deep cerebellar nuclei 
with no changes in dendritic tree complexity40. In C. elegans, Cdc42 and Rac1 
activated forms associate with a complex consisting of the polarity inducing 
scaffold proteins Par3 and Par6 and the atypical protein kinase C (aPKC). Par3 
and Par6 are initially distributed at the tip of all the processes of cultured 
embryonic rat hippocampal neurons prior to axon specification41. As axon 
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growth is initiated, local phosphatidylinositol 3-kinase (PI3K) activity leads to the 
redistribution of Par3 and Par6, so that they become selectively localised at the 
tips of elongating axons and absent from putative dendrites42. Interestingly, the 
overexpression of either Par3 or Par6 prevents the specification of a single 
axon. In addition to the intrinsic signals described above, extrinsic signals, such 
as neurotrophic factors, can modulate neuron polarity during morphological 
development41.   
 
Although pyramidal neuron apical and basal dendrites develop more side 
branches after birth, dendritic structure is still very simple until afferent 
synapses invade the hippocampal region by postnatal days 3-5 (P3-5). At this 
point, dendrites reach their full potential in terms of elongation, branching, 
pruning and dendritic spine development, acquiring mature dendritic 
morphology by P20 in the rat. The pattern of mature dendritic arborisation is 
determined by a combination of cell intrinsic programs and extrinsic micro-
environmental cues7. There are five main processes through which mature 
dendritic arbours are formed. First, dendrites grow and acquire a shape and 
function that is distinct from axons. This step seems to be modulated, at least to 
some extent, by neurotrophic factors. Second, dendrites grow towards a defined 
target so that correct neuronal connections can be established. Semaphorin-3A 
(Sema3A) is a key molecule that regulates both axon and dendrite guidance in 
the nervous system. In accordance with this, Sema3A deficient mice show 
defects in the guidance of cortical pyramidal neuron dendrites43. Third, dendritic 
branches are formed at defined intervals. Fourth, mature dendrites develop 
dendritic spines. Dendritic spines are micron-sized protrusions of the dendritic 
membrane that receive over 90% of excitatory input and are highly dynamic44. 
They are found on both excitatory and inhibitory neurons including, 
glutamatergic pyramidal neurons of the neocortex and hippocampus and 
GABAergic cerebellar Purkinje neurons. The number and shape of dendritic 
spines are varied and highly changeable and are regulated by both 
physiological and pathological events45. Actin filaments dynamics are the main 
driver behind changes in spine number, shape and function46,47. Since, as 
mentioned above, Rho GTPases play an important role in regulating the actin 
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cytoskeleton, Rho GTPases are major effectors of changes in spine number, 
shape and size, thereby tuning synaptic strength. Inhibition of Rac1 in 
hippocampal organotypic cultures induces long and thin spines and reduces 
spine growth and motility. In contrast, new and protrusive dynamic spines are 
produced in the absence of Rho kinase activity48. In the final stage of dendrite 
development, dendrites are precisely controlled to stop growing and acquire 
their mature shape49,50. An important consequence of the intricate control of 
dendrite growth and branching is that mature hippocampal pyramidal neuron 
dendrites are spatially arranged so that they are non-overlapping, a 
phenomenon known as tiling51. Since, tiling avoids the clumping and 
overlapping of dendrites, it maximises the available dendrite surface that can 
receive afferent synaptic input. Tiling is brought about by contact-mediated 
mutual repulsion of dendrites between similar neurons; a process that is 
controlled by a number of recently identified cell surface molecules in 
invertebrates51. The molecular mechanisms that regulate tiling in the 
mammalian nervous system are currently largely unknown. 
 
1.1.4. Hippocampal functions and associated neuropathologies  
The hippocampus has been widely studied due to its roles in learning52, 
memory53, navigation and spatial orientation54-56. 
In 1957, Scoville and Milner reported a case study of a patient whose 
epileptic seizures were ameliorated following the bilateral removal of the medial 
temporal lobe. Consequently, the patient suffered a severe loss of memory of 
the events immediately prior to the surgery, as well as a partial retrograde 
amnesia of events in the three years leading up to his operation. The patients’ 
cognitive, perceptual and motor learning abilities remained unaltered. These 
observations suggested that the hippocampal area plays a critical role in our 
declarative memory: the memories that can be consciously recalled, such as 
facts, knowledge and personal experience53,57. 
Memories are believed to be stored in the brain’s synaptic connections, 
particularly within the hippocampus. Therefore, synaptic plasticity is widely 
considered to be the cellular mechanism behind learning and memory58. One of 
the most studied forms of synaptic plasticity is long-term potentiation (LTP) 
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within the hippocampus. LTP is an electrophysiological measure of a sustained 
increase in synaptic efficacy or strength. LTP can be divided into early-phase 
(E-LTP) and late-phase (L-LTP) events that are induced by different 
mechanisms and have different properties59. E-LTP last for 1-2 hours following 
a single high frequency burst of electrical activity and consists of the 
modification of existing synapses. E-LTP results from the phosphorylation of 
post-synaptic proteins, induced by rapid calcium (Ca2+) influx through NMDA 
channels and the activation of Ca2+ regulated cytosolic proteins, together with 
the phosphorylation of pre-synaptic proteins by a process that is facilitated by 
the neurotrophin brain-derived neurotrophic factor (BDNF)58,59. E-LTP is 
responsible for short-term memory or episodic memory. L-LTP results from 
repetitive high frequency bursts of electrical activity and lasts from several hours 
to several days. L-LTP requires new mRNA and protein synthesis to induce 
structural changes in dendritic spines and synapses and alterations in the 
repertoire and expression levels of synapse related proteins. L-LTP appears to 
be facilitated by BDNF that is released from hippocampal neurons in an activity 
dependent manner58. L-LTP plays a role in the formation of long-term memory 
(LTM) and learning52,58,59. The roles of BDNF in E-LTP, L-LTP, LTM and 
learning will be further discussed below. 
 
Perturbations of normal hippocampal circuitry and function underlie many 
common neuropathological conditions. For example, the hippocampus is the 
primary brain structure affected in Alzheimer's disease. Post-mortem analysis of 
the hippocampi from Alzheimer’s sufferers and rodent models of Alzheimer’s 
disease have revealed that the disease is associated with the loss of cholinergic 
afferents from basal forebrain neurons60; the emergence of pyramidal neurons 
with dystrophic dendrites possessing a reduced number of spines61 and a 
reduction in synaptic transmission and reduced synaptic plasticity62. Together, 
these abnormalities lead to the reduction of synaptic connectivity within the 
hippocampus and, consequently, the well-established symptoms of Alzheimer’s 
disease such as memory decline, disorientation and ultimately amnesia. 
Epilepsy in humans and animal models is associated with extensive neuronal 
loss within the hippocampal formation (pyramidal neurons, DG granule cells, EC 
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neurons, subiculum neurons and interneurons) and aberrant axon collaterals 
that result in the formation of new circuits and disruption of existing circuits63,64. 
Another important neuropathy associated with hippocampal damage is 
schizophrenia. A decreased number of hippocampal interneurons and a 
generalised shrinkage of the hippocampus have been frequently reported65,66. 
Post-mortem and magnetic resonance imaging studies have shown that major 
depressive disorder (MDD) is also associated with a reduction in volume of the 
hippocampal formation67. Chronically elevated levels of circulating 
glucocorticoids appear to be the underlying cause of hippocampal formation 
shrinkage in MDD. The reduction in volume of the hippocampal formation does 
not appear to be due to significant neuronal death, but may reflect the retraction 
of pyramidal neuron dendritic arbours, the loss of glial cells or a decrease in 
adult neurogenesis within the DG67.  
 
Active adult neurogenesis occurs in the subgranular zone (SGZ) of the 
DG, where new DG granule cells are generated, and in the subventricular zone 
of the lateral ventricles, where newly generated neurons migrate through the 
rostral migratory stream to the olfactory bulb68. In the case of the SGZ, newly 
generated, immature neurons migrate into the inner granule cell layer and 
differentiate into DG granule cells. Newly born granule cells project their 
dendrites into the molecular layer and their axons to the CA3 pyramidal cell 
layer to establish new synaptic connections. From a functional point of view, 
hippocampal neurogenesis plays an important role in structural plasticity and 
network maintenance68. Newborn neurons are critical for learning and memory 
and exhibit hyper-excitability and enhanced synaptic plasticity of their 
glutamatergic inputs during a critical period of maturation in the hippocampus69. 
Interestingly, the induction of LTP at perforant pathway-granule cell synapses 
stimulates the proliferation of progenitor cells in the DG and promotes the 
survival of newly differentiated neurons70.  
Behavioural studies have attempted to correlate the number of newborn 
granule cells with an animal’s cognitive ability; however, results have been 
inconsistent71. Nevertheless, some studies have indicated that adult 
neurogenesis is required for certain hippocampus-dependent tasks, but not 
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others. For instance the ablation of adult neurogenesis in rats by 
methylazoxymethanol acetate (MAM) treatment prevents the improvement of 
long-term recognition memory by environmental enrichment in rats72,73. 
Aberrant adult neurogenesis appears to contribute to neuropathological 
conditions. For example, the induction of seizures in rats by kainic acid 
administration induces increased SGZ progenitor proliferation that is associated 
with long-term cognitive impairment74. Key molecules involved in Alzheimer's 
disease pathogenesis, such as ApoE, presenilin-1 (PS1), and amyloid precursor 
protein (APP) and its metabolites, have been shown to modulate hippocampal 
neurogenesis75. Alterations in hippocampal neurogenesis have been 
demonstrated at very early stage of Alzheimer's disease progression, and it is 
possible that these perturbations in neurogenesis may exacerbate neuronal 
vulnerability to the causative agents of Alzheimer’s disease, enhance disease 
progression and contribute to memory impairment75. Furthermore, although a 
reduction in neurogenesis by itself is not likely to induce depression, 
antidepressant treatments increase neurogenesis in the DG76.  
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1.2. Regulation of neuron survival and outgrowth  
1.2.1. The “neurotrophic hypothesis” 
 In the developing nervous system, more neurons are generated than the 
ones required in the adult. Initial observations in the developing peripheral 
nervous system (PNS) of chick and rodents revealed that many newly 
generated neurons die shortly after their axons reach their target fields77-79. This 
developmental neuronal death removes superfluous neurons and matches the 
number of neurons to the density of target field innervation that is required. 
According to the “Neurotrophic Hypothesis” the target field contains limiting 
amounts of survival promoting neurotrophic factors and only the neurons that 
are able to obtain sufficient amounts of neurotrophic factor support will 
survive80. Depending on the peripheral ganglion in question, 20% to 80% of 
neurons will not obtain sufficient neurotrophic factor support from their target 
fields and will therefore die by apoptosis. This hypothesis was initially 
formulated and supported by experiments demonstrating that Nerve Growth 
Factor (NGF), the first neurotrophic factor to be identified, promotes the in vitro 
survival of developing chick and rodent sympathetic neurons and some kinds of 
peripheral sensory neurons77,79,81,82. More recently, this in vitro data has been 
supported by in vivo evidence80,82,83. Anti-NGF antibodies administered during 
the phase of target field innervation eliminate NGF dependent neurons, 
whereas the addition of exogenous NGF prevents developmental neuronal 
death in these populations. Moreover, NGF knockout (KO) mice and mice with a 
null mutation in the gene encoding the NGF receptor, tropomyosin-related 
kinase A (TrkA), display a significant loss of NGF dependent neurons compared 
to wild type (WT) mice80,82-85. Over time, the neurotrophic hypothesis has been 
modified in the light of new data demonstrating that neurotrophic factors 
promote differentiation, target field innervation, axon terminal arborisation and 
regulate the functional properties of neurons, in addition to supporting neuronal 
survival80. Moreover, some developing peripheral neurons require the 
sequential support of more than one neurotrophic factor as they develop, 
intermediate target fields can be a source of neurotrophic factor support and 
some neurotrophic factors can be synthesised by neurons themselves and act 
in a paracrine and/or autocrine manner within ganglia. In addition, the 
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neurotrophic hypothesis does not apply to some populations of CNS neurons 
(see 1.2.3. below). Nonetheless, the neurotrophic hypothesis has largely stood 
the test of time and remains the best explanation of how peripheral neuron 
numbers are matched to the functional requirements of target fields80. 
 
1.2.2. The Neurotrophin family of neurotrophic factors 
Since the discovery and characterisation of NGF, three other 
homologous proteins have been discovered in mammals: BDNF, neurotrophin-3 
(NT-3), and neurotrophin-4 (NT-4). Together, NGF, BDNF, NT-3 and NT-4 
make up the Neurotrophin family of neurotrophic factors that act directly on 
neurons to support their survival, target field innervation, functional 
differentiation and maturation and synaptic activity83,86. These four molecules 
are structurally and functionally related and are synthesised and secreted by 
innervated target organs, endocrine cells, cells from the immune system, glial 
cells, and neurons. Neurotrophins are functional as non-covalent homodimers 
and signal through two types of receptors: the Trk (tropomyosin-related kinase) 
receptors that belong to the tyrosine kinase family, and p75NTR (p75 
neurotrophin receptor), which is a common receptor for all the neurotrophins87-
89. p75NTR belongs to the tumour necrosis factor (TNF) receptor superfamily 
(TNFRSF) and has a death domain, a region of approximately 80 amino acid 
residues, in the intracellular cytoplasmic domain. 
The Neurotrophins preferentially bind to one member of the Trk family. 
NGF preferentially binds to TrkA, BDNF and NT-4 to TrkB and TrkC is the 
preferred receptor for NT-3, although NT-3 displays promiscuity and can also 
bind to and activate TrkA and TrkB in the absence of p75NTR expression88,89 
(Fig.6). Upon binding to their cognate Trk receptor, neurotrophins induce 
receptor dimerization and subsequent phosphorylation of multiple tyrosine 
residues in the intracellular tyrosine kinase domain. Adaptor proteins, such as 
Shc and Frs2, bind to phosphorylated tyrosine residue 490 and initiate 
intracellular signalling cascades, such as the Ras/extracellular signal regulated 
kinase (ERK) and PI3K/Ak transforming/protein kinase B (Akt/PKB) pathways. 
Activation of these pathways enhances neuronal survival, differentiation and 
maturation, promotes target field innervation and regulates the functional 
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properties of neurons89. In addition, phospholipase C gamma (PLCγ) binds 
directly to phosphorylated tyrosine residue 785, leading to Ca2+ and protein 
kinase C (PKC) mobilization, enhanced process outgrowth and synaptic 
plasticity89 (Fig.7).  
 
 
 
 
 
 
 
 
 
 
Figure 6: The Neurotrophin family of neurotrophic factors and their receptors.  
NGF binds to TrkA, BDNF and NT-4 to TrkB and NT-3 to TrkC. All the Neurotrophins can bind 
to the common p75NTR receptor. Pro-NGF and pro-BDNF can also interact with p75NTR, but 
not Trk receptors88. 
 
Neurotrophin signalling from the p75NTR can have different outcomes 
depending on whether the cognate Trk receptor is expressed and whether other 
non-Trk receptors are present. For example, p75NTR can potentiate signalling 
by TrkA to enhance NGF-promoted survival and target field innervation as well 
as increasing the specificity of Trk receptors for their preferred neurotrophin89,90. 
In the presence of cognate Trk expression, neurotrophins binding to p75NTR 
can promote process outgrowth by modulating the activity of the small GTPase, 
RhoA, and promote survival via activation of nuclear factor-B (NF-B) 
signalling. In the absence of cognate Trk expression, neurotrophin binding to 
p75NTR leads to apoptosis by a number of signalling mechanisms including: 
TNF-receptor associated factor 6 (TRAF6) mediated activation of Jun N-
terminal kinase (JNK), nuclear translocation of the p75NTR intracellular domain 
bound to the transcription factor neurotrophin receptor interacting factor (NRIF) 
and/or interference of PI3K/Akt survival signalling by p75NTR induced 
generation of ceramide by membrane sphingomyelinase89,90. 
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 Each of the four members of the neurotrophin family is synthesised as a 
proneurotrophin precursor protein that is proteolytically cleaved to generate the 
corresponding mature neurotrophin91. The pro-domains of neurotrophins have 
been shown to play a critical role in ensuring correct protein folding of mature 
neurotrophins and their subsequent targeting to the secretory pathway. Pro-
NGF and Pro-BDNF can induce apoptosis, in the absence of mature 
neurotrophin induced Trk signalling, by binding to p75NTR.  Importantly, the 
receptor sortilin can form a high affinity pro-neurotrophin receptor complex with 
p75NTR that more efficiently signals cell death than p75NTR alone91.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Neurotrophin receptor signalling.  
Following ligand binding, Trk receptors recruit and promote the phosphorylation of PLC-  and 
adaptor proteins, such as Shc and Frs2. The recruitment and phosphorylation of adaptor 
proteins leads to the subsequent activation of PI3K and ERK signalling pathways and enhanced 
neuronal differentiation and survival. p75NTR receptor ligation leads the recruitment of adaptor 
proteins, like TRAF6, RIP2 and Rac1, and the subsequent activation of NF- B and/or JNK 
signalling pathways and/or the modulation of RhoA activity. Depending on the cellular context, 
p75NTR can promote neuronal survival, apoptosis, neurite elongation or growth arrest 
(adapted92). 
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In addition to the neurotrophins, a number of other protein families have 
been identified that regulate the differentiation, survival, growth, maturation and 
functional properties of certain population of CNS and PNS neurons. These 
include; the glial cell-derived neurotrophic factor (GDNF) family (GDNF, 
neurturin, artemin and persephin)93, the neurotrophic cytokines (ciliary 
neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF), oncostatin-M 
(OSM), cardiotrophin-1 (CT-1) and interleukin-6 (IL-6))83, the hepatocyte growth 
factor (HGF)94 and the macrophage-stimulating protein (MSP)95. With the 
exception of a potential role for GDNF in promoting synapse formation in the 
hippocampus96, there is little experimental evidence, to date, suggesting that 
members of these protein families play significant neurotrophic roles in the 
developing and adult hippocampus. For this reason, the biology of these 
neurotrophic factors and their receptors will not be discussed further. 
 
1.2.3. The roles of Neurotrophins in the Hippocampus 
The highest concentrations of NGF mRNA within the CNS are found in 
the cortex and hippocampus97, major targets of the TrkA-positive, NGF-
responsive cholinergic neurons of the basal forebrain nuclei98. Recent studies 
examining mice with CNS specific conditional deletions of TrkA and NGF has 
revealed that, contrary to the neurotrophic hypothesis, NGF/TrkA signalling is 
not required to support the developmental survival of the vast majority of basal 
forebrain cholinergic neurons (BFCNs). However, NGF/TrkA signalling is 
required for the correct development of cholinergic circuitry within the 
hippocampus and for enhancement of the cholinergic phenotype99,100. The 
levels of NGF within the hippocampus are modulated by BFCN induced 
depolarization of hippocampal neurons101,102. NGF, via its modulation of BFCN 
function, has been shown to play a role in facilitating hippocampal LTP in the 
adult rat brain103,104. NGF also appears to directly contribute to LTP in the rat 
DG by direct activation of TrkA on DG neurons105 and infusion of exogenous 
NGF into the lateral ventricles of rats improves LTM formation by a mechanism 
that is associated with the phosphorylation of hippocampal TrkA, an increase in 
the expression of synaptic proteins and an increase in the number and maturity 
of dendritic spines on dendrites projecting from CA3 pyramidal neurons106. 
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Whilst TrkA expression is low in the adult rodent hippocampus107, 
embryonic mouse and rat hippocampal neurons express TrkA in culture and 
NGF rescues these neurons from glutamate or staurosporine induced 
apoptosis108. The anti-apoptotic effects of NGF require both TrkA and p75NTR 
signalling. NGF also promotes axon elongation from cultured mouse embryonic 
hippocampal neurons by a mechanism that is mediated by p75NTR and 
involves activation of casein kinase 2 (CK2), inhibition of PTEN and subsequent 
phosphorylation and inhibition of glycogen synthase kinase-3 beta (GSK-3β)109. 
In addition, p75NTR mediated NGF signalling regulates dendrite morphology in 
cultures of embryonic mouse hippocampal neurons. NGF reduces the number 
of primary dendrites and promotes the elongation of remaining dendrites by 
protein tyrosine phosphatase 1B (PTP1B) mediation of NF-B activation110,111. 
 
NT-3 and TrkC mRNAs are both expressed at high levels in the 
developing and adult rodent hippocampus107,112,113. Despite this, NT-3 only 
marginally increases the survival of E17 rat hippocampal neurons cultured for 6 
days in defined medium114 and does not enhance the survival of E18 rat 
hippocampal neurons after 8 days in culture115. However, NT-3 does induce 
TrkC phosphorylation, c-fos protein expression and the activation of p21Ras 
and mitogen-activated protein kinase (MAPK) in embryonic rat hippocampal 
cultures, in addition to promoting the expression of calbindin-D28K in a sub-
population of pyramidal neurons115,116. NT-3 also promotes the expression of 
the dendritic marker, MAP-2 and the synaptic marker, synapsin1 in cultures of 
E16 rat hippocampal neurons117. Interestingly, It appears as if spontaneous 
activity within pyramidal neurons leads to glutamate mediated autocrine release 
of NT-3, which then promotes the expression of calbindin-D28K 118. 
NT-3 promotes the formation of active excitatory synapses in long-term 
cultures of E16 rat hippocampal neurons by increasing the number and density 
of membrane docked pre-synaptic vesicles in the absence of significant 
morphological changes to dendrite architecture119. The role of NT-3 in 
hippocampal synaptogenesis and synapse maturation has been investigated in 
TrkC null mutant mice120. The loss of NT-3/TrkC signalling does not alter the 
innervation of the hippocampus by the EC and commissural afferents per se, 
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nor does it alter the topographical pattern of hippocampal connections. 
However, TrkC mutant pups display a reduction in the number of axon 
collaterals associated with EC and commissural afferents together with a 
reduction in the expression of pre-synaptic proteins associated with vesicle 
exocytosis and neurotransmitter release120.  
In addition to regulating synaptogenesis, NT-3 modulates dendrite 
morphology in short-term (4-6 days) cultures of embryonic rat hippocampal 
neurons. NT-3 reduces the complexity and length of dendrites in these cultures 
by a mechanism that involves PLC-γ mediated opening of the non-selective 
cation channel, TrpC5, subsequent influx of Ca2+ and Ca2+ dependent activation 
of Ca2+/calmodulin-dependent protein kinase II (CaMKII)121. In contrast, NT-3, 
promotes axon elongation and branching from E18 rat hippocampal neurons 
after 48 hours in culture122. 
 
The neurotrophic properties of BDNF have been extensively investigated 
within the hippocampus. BDNF expression in the developing hippocampus is 
relatively low during the embryonic period and increases markedly during the 
first few postnatal weeks123. Whilst exogenous BDNF does not promote the 
survival of embryonic rat hippocampal neurons cultured at high-density114, it 
does enhance their survival in low-density cultures124. This, together with the 
observation that hippocampal neurons from Bdnf null mutant mouse embryos 
show reduced survival compared to wild type neurons in high-density cultures, 
suggests that autocrine BDNF normally supports hippocampal neuron survival 
in high-density cultures124. Despite this, Bdnf null mutant mice do not display an 
overt loss of neurons in the hippocampus, although these mice die soon after 
birth before the hippocampus is fully developed125,126. Conditional Bdnf KO 
mice, that lack BDNF specifically in the CNS and survive to adulthood, also 
show no significant hippocampal neuron loss123. Similarly, mice with a reduced 
expression of TrkB do not have a reduced number of pyramidal neurons or 
interneurons within CA1, although they display a significant loss of cortical 
pyramidal neurons127. 
BDNF increases dendrite number and dendrite branching in cultures of 
embryonic rodent pyramidal neurons128,129. However, BDNF does not seem to 
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regulate dendritic complexity in postnatal rodent hippocampal slice cultures130. 
In accordance with this, conditional deletion of Bdnf in the mouse CNS does not 
affect the complexity of CA1 pyramidal neuron dendrites123.  
BDNF has been shown to play an important role in regulating synapse 
formation and synaptic activity during development, both in vitro and in vivo. 
BDNF promotes the formation of excitatory synapses in long-term hippocampal 
cultures derived from E16 rat embryos119. Interestingly, BDNF also increases 
the number of inhibitory synapses in these cultures, by a mechanism that 
appears to rely upon BDNF promoted elongation of interneuron axons, thereby 
suggesting that pyramidal neurons and interneurons within the cultures both 
express functional TrkB119. In accordance with this, late gestation mouse 
embryos overexpressing BDNF in the CNS display precocious development of 
GABAergic synapses within the hippocampus and an upregulation of the KCC2 
potassium/chloride co-transporter, that turns GABA responses from excitatory 
to inhibitory, within pyramidal neurons131. Whilst BDNF appears to potentiate 
GABAergic synapse formation and activity in the developing hippocampus, it 
has been reported to inhibit the GABAergic responses of pyramidal neurons 
within the adult hippocampus132. Acutely applied BDNF enhances excitatory 
glutamatergic synaptic transmission within 5 minutes in embryonic rat 
hippocampal cultures133-135. It appears as if BDNF mediated enhanced synaptic 
transmission requires the activation of pre-synaptic TrkB receptors, since viral 
transfection of a signalling deficient truncated TrkB cDNA into cultured pre-
synaptic hippocampal neurons, but not post-synaptic neurons, prevents BDNF 
induced synaptic potentiation136. 
BDNF can potentially act on pre-synaptic axons and/or post-synaptic 
dendrites to promote the morphological and molecular changes that lead to 
synapse formation in the developing hippocampus. The relative importance of 
these two modes of action has been addressed in vivo by using conditional 
TrkB mouse mutants that lack TrkB expression in specific hippocampal neuron 
populations. Embryonic deletion of TrkB specifically from CA3 neurons results 
in a significant reduction in the density of CA3 neuron axon varicosities in the 
basal dendritic field of CA1 neurons and a significant loss of staining for the pre-
synaptic marker synaptophysin compared to wild type mice137. In contrast, CA1 
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neuron dendrite complexity and dendritic spine density are not altered and 
staining for the post-synaptic marker PSD-95 in CA1 is similar to that of wild 
type mice. Whilst embryonic deletion of TrkB from both CA1 and CA3 neurons 
does not alter CA1 neuron dendrite size and complexity, it does significantly 
reduce the number of spines on the dendrites of these neurons and significantly 
decreases the expression of both synaptophysin and PSD-95. Deletion of TrkB 
from CA1 and CA3 neurons in the second postnatal month after synapse 
formation is complete does not alter CA1 dendritic spine number or the 
expression of pre or postsynaptic markers. Therefore, it suggests that 
BDNF/TrkB signalling is required both pre- and post-synaptically for correct 
synapse formation within the developing, but not adult hippocampus137.  
 
In addition to its role in regulating synaptogenesis and synaptic activity in 
the developing hippocampus, BDNF is crucial for synaptic plasticity, LTP, long-
term depression (LTD) and LTM in the postnatal hippocampus. For example, 
BDNF increases dendritic spine density on apical dendrites of pyramidal 
neurons in postnatal rat hippocampal slices138-140 by a mechanism that is 
dependent on ERK1/2 activation130. Whilst, as mentioned above, exogenous 
BDNF does not increase the length or complexity of CA1 or CA3 pyramidal 
neuron dendrites in postnatal slice cultures130, it does significantly increase the 
number of basal dendrites and the extent of axonal branching in DG granule 
cells141. In addition to modulating spine density in hippocampal slice cultures, 
BDNF also increases the number of membrane docked pre-synaptic 
neurotransmitter vesicles in the synaptic buttons of pyramidal neuron axons and 
enhances quantal excitatory neurotransmitter release139.   
BDNF can be secreted from pre-synaptic axon terminals and/or post-
synaptic spines in an activity dependent manner58, although the secretion of 
BDNF from dendrites has recently been questioned142. A polymorphism in 
BDNF, whereby valine (Val) 66 is substituted by methionine (Met), reduces 
activity dependent BDNF secretion143. In addition to enhancing BDNF secretion, 
neural activity directly promotes the transcription of BDNF144.  Released BDNF 
can act either on pre-synaptic terminals or post-synaptic spines at glutamatergic 
synapses to initiate TrkB dependent signalling pathways and induce LTP. The 
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role of secreted BDNF in E-LTP has been relatively well characterised. BDNF 
facilitates the induction of E-LTP by enhancing synaptic responses to tetanus 
stimulation by a mechanism that is thought to involve the promotion of synaptic 
vesicle docking and the redistribution and phosphorylation of synaptic 
proteins58. Short-term episodic memory is largely dependent on E-LTP and is 
impaired in humans carrying the Val66Met BDNF polymorphism demonstrating 
the important role of activity dependent BDNF secretion in establishing and 
maintaining E-LTP143.  
As previously mentioned, L-LTP is dependent on new protein synthesis. 
One of the proteins that is newly synthesised in response to L-LTP inducing 
stimuli is BDNF itself58. The central role of BDNF in establishing L-LTP has 
been demonstrated by a number of different approaches. For example, there is 
a significant reduction in theta burst and forskolin induced L-LTP in Bdnf+/- mice 
compared to wild type mice145,146. In addition, L-LTP induction is inhibited in 
hippocampal slices when they are incubated with either an anti-BDNF or TrkB 
antibody or a TrkB-Fc chimera that sequesters free BDNF147. Moreover, L-LTP 
induction is also impaired in TrkB null mutant mice compared to wild type 
mice148. However, L-LTP induced by tetanic stimulation is normal in Bdnf+/- 
mice, suggesting that not all forms of L-LTP require BDNF149. Mature BDNF is 
generated from pro-BDNF by plasmin dependent cleavage, a process that is 
dependent on the generation of plasmin from plasminogen by tissue 
plasminogen activator (tPA). Transgenic mice lacking functional tPA and/or 
plasminogen expression have been used to demonstrate that the conversion of 
pro-BDNF to mature BDNF by tPA/plasmin is essential for the generation of L-
LTP at hippocampal synapses150. Interestingly, pro-BDNF appears to regulate 
NMDA receptor-dependent LTD at hippocampal synapses, an effect that is 
mediated by p75NTR151. By binding to p75NTR, pro-BDNF also induces growth 
cone collapse, dendritic pruning, a reduction in dendritic spine formation and the 
removal of synaptic AMPA glutamate receptors from hippocampal 
neurons152,153. 
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There is strong experimental evidence that BDNF plays a role in the 
acquisition of long-term memory. For example BDNF mRNA levels are 
increased in the hippocampus of rodents that are given spatial task training 
such as the Morris water maze (MWM)154. Hippocampal BDNF mRNA levels 
are also increased in aversive and context dependent fear conditioning (CDFC) 
paradigms155,156. In accordance with this, Bdnf+/- mice are impaired in MWM 
acquisition157 and CDFC158 compared to wild type mice. Similarly, mice with a 
conditional postnatal deletion of TrkB in the forebrain are impaired in the 
acquisition of spatial tasks compared to wild type mice148  whereas mice 
overexpressing TrkB display enhanced learning capabilities159. Moreover, the 
infusion of an anti-BDNF antibody or antisense BDNF mRNA into the 
hippocampus of rats before training prevents memory formation and retention in 
a number of learning paradigms155,160,161. 
 
1.2.4. Non-Neurotrophin regulators of hippocampal survival, process 
outgrowth and function  
 Apart from the Neurotrophins, other examples of secreted proteins that 
modulate hippocampal neuron survival, process outgrowth and function include 
the founding members of the TNF and the transforming growth factor β (TGF-β) 
superfamilies, TNF-α and TGF-β. 
 In the adult CNS, TNF-α is mainly expressed by microglia and 
astrocytes, particularly after injury, ischemia or infection, although neurons can 
also express TNF-α162,163. Both TNF-α and TNF receptors have been detected 
in the developing brain162,163. TNF-α can signal through two different receptors, 
TNFR1, which contains an intracellular death domain, and TNFR2, which lacks 
a death domain164. TNF-α induces apoptosis in 5 days cultures of E15 mouse 
hippocampal neurons in a dose dependent manner165. However, hippocampal 
neurons in cultures established from Tnfr1-/- mice are refractory to TNF-α 
induced cell death, whereas hippocampal neurons from Tnfr2-/- are more 
susceptible to the apoptotic effects of TNF-α. TNF-α induced activation of 
TNFR1 promotes apoptosis in hippocampal cultures via NF-B dependent 
signalling and activation of TNFR2 by TNF-α promotes hippocampal neuron 
survival by activating p38 MAPK signalling pathways165. 
Chapter 1                                                                                                   General Introduction 
 
 
  27
 In addition to regulating the survival of developing hippocampal 
neurons, TNF-α also regulates process outgrowth from cultured hippocampal 
neurons166. TNF-α reduces the length and degree of branching of axons and 
dendrites in glial cell enriched low-density cultures of E16 embryonic mouse 
hippocampal neurons without affecting neuron survival. Interestingly, culturing 
hippocampal neurons on activated glial cells that secrete TNF-α can mimic this 
effect. TNF-α induced reduction in hippocampal neuron process outgrowth and 
branching is mediated via activation of the GTPase RhoA signalling pathway166. 
TNF-α has been shown to regulate the expression of NGF and BDNF in the 
developing hippocampus167. Tnf-α-/- mice contain significantly more NGF protein 
in the developing hippocampus at P14 and P21, but not in the adult, compared 
to wild type mice. In contrast, adult Tnf-α-/- mice express lower levels of BDNF 
protein in their hippocampi compared to wild type mice. In addition to altering 
neurotrophin levels within the hippocampus, the loss of TNF-α also results in a 
decrease in the complexity of the apical dendrites of neonatal CA1 and CA3 
pyramidal neurons when compared to wild type mice and improves the 
performance of adult mice in spatial learning tasks167. Finally, increased levels 
of TNF-α mRNA and protein have been detected in various brain regions in 
several neurological disorders including: ischemia168, traumatic brain injury169, 
multiple sclerosis170, Alzheimer’s disease171 and Parkinson’s disease172.  
 
 Like TNF-α, TGF-β expression is upregulated after brain injury. However, 
in contrast to TNF-α whose upregulation following injury is associated with 
negative outcomes within the CNS, the injury induced increase in TGF-β 
expression has been suggested to be part of an endogenous protective 
mechanism, in particular within the hippocampus173. In support of this, TGF-β 
protects cultured neonatal rat hippocampal neurons from staurosporine-induced 
apoptosis by inhibiting the conversion of pro-caspase-3 to active caspase-3174. 
More recently, TGF-β was shown to increase dendritic length, as well as 
GABAergic connectivity, in cultures of embryonic mouse hippocampal 
neurons175. Oligomeric, soluble amyloid-β (Aβ) has a number of deleterious 
effects on cultured hippocampal neurons including induction of apoptosis, 
reducing the length and increasing the number of primary dendrites and 
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reducing GABAergic connectivity. Importantly, TGF-β ameliorates the 
deleterious effects of Aβ on cultured hippocampal neurons by a signalling 
pathway that involves activation of NF-B and induction of the expression of the 
hairy and enhancer of split 1 (Hes-1) transcription actor175.  
 
 Other members of the TNF-α and TGF-β superfamilies have recently 
been implicated in the regulation of nervous system development, connectivity 
and function176-181. Proteins that were primarily identified and characterised from 
studies on the immune system, organogenesis and cellular specification are 
now emerging as potent regulators of neuronal differentiation, survival, growth, 
maturation and function. These novel neuroactive factors are now also being 
explored in the context of neuropathology, either as neuroprotective or 
neurotoxic proteins. The TNF-α and TGF-β superfamilies contain a large 
number of members, many of which have yet to be tested for potential 
regulatory roles in the developing and adult nervous system. The following 
sections will focus on the structure, expression and function of members of the 
TNF-α and TGF-β superfamilies.  
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1.3. The Tumour Necrosis Factor superfamily 
 The discovery of TNF was closely associated with the pursuit of a 
treatment for cancer. In 1891, American oncologist W. Colley observed that 
bacterial extracts could lead to the shrinkage of certain tumours182. Later, Shear 
and colleagues isolated lipopolysaccharide (LPS) from gram-negative bacterial 
extracts and verified that LPS could induce tumour necrosis183. In 1962, 
O’Malley and co-workers demonstrated that LPS injection into mice induced the 
release of a factor into their serum that caused tumour regression184 and, in 
1975, this factor was renamed Tumour Necrosis Factor by L. Old and 
colleagues after the confirmation that it was able to kill cancer cells in mice and 
in culture185,186.  
Over time, several other proteins structurally related to TNF were 
discovered and characterised. The TNF superfamily (TNFSF) includes 19 
ligands and the TNF receptor superfamily (TNFRSF) contains 29 receptors. 
Together the TNFSF and TNFRSF superfamilies regulate the survival, death, 
proliferation and differentiation of numerous cell types. Although TNFSF 
members were first identified in the immune system, they are also expressed in 
lymphoid, ectodermal, mammary and neuronal tissues187. The main biological 
activities of TNFSF members are to induce and regulate the protective immune 
response following infection, to induce inflammation and to regulate the 
organogenesis and maintenance of secondary lymphoid organs. Members of 
the TNFSF have been associated with a number of different pathological 
conditions including: cancer, autoimmune diseases, neuropathologies, 
cardiovascular diseases and metabolic disorders188,189. 
 
1.3.1. TNF ligands 
Ligands of the TNFSF are predominantly synthesised as type II 
transmembrane proteins with amino-terminal intracellular domain and carboxy-
terminal extracellular domain. Two exceptions to this are TNF-β and the 
vascular endothelial cell growth inhibitor/TNF-like factor 1A (VEGI/TL1A) that 
are both secreted190 (Fig.8). 
Some transmembrane TNFSF ligands can also exist and function as 
soluble forms following release from the cell surface by proteolysis191,192. 
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Examples of TNFSF ligands that are cleaved from the plasma membrane 
include TNF-α and the receptor activator of NF-B ligand (RANKL), that are 
both cleaved by the protease ADAM (a disintegrin and metalloprotease 
domain), and Fas ligand (CD95L/FasL) that is cleaved by matrilysin. In addition, 
B-cell-activating factor (BAFF), ectodyplasin-A (EDA), TNF-like weak inducer of 
apoptosis (TWEAK) and a proliferation-inducing ligand (APRIL) are released 
from the plasma membrane by members of the furin protease family190. The 
solubilisation of some ligands is very important for their physiological function. 
For instance, a mutation in the furin gene that cleaves EDA from the plasma 
membrane is sufficient to cause the genetic disorder X-linked hypohidrotic 
ectodermal dysplasia (XLHED)191. Conversely, the robust cytotoxic activity of 
membrane bound FasL is dramatically reduced upon cleavage from the plasma 
membrane192. The transmembrane location of most TNFSF ligands suggests 
that they primarily act locally; however, soluble forms may allow these ligands to 
act on distant cellular targets187,190,193. 
 
Both soluble and transmembrane TNFSF proteins are active as self-
assembled, non-covalent trimers. The C-terminal domain of these proteins 
contains a “TNF homology domain” (THD) that consists of a 150 amino acid 
long sequence of aromatic and hydrophobic residues responsible for trimer 
assembly. Each monomer folds into anti-parallel β-pleated sheets with a 
“jellyroll” topology, which then interacts with other, folded monomers at 
hydrophobic interfaces193,194. The THD domains are responsible for the binding 
of trimeric ligands to their respective receptors. Therefore, each ligand complex 
has three binding sites to activate three receptors195. The external receptor 
binding surfaces of ligand trimers show little sequence similarity amongst 
TNFSF members, which is crucial for ensuring receptor selectivity. Despite this, 
some ligands and receptors can bind to more than one partner, which increases 
system complexity195 (Fig.8). There is a 25%-30% amino acid similarity of the 
THD sequence among TNFSF ligands that is confined to internal aromatic 
residues not involved in receptor binding. The amino acid conservation in the 
internal region of the THD allowed for the identification of additional ligands of 
the TNFSF, such as TNF-related apoptosis-inducing ligand (TRAIL), RANKL, 
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TL1A and BAFF. Among the TNFSF ligands, TRAIL and FasL have the highest 
homology in this domain190. TNFSF ligands also include; lymphotoxin β (LT-β), 
OX40L, CD40L, CD27L, CD30L, 4-1BBL, a cellular ligand for herpes virus entry 
mediator and lymphotoxin receptor (LIGHT) and glucocorticoid-induced TNFR 
family-related receptor ligand (GITRL)188. 
 
Typically, most TNFSF ligands are predominantly expressed in cells of 
the immune system, such as macrophages, natural killer (NK) cells, B cells, T 
cells, dendritic cells, monocytes and lymphoid cells190. Exceptions to this 
include EDA1 and EDA2, which are expressed in skin, and TL1A, which is 
expressed in endothelial cells. APRIL is also expressed by tumour cells and 
RANKL by osteoblasts188,190 (Table 1). 
 
 
 
Figure 8: The TNF superfamily. 
The 19 ligands are represented in blue and the 29 receptors showing the number of cysteine-
rich domains in grey and the death domains in red. The arrows correspond to the interactions 
between ligands and receptors. The question marks symbolize ligands yet to be discovered188. 
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1.3.2. TNF receptors  
 The 29 TNF receptors so far discovered share highly conserved 
cysteine-rich domains (CRDs) in their extracellular portion (Fig.8). The 
canonical motif of these domains comprises three disulfide bonds surrounding a 
core motif of CXXCXXC, an arrangement that creates an elongated molecule. 
The number of CRDs amongst TNFRSF members is highly variable. For 
example, BAFF receptor (BAFFR) has only a single partial CRD whilst CD30 
has six CRDs196.   
TNF receptors are predominantly type I transmembrane proteins with a 
carboxy-terminal intracellular domain and an amino-terminal extracellular 
domains. Exceptions to this include B-cell maturation antigen (BCMA), 
transmembrane activator and cyclophilin ligand interactor (TACI), BAFFR and 
X-linked EDA receptor (XEDAR) which, because they lack a signal peptide 
sequence are termed type III transmembrane proteins190. Soluble TNF 
receptors have also been identified. These can either be generated by a 
proteolytic process, as is the case for CD27, CD30, CD40, TNFR1 and TNFR2, 
or by alternative splicing in the case of CD95 and 4-1BB190,193. These soluble 
receptors can modulate the binding of their ligands to transmembrane 
receptors, thereby regulating ligand-receptor signalling in specific cell 
environments190,193.  
  
 TNFRSF members can be sub-divided into three main groups according 
to the intracellular signalling cascades that they initiate and their modes of 
action188,190. The first group includes members that share a death domain in the 
cytoplasmic tail. This region has approximately 80 amino acids residues and the 
lack of this domain prevents TNFSF ligand induced apoptosis. The known death 
receptors are TNFR1, CD95, death receptor (DR3), DR4/TRAILR1, 
DR5/TRAILR2, DR6, EDAR and the low affinity p75NTR. The receptors of the 
second group contain one to five TNF-receptor associated factor (TRAF)-
interacting motifs (TIMs) in their cytoplasmic domain. Lastly, the third group is 
comprised of decoy receptors that do not have functional signalling domains 
and reduce cell signalling by sequestering TNFSF ligands. Members of this 
group include decoy receptor 3 (DcR3), DcR1/TRAIL-R3 and osteoprotegerin 
Chapter 1                                                                                                   General Introduction 
 
 
  33
(OPG). DcR1/TRAIL-R3 is anchored to the membrane by a covalently liked C-
terminal glycolipid and DcR3 and OPG are secreted as soluble proteins188,190. 
The first step for ligand induced TNFRSF signalling was thought to be 
ligand induced trimerization of receptors. However, it is now known that some 
members of the TNFRSF exist as pre-assembled oligomers on the cell surface 
due to actions of the pre-ligand assembly domain (PLAD), which is usually in 
the first CRD197,198. PLAD domains facilitate the binding to and recognition of 
the trimeric ligands (Fig.9).  
 
 
 
 
 
 
 
 
 
 
Figure 9: The pre-ligand assembly domain model. 
(A) The PLAD facilitates the ligand binding conferring a more stable configuration. (B) View from 
above: After ligand/receptor binding, ligands and receptors maintain a trimeric symmetry197. 
  
Although both TNFSF ligands and receptors share common domains 
between them, there is significant specificity in ligand-receptor interactions. The 
specificity of ligand-receptor interactions is due to differences in the size and 
location of the contact area between ligands and receptors, different 3D 
conformations of both receptors and ligands, alternative modes of interaction 
between cognate ligands and receptors, the great variety of residues involved in 
binding recognition sites and different orientations of the CRDs in relation to 
their ligands199. TNFSFRs are expressed in a variety of cell types including 
immune cells, endothelial cells, lung, colon, spleen, thymus, lymph nodes, 
osteoblasts, embryonic skin, transformed cells, brain and ganglia of the 
PNS177,178,188,190 (Table 1). 
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Table 1: Cellular location and expression of the TNFSF and TNFRSF members190.  
 
 
1.3.3. Intracellular signalling pathways downstream of TNFRSF activation 
 When stimulated by their respective ligand, TNFRSF members with a 
death domain recruit intracellular death domain-containing adaptors such as 
Fas associated death domain (FADD) and TNFR associated death domain 
(TRADD)200. These adaptors, in turn, trigger the activation of the executioner 
caspases, caspases 3, 6 and 7, thereby inducing apoptosis. Fas, DR4/TRAILR1 
and DR5/TRAILR2 directly interact with FADD while TNFR1 and DR3 directly 
interact with TRADD. After binding to its receptor, FasL promotes assembly of 
the death-inducing signalling complex (DISC) that includes FADD, TRADD and 
pro-caspase 8. DISC formation leads to cleavage of pro-caspase 8 to mature 
caspase 8, which in turn activates executor caspases, resulting in apoptosis201. 
The association of ligand bound TNFR1 with TRADD can have two outcomes, 
either apoptosis or the transcription of inflammation related genes. TRADD can 
associate with FADD and pro-caspase 8 to form the DISC and activate 
executioner caspases201. Alternatively, TRADD can recruit TRAF1, TRAF2 and 
the receptor-interacting protein (RIP) leading to the activation of JNK and 
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nuclear NF-B, thereby preventing apoptosis and initiating inflammatory 
responses188 (Fig.10). Similarly, TL1A can both induce apoptosis in tumour 
cells, via a caspase 3 dependent mechanism, and promote the proliferation of 
endothelial cells by activating the canonical NF-B and JNK signalling 
pathways202. The receptor for TL1A has since been identified as DR3, a death 
domain containing receptor188. Therefore, for TNFRSF members containing a 
death domain, the balance between the initiation of death promoting and non-
death promoting signalling pathways is determined by the relative expression 
levels of TNFSF ligands, receptors and receptor associated adaptor proteins, 
which are in turn dependent on the cell type and the extracellular environment 
of the cell188,203. 
 
The second group of TNFSF receptors contain TIMs in their cytoplasmic 
domain. After ligand-induced activation, these receptors recruit TRAF family 
members to the TIMs leading to the activation of several signalling pathways, 
such as the ERK, PI3K, p38 MAPK, JNK and NF-B pathways188. Once 
initiated, these signalling pathways regulate a number of processes including 
cell proliferation, differentiation and apoptosis. The TRAF family comprises six 
evolutionary conserved proteins that are characterized by a highly conserved 
TRAF domain. This domain mediates the binding of TRAFs to activated TNF 
receptors, regulates the formation of homo or heterodimers of TRAFs and 
modulates the interaction of TRAFs with downstream signalling molecules203,204.  
It is known that TRAF2, 5 and 6 mediate the activation of JNK and NF-B 
signalling pathways188. For example, the binding of BAFF to BAFFR promotes 
the survival, differentiation and maturation of B cells via activation of the non-
canonical NF-B pathway. Following ligand binding activated BAFFR binds 
TRAF3 that, by activating NF-B inducing kinase (NIK), results in the IKKα 
dependent phosphorylation of the p100 NF-B subunit. Phosphorylated p100 is 
partially degraded giving rise to the p52 NF-κB subunit that subsequently 
translocates to the nucleus, together with the RelB NF-B subunit, to regulate 
the transcription of survival promoting genes205. Ligand binding to TIM 
containing TNFSF receptors can also induce apoptosis. For example, the 
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TNFSF member LIGHT can induce death in some adenocarcinomas via 
activation of LTβR206. 
Decoy receptors do not have signalling motifs but instead compete with 
functional receptors for their cognate ligands, therefore modulating TNFRSF 
signalling in vivo187,190,203 (Fig.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: TNFRSF signalling pathways.  
Ligand bound CD95, DR4 or DR5 interact with FADD, which in turn activates the caspase 
cascade leading to apoptosis. The activation of DR6 can lead to either Grb2 mediated MAPK 
activation, TRADD mediated activation of AP1, p38 and NF-B signalling pathways or TRADD 
mediated initiation of apoptosis. TRADD also mediates signalling from activated TNFR1 and 
DR3 that can lead to survival and/or proliferation and/or the expression of inflammatory 
cytokines. Alternatively, the engagement of TRADD with ligand bound TNFR1 or DR3 can 
induce caspase-dependent apoptosis. TNFR2 activates TRAF2 directly. Lastly, other members 
of the TNFSF can trigger the NF-B signalling pathway through TRAF 6 (adapted188).   
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Some TNFSF ligands and their cognate receptors are capable of 
signalling in a bidirectional manner.  In addition to ligands initiating signalling 
from their receptors, the binding of soluble or transmembrane receptors to their 
membrane bound ligands and can also induce intracellular signalling from these 
ligands, a process that has been termed reverse signalling.  Reverse signalling 
was initially demonstrated for membrane bound CD40L on T cells207 and OX40L 
on B cells208. Soon after, CD30L was shown to be capable of reverse 
signalling209. The cross-linking of CD30L by a CD30-Fc fusion protein induced 
the production of IL-8 by freshly isolated neutrophils. Interestingly CD30L, but 
not CD30, is expressed on neutrophils ruling out autocrine CD30L/CD30 
signalling in neurotrophils209. 4-1BBL, also known as CD137L, has recently 
been shown to be capable of reverse signalling in the kidney210. CD137L is 
expressed on the surface of tubular epithelial cells within the kidney. Following 
ischemic kidney damage, NK cell expressed CD137 engages tubular cell 
CD137L resulting in the production of the chemokine receptor 2 ligands, CXCL1 
and CXCL2, by these cells. CXCL1 and CXCL2 induce neutrophil recruitment 
that in turn initiates a cascade of pro-inflammatory events that result in damage 
to tubular epithelial cells in an ischemia/reperfusion model of kidney damage210. 
The founding member of the TNFSF, TNF-α, can also reverse signal, a 
discovery that was first made in a mouse macrophage cell line211. Reverse 
signalling through transmembrane TNF-α has also been shown to confer 
resistance on human monocytes and macrophages to lipopolysaccharide 
induced apoptosis212. In contrast, activation of membrane bound TNF-α by 
soluble TNFR1 appears to induce the expression and release of TGF-β1 from 
human monocytes and secreted TGF-β1 then acts, in an autocrine manner, to 
promote monocyte apoptosis via elevated ERK1/2 and p38 MAPK signalling213. 
 
1.3.4. Physiological roles of the TNFSF 
As mentioned above, TNFSF members and their receptors are mainly 
involved in regulating the function of the immune system by modulating the 
survival, differentiation and proliferation of immune cells. Additionally, they are 
also implicated in the aetiology of a number of pathological conditions.  
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 The secondary lymphoid organs, comprising the spleen, lymph nodes, 
Peyer’s patches, tonsils, appendix and adenoids, are the principal locations for 
the generation of adaptive immune responses due to the presence of mature, 
but antigen naive, B and T lymphocytes and antigen-presenting cells. 
Interestingly, mice with a null mutation for LTβ or LTβR do not develop lymph 
nodes and have an abnormal spleen structure and defective humoral immune 
responses214. Furthermore, the deletion of RANKL or its receptor, RANK, also 
prevents the development of lymph nodes215,216. Besides LTβ and RANK, other 
members of the TNFSF and TNFRSF families, such as TNF-α, CD40 and 
OX40, are also required for the organogenesis and maintenance of lymphoid 
organs188,190. Additionally, an interaction between CD40 and CD40L has been 
shown to be required for the induction of B cell-mediated co-stimulatory activity 
for T cell activation and the development of T cell effector functions217. CD40L 
deficient mice are severely impaired in primary T-cell responses and 
immunoglobulin class switching, and T cells lacking CD40L fail to enter the cell 
cycle and clonally expand in vivo217. Similarly, an interaction between B cell 
expressed OX40L and OX40 on the surface of activated T cells is necessary for 
the differentiation of activated B cells, into high immunoglobulin-producing B 
cells, in vivo218. 
 Many TNFSF and TNFRSF members have been shown to play important 
roles in regulating haematopoiesis and controlling blood cell number. For 
example, APRIL, BAFF, BAFFR and TNF-α promote B cell proliferation, CD40 
and RANK activate dendritic cells, CD27 and OX40 co-stimulate T cells, OX40, 
CD27 and HVEM regulate the expression and survival of CD4+ and CD8+ T 
cells and LIGHT–HVEM signalling seems to play a role in T cell 
proliferation188,190. Once activated by antigen, T cells begin to express FasL 
which engages with Fas, expressed on the same or neighbouring T cells, to 
attenuate the immune response by initiating Fas associated death signalling219. 
Moreover, TRAIL can promote T cell apoptosis by inhibiting cell cycle 
progression220.  
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TNFSF and TNFRSF members are also important in regulating the 
innate immune response following microbial or viral infection, largely by 
initiating an inflammatory response. For example, mice with a null mutation in 
Tnf-α or Tnfr1 show a significant reduction in host immune defence after 
infection with Listeria monocytogenes, Mycobacterium tuberculosis, and 
Salmonella typhimurium221,222. TNF-α has been recognized as an important 
defensive molecule against Mycobacterium tuberculosis infection due to its 
ability to increase the phagocytic capacity of macrophages222. TNF-α also plays 
a central role in the recruitment of inflammatory cells and in the initiation of 
inflammatory processes by stimulating cytokine and cell adhesion molecule 
production221,222. Other members of the TNFSF and TNFRSF families have also 
been associated with regulating inflammatory responses. For example, TL1A 
and its receptor, DR3, have been implicated in promoting the production of IFN-
 in ulcerative colitis and Crohn’s disease223. In a murine collagen arthritis 
model, BAFF and APRIL play a role in mediating T cell immune responses224. 
RANKL ligand appears to promote inflammation, via the promotion of TNF-α 
and IL-1 expression, while its decoy receptor, OPG, has the opposite effect, an 
observation that might be beneficial in developing a treatment to ameliorate 
rheumatoid inflammation225.     
 
Although TNF-α was initially characterised as a cytokine with the 
potential to kill tumours, there is an astonishing amount of evidence that TNF-α 
mediates the proliferation, invasion and metastasis of tumour cells226. For 
example, Tnf-α and Tnfr1 KO mice are resistant to developing induced skin 
tumours compared to wild type mice227,228. Experimental lung and liver 
metastases are also attenuated in Tnfr1-/- mice compared to wild type mice226. It 
suggests that malignant cells and macrophages synthesise and release TNF-α 
in some cancers and that released TNF-α can promote tumour development by 
a number of mechanisms that include the induction of other pro-inflammatory 
cytokines resulting in a prolonged inflammatory response; direct damage to 
DNA as a result of increased telomerase expression and inducing the epithelial 
to mesenchymal transition of malignant cells and promotion of angiogenesis in 
tumours226. TNF-α, and other pro-inflammatory cytokines, initiate NF-B 
Chapter 1                                                                                                   General Introduction 
 
 
  40
signalling from their cognate receptors. Activation of the NF-B signalling 
pathway can lead to IKKβ mediated phosphorylation of the tumour suppressor 
TSC1 that inhibits its tumour suppressing activity229. Moreover, upregulation of 
NF-B signalling can also lead to increased expression of genes that promote 
invasion and metastasis, such as matrix metalloproteinase 9 (MMP-9), cyclo-
oxygenase 2 (COX2) and vascular endothelial growth factor (VEGF). NF-B 
signalling can also suppress apoptosis, which in turn favours 
tumourigenesis189,190,226.  In contrast to TNF-α, other members of the family 
have been explored due to their anti-tumour potential. For example, TRAIL has 
been shown to induce apoptosis in several transformed cell lines, but not in 
normal cells230.  
 
TNFSF and TNFRSF members have been implicated in the development 
of autoimmune diseases, diseases that are characterised by the immunogenic 
recognition of self-proteins that results in organ damage due to increased 
production of pathogenic inflammatory molecules and auto- antibodies231. Anti-
TNF-α therapy has been successful in reducing disease activity in rheumatoid 
arthritis232 and in treating skin lesions in psoriasis233. Curiously, elevated levels 
of BAFF are detected in the serum of patients with systemic lupus 
erythematosus, suggesting that anti-BAFF antibodies, or inhibitors of 
BAFF/BAFFR signalling, may present a therapeutic avenue for this condition234.  
TNF-α is produced in the blood and myocardium of patients that are 
suffering from chronic heart failure, facilitating the progression of disease. 
Therefore, new therapies have been developed to neutralize the damaging 
effects of TNF-α in patients with heart failure235. RANKL has an important role in 
modulating bone formation. RankL deficient mice display severe osteopetrosis, 
defects in tooth eruption and a complete lack of osteoclasts as a result of an 
inability of osteoblasts to support osteoclastogenesis216. In accordance with this, 
mice deficient for the RANKL decoy receptor, OPG, show reduced bone density 
and increased bone porosity that is reminiscent of osteoporosis236.  
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1.3.5. TNFSF in the nervous system  
Recently, some TNSF and TNFRSF members have been shown to play 
important roles in the developing PNS by either regulating neuronal survival or 
by modulating the extent of axonal growth and arborization, and hence target 
field innervation. For example, TNF-α and TNFR1 are co-expressed in cultured 
E16 mouse superior cervical ganglia (SCG) and trigeminal sensory neurons and 
blocking antibodies against either TNF-α or its receptor enhances the survival of 
SCG and trigeminal neurons cultured in the absence of NGF at this embryonic 
age237. In accordance with this, TNF-α reduces NGF-promoted survival of 
cultured E16 SCG and trigeminal neurons and these neurons show significantly 
greater survival in the absence of NGF in cultures established from Tnf-α 
deficient embryos compared to cultures established from wild type mice. In 
addition, the SCG and trigeminal ganglia of Tnf-α KO embryos contain more 
healthy neurons and less pyknotic neurons than their wild type counterparts. 
Together, this data suggests that TNF-α acts by an autocrine loop to modulate 
the NGF-promoted survival of developing mouse sensory and sympathetic 
neurons during the period of naturally occurring developmental cell death237.  
LIGHT has been shown to negatively regulate axonal growth and 
branching from cultured mouse nodose sensory neurons during the perinatal 
period by a mechanism that involves HVEM mediated inhibition of NF-B 
signalling177. Similarly, RANKL/RANK signalling has been shown to negatively 
regulate neurotrophin-promoted neurite outgrowth and branching from cultured 
postnatal mouse SCG, nodose and trigeminal neurons by a signalling process 
that involves the phosphorylation of residue serine536 (ser536) of the NF-B 
p65 subunit176. In contrast, GITRL-GITR signalling enhances the NGF-promoted 
elongation and branching of cultured postnatal mouse SCG neuron processes, 
over a narrow postnatal developmental window (P1 to P3), by activating 
ERK1/2 dependent signalling178. Importantly, Gitr null mutant neonatal mice 
display a significant reduction in the density of sympathetic target field 
innervation compared to wild type neonates178. Unlike TNF-α, neither 
LIGHT/HVEM, RANKL/RANK nor GITRL/GITR signalling regulate the survival 
of developing sensory or sympathetic neurons176-178. The expression of FN14 
mRNA, but not its ligand, TWEAK, is dramatically increased in adult mouse 
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dorsal root ganglion (DRG) neurons following sciatic nerve transection238. 
Although viral overexpression of FN14 in PC12 cells increases neurite 
outgrowth, the physiological significance of this is unclear, since overexpression 
of FN14 does not promote process outgrowth from cultured adult mouse DRG 
neurons238. Fas expression has been detected in neonatal mouse DRG 
neurons239. Cross linking of Fas with anti-Fas antibody increases the extent of 
NGF independent neurite outgrowth in explant and dissociated cultures of 
neonatal mouse DRG. The ability of Fas to promote neurite outgrowth from 
DRG neurons appears to depend on ERK activation. Interestingly, ligation of 
Fas improves functional repair after sciatic nerve lesion in adult mice and 
functional repair after sciatic nerve lesion is significantly impaired in Fas mutant 
mice compared to wild type mice239. 
 
Neuromodulatory roles for TNFSF and TNFRSF members have also 
been identified in the CNS. For example, FasL and its receptor are expressed in 
the hippocampus of embryonic and neonatal mice and FasL, or an activating 
anti-Fas antibody, increases the number of axonal and dendritic branches in 
4DIVs cultures of E15 mouse hippocampal neurons without affecting neuronal 
survival240. Importantly, neonatal mice deficient in functional Fas or FasL exhibit 
reduced dendritic branching in CA1 in vivo compared to normal mice240. 
Interestingly, as mentioned previously, TNF-α has the opposite effect to 
FasL/Fas signalling by negatively regulating the length and branching of 
hippocampal pyramidal neurons via a signalling mechanism involving RhoA166. 
The TRAIL receptor, DR5 is expressed in the developing CNS, particularly in 
the developing hippocampus, cerebellum and olfactory bulb241. DR5 expression 
appears to be highest in proliferating progenitor cells and, although still 
persisting in newborn neurons, DR5 expression decreases as development 
proceeds, thereby suggesting that DR5 may play a role in modulating 
proliferation and/or differentiation within the developing CNS241. TWEAK and its 
receptor, FN14 are expressed by microglia, astrocytes, neurons and endothelial 
cells within the adult rodent CNS242. It has been reported that TWEAK/FN14 
signalling increases neuronal death in the mouse middle cerebral artery 
occlusion (MCAO) model of stroke via activation of NF-B signalling243. 
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Conversely, enhanced TWEAK/FN14 signalling has been claimed to account for 
the ability of a preconditioning, sub-lethal hypoxic insult to ameliorate neuronal 
death following MCAO in mice244. TWEAK/FN14 signalling also promotes the 
expression of pro-inflammatory cytokines and matrix metalloproteinases within 
the CNS and neutralization of TWEAK or FN14 has shown therapeutic potential 
in rodent models of ischemia and multiple sclerosis242. 
 
Whilst certain TNFSF and TNSFR members have been shown to 
regulate some aspects of neuronal development in the developing PNS and 
CNS, and others appear to modulate neuronal function in the adult CNS under 
normal and pathophysiological conditions, putative roles for the many other 
members of these large protein families in the developing and adult nervous 
system remain to be investigated.  
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1.4. TGF-β superfamily  
TGF-β1 is the prototypic molecule of a superfamily with more than 50 
members characterised to date. In 1980, the “autocrine secretion” hypothesis 
tried to explain the mechanism by which a growth factor could cause the 
malignant transformation of cells. This hypothesis suggested that transformed 
cells could produce their own growth factor as well as the receptor for this 
transforming factor, thereby regulating their own proliferation, survival and 
malignant transformation without the need for an exogenous supply of growth 
factors245. “Transforming growth factor” was initially extracted from transformed 
cell lines and characterised by the ability to confer a “transformed” phenotype 
on rat kidney fibroblasts246,247. Later, scientists understood that the 
“transformed” phenotype reflected cell growth and not necessarily malignant 
transformation. Moreover, TGF-β was also purified from numerous normal 
tissues and further studies implicated this factor in promoting wound healing248 
and inhibiting cell growth249. It soon became apparent that the biological activity 
of TGF-β was multifunctional and it was involved in regulating a number of 
biological activities. The TGF-β superfamily is a wide-ranging group of cytokines 
involved in regulating proliferation, differentiation, apoptosis, extracellular matrix 
formation, hematopoiesis, angiogenesis, chemotaxis, immune and nervous 
system function. During embryogenesis TGF-β superfamily members are 
involved in pattern formation and tissue specification and in the adult they are 
involved in disease and tissue repair250. 
 
1.4.1. TGF-β superfamily Ligands 
The TGF-β superfamily has been grouped in subfamilies according to 
DNA sequence similarities (Fig.11). These groups include: TGF-βs, 
activins/inhibins, decapentaplegic (Dpp) and vegetal-1 (Vg1)-related (DVR) 
group (also known as bone morphogenetic proteins (BMPs)/growth and 
differentiation factors (GDFs)) and GDNF subfamily (the most distantly related 
group to TGF-βs). Furthermore, there are other more distantly related members, 
such as the inhibin α-chain and Mullerian inhibiting substance (MIS)250.  
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Figure 11: The TGF-β superfamily. 
Members are traditionally subdivided into TGF-β, activins/inhibins, DVR or bone morphogenetic 
proteins (BMPs)/growth and differentiation factors (GDFs) and the most distantly related group 
of GDNF family ligands251. 
 
The majority of TGF-β superfamily ligands are synthesized as dimeric 
pre-proproteins. The large precursor molecule comprises an amino-terminal 
signal peptide that targets the molecule to the secretory pathway, a prodomain 
of variable size responsible for correct protein folding and dimerization of 
subunits and a carboxy-terminal domain constituting the mature protein. Homo 
or hetero-dimerization of the C-terminal domain produces biologically active 
molecules252. Because dimerization of the C-terminal domain requires the 
prodomain, it occurs within the cell before cleavage of the precursor protein. 
The cleavage of the prodomain is mediated by proteases of the subtilisin-like 
proprotein convertase (SPC) family, such as furin, and this mechanism is 
required for the release of the mature and bioactive protein253,254. The cleavage 
occurs at a dibasic cleavage site (RXXR motif) immediately preceding the 
bioactive domain that then is released as a fragment of 110-140 amino 
acids252,255. However, there are few exceptions and variations of this 
mechanism. For example, the nodal precursor has been shown to bind to 
activin receptors and initiate signalling from them without being processed256. 
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TGF-β subfamily members are secreted as a large latent complex (LLC) in 
which their propeptide, or latency associated peptide (LAP), prevents the 
activity of the mature protein. Dissociation from the LAP requires the cleavage 
of the mature domain that consequently becomes biologically active257,258. Other 
exceptions are GDF-8 and GDF-11, which are capable of forming a latent 
complex with their cleavable prodomains259.  
 
Whereas the prodomain is usually poorly conserved among TGF-β 
superfamily members, the mature domain is highly conserved and contains 
characteristic features of the superfamily. A common feature is the cysteine 
knot motif that is also shared by other growth factors, such as NGF and the 
platelet-derived growth factor (PDGF), suggesting a common ancestor among 
these molecules260. The cysteine knot motif is formed by three intramolecular 
disulphide bonds among six strictly conserved cysteine residues (Fig.12). Two 
cysteine bonds build an eight-member ring structure through which the third 
cysteine bond passes. A seventh cysteine residue makes an intermolecular 
disulfide bond that link two monomers into a functional dimer. In addition, this 
disulfide bond provides additional stabilization of hydrophobic interactions 
responsible for maintaining the dimer250. Curiously, TGF-β superfamily 
members, GDF-3 and GDF-9 lack the seventh cysteine residue, suggesting a 
different form of interaction between their monomers261. Although homodimers 
are most commonly formed, heterodimers can also occur between monomers of 
different TGF-β superfamily members. For example, nodal ligand can inhibit 
BMP signalling by heterodimerizing with some BMP monomers262.  
 
 
 
 
 
 
 
 
 
Figure 12: The cysteine knot motif is 
conserved among members of the TGF-β 
superfamily:  (A) The mature domains share 
seven characteristic cysteine residues in 
each monomeric subunit. Three 
intramolecular disulphide bonds are formed 
between six cysteine residues. (B) Two 
cysteine bonds (CII—CV and CIII—CVI) form 
an eight-member ring structure through 
which the third cysteine bridge (CI—CIV) 
passes250. 
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1.4.2. TGF-β superfamily Receptors 
The receptors of the TGF-β superfamily are serine/threonine kinases that 
are divided into two subfamilies, type I and type II receptors. However, this 
feature is not shared by GDNF subfamily receptors, which consist of the Ret 
tyrosine kinase together with a GPI-linked alpha subunit263. Both type I and II 
receptors are glycoproteins of about 500 amino acids comprising a short 
extracellular N-terminal cysteine rich domain that is responsible for ligand 
binding, a transmembrane region and a highly conserved intracellular 
serine/threonine kinase domain that initiates signal transduction following ligand 
binding264.  Although both receptors have the capacity to bind ligands and 
initiate signal transduction, binding of ligand to either homodimeric receptor is 
not sufficient to activate signalling and, a functional interaction between type I 
and II receptors is necessary for signal transduction to occur. Pre-formed 
homodimers of type I receptors and type II receptors come together to form a 
heterotetrameric, active receptor complex. Although ligand binding brings both 
receptor types into close proximity, they do not interact directly with each 
other265-267. Type II receptor dimers are thought to be constitutively active and 
potentially could induce autophosphorylation of their own intracellular residues, 
however, signalling from type II receptors in the absence of type I receptors 
does not appear to occur268,269. Following ligand binding to the heterotetrameric 
receptor complex, type II receptors phosphorylate type I receptors at the GS 
domain, a conserved sequence upstream of the kinase domain that is rich in 
glycine and serine residues (SGSGSG). This sequence is conserved among all 
type I receptors, and its phosphorylation enables the activation of intracellular 
signalling pathways270.  
 
There are two possible mechanisms of ligand-receptor interactions 
amongst TGF-β superfamily members. TGF-βs and activins have a much 
higher affinity for type II receptors than type I receptors and first bind to 
homodimers of type II receptors, thereby allowing the subsequent incorporation 
of type I receptor homodimers into an active heterotetrameric receptor complex. 
These ligands cannot bind to isolated type I receptor homodimers271. TGF-β2, 
however, needs a heterotetrameric complex to be pre-formed to be able to bind 
Chapter 1                                                                                                   General Introduction 
 
 
  48
to its type II receptors and initiate intracellular signalling272.  Like TGF-βs and 
activins, BMP subfamily ligands also bind to type II receptors in the absence of 
type I receptors. However, high affinity binding of BMPs to the heterotetrameric 
receptor complex, and the subsequent initiation of signal transduction requires, 
cooperative binding between both type I and II receptors273.  
 
There are five type II receptors and seven type I receptors in mammals 
and different combinations of type I and type II receptors can form functional 
receptor complexes (Fig.13). Individual receptor complexes can bind different 
ligands and individual ligands can bind different receptor complexes, with the 
result that can be reflected in the differential signalling pathway that is 
activated271,272,274. For example, the type II receptors, activin receptor II (ActRII) 
and ActRIIB can interact with the type I receptors, activin receptor-like kinase 4 
and 7 (ALK-4 and ALK-7) to mediate activin signalling. ActRII and ActRIIB can 
also interact with the type I receptors, BMPR-Ia (ALK-3) and BMPR-Ib (ALK-6) 
to mediate BMP/GDF signalling. As mentioned above, heterodimeric TGF-β 
superfamily ligands provides another layer of complexity to the system271,272,274. 
 
A class of TGF-β superfamily co-receptors, sometimes called type III 
receptors, have also been characterised. Type III receptors are not capable of 
signal transduction, but can modulate the affinity of certain ligands to their 
signalling receptors. For example, the membrane-anchored proteoglycan, 
betaglycan binds TGF-βs and presents them to the TGF-β type II receptor  
enhances the responsiveness of cells expressing TβRII to TGF-β1 and lets 
them respond to TGF-β2, a TGF-β that otherwise cannot initiate signal 
transduction275. The betaglycan-related glycoprotein, endoglin can also facilitate 
the binding of TGF-β superfamily ligands to their receptors. However, endoglin 
cannot bind ligands in the absence of TGF-β superfamily receptors. For 
example, endoglin binds to TβRII, thereby allowing it to interact with TGF-β1 
and TGF-β3276. The interaction of endoglin with Activin A and BMP-7 is 
facilitated by prior association of endoglin with ActRII or ActRIIB277. Endoglin 
can also associate with the type I receptors, BMPR-Ia and BMPR-Ib allowing 
them to bind to BMP-2. Endoglin does not appear to increase the affinity of 
Chapter 1                                                                                                   General Introduction 
 
 
  49
ligands to their receptors and further studies are required to understand the role 
of this glycoprotein276,277.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Interactions of type II and type I receptors define downstream signalling 
mechanisms. The table shows known interactions of type II and type I transmembrane 
serine/threonine kinases and the respective R-Smads activated274.  
 
1.4.3. Cell Signalling 
1.4.3.1. The Smad pathway 
Smad proteins interact directly with activated type I receptors to initiate 
intracellular signalling following ligand binding to type I/type II receptor 
complexes. Smads were first identified in D.melanogaster and C.elegans and 
termed Mad and Sma, respectively. Vertebrate homologues of these proteins 
were termed Smads after their identification278,279. According to structural and 
functional properties, the Smad family can be subdivided in three groups. The 
first group are the receptor regulated Smads (R-Smads) which become 
phosphorylated on two serine residues at their C-terminal by specific type I 
receptors kinases following ligand binding. The R-Smads comprise Smad1, 
Smad2, Smad3, Smad5 and Smad8. The main Smad signalling pathways are 
initiated by the phosphorylation of Smad2 and Smad3 that associated with 
activin and TGF-β receptors280 and Smads1, 5 and 8 that specifically interact 
Chapter 1                                                                                                   General Introduction 
 
 
  50
with ALK-1, ALK-2, BMPR-Ia and BMPR-Ib274,281,282 (Fig.13). The 
phosphorylation of R-Smads allows them to form heteromeric complexes with 
the common mediator Smad or co-Smad, Smad4 that is the only member of the 
second group of Smads. Smad4 allows activated R-Smads to translocate to the 
nucleus where they regulate transcription280. Negative feedback of Smad 
signalling is mediated by the induction of the third group of Smads, the inhibitory 
Smads (I-Smads), which are Smad6 and Smad7. Smad6 and Smad7 are 
induced in response to TGF-β superfamily ligands in a Smad-dependent way 
and can inhibit the signalling activity of R-Smads at three different levels. I-
Smads can inhibit the phosphorylation of R-Smads by stable association with 
activated type I receptors283. Alternatively, I-Smads can compete with Smad4 
for binding to activated R-Smads284. Finally, I-Smads can interact with proteins 
that target TGF-β receptors for degradation285.  
 
Structurally, Smads have two conserved domains, the N-terminal Mad 
homology 1 (MH1) and the C-terminal MH2 domains, which are separated by a 
less conserved proline-rich linker region286. The MH1 domain regulates nuclear 
translocation, interaction with nuclear proteins, DNA binding and transcriptional 
activity. Smad4 and all R-Smads, except Smad2, share this domain, while the 
divergent I-Smads have only a weak sequence homology to other Smads in the 
MH1 domain. All 7 Smads share the MH2 domain that regulates Smad 
oligomerization, recognition by type I receptors and interaction with cytoplasmic 
and nuclear proteins286. In the nucleus, R-Smad complexes recruit 
transcriptional co-activators or co-repressors to regulate the transcription of 
target genes. The identity of target genes and the choice between 
transcriptional activation or repression depends on the cell type, the TGF-β 
receptor complex initially activated and the activating ligand. In addition, R-
Smads can integrate signals from other signal transduction pathways274 
(Fig.14). 
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1.4.3.1.1. Cross-talk between R-Smads and other signalling pathways 
Other kinase signalling pathways can regulate Smad signalling and such 
signalling cross-talk is important to control the growth and differentiation of 
many cell types. The Smad linker region can be phosphorylated by MAPKs, 
GSK-3β and cyclin-dependent kinases (CDKs), effectively integrating inputs 
from other signalling pathways274. For example, activated Ras can 
phosphorylate the linker regions of Smad2 and Smad3 in transformed epithelial 
cells, thereby preventing their nuclear localisation and antagonizing TGF-β 
signalling287. MAPK pathways can also enhance TGF-β signalling. For instance, 
JNK phosphorylates Smad3 in endothelial cells, facilitating its phosphorylation 
by type I receptors, its subsequent nuclear translocation and its transcriptional 
regulatory activity288.  
Smad signalling can also be modulated by changes in cytoplasmic Ca2+ 
levels. Activation of CaMKII by elevated levels of intracellular Ca2+ leads to 
phosphorylation of Smad2 preventing its accumulation into the nucleus289. 
Similarly, phosphorylation of Smad3 by PKC prevents Smad3 from binding to 
the promoters of its target genes, thereby abrogating the ability of TGF-β to 
inhibit the proliferation and promote the apoptosis of Mv1Lu cells290. 
 
Moreover, synergy has been identified between Notch and TGF-β 
dependent signalling pathways. Ligand binding induces the proteolytic cleavage 
of the transmembrane receptor Notch, resulting in the release of the Notch 
intracellular domain (NICD) into the cytoplasm. Cytoplasmic NICD is 
translocated to the nucleus where it binds to CSL (also known as RBP-Jk and 
CBF-1), a transcription factor that normally suppresses transcription. The 
NICD/CSL complex induces the transcription of target genes involved in cell 
fate, such as the basic helix-loop-helix (bHLH) family transcription factors Hes1 
and Hey1291. In the myogenic cell line, C2C12, BMP-4 initiates a signalling 
cascade that leads to Smad1 and NICD interaction, subsequent transcription of 
Hey1 and Hes1 and the inhibition of myogenic differentiation292. BMP-2 can also 
promote the transcription of Hey1 leading to the inhibition of osteoblast 
maturation293. 
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TGF-β and Wnt dependent signalling pathways can also interact in a 
synergistic manner to regulate biological processes. Wnt signalling promotes 
the stabilization and accumulation of β-catenin in the cytoplasm of cells 
resulting in increased nuclear translocation of β-catenin. Nuclear β-catenin is a 
co-activator of the transcription factors of the lymphoid enhancer binding factor 
1/T cell-specific factor (LEF1/TCF) family, which transcribe genes responsible 
for tissue specification during development. Treatment of several cell lines with 
TGF-β leads to the interaction of phosphorylated Smad3 with LEF1/TCF and 
enhanced transcription of LEF1/TCF target genes, independently of nuclear β-
catenin294.  
 
1.4.3.2. Non-Smad pathways 
In addition to the Smad pathway, other non-Smad signalling pathways 
have been proposed to be activated downstream of TGF-β superfamily 
serine/threonine kinase receptors (Fig.14). The addition of TGF-β1 to Mv1Lu 
cells induces a rapid and transient Smad-independent increase in JNK activity 
followed by a sustained increase in JNK activity that is dependent on Smad 
phosphorylation288. In addition, Smad-independent p38 MAPK activation is 
required for TGF-β induced apoptosis in mouse mammary gland epithelial 
cells295. JNK and p38 MAPK are thought to be activated by several upstream 
MAPK kinase kinases (MAPKKK), such as TGF-β activated kinase 1 (TAK1), 
that can be activated by both TGF-β and BMP-4296, and MEKK1274. However, 
further studies are necessary to fully characterise the interactions between 
TGF-β superfamily receptors and MAPK pathways.  
TGF-β1 treatment of PC-3U human prostate carcinoma cells induces the 
rapid formation of lamellipodia that is dependent upon the activation of the Rho 
GTPases, Cdc42 and RhoA in a Smad-independent manner297. Moreover, TGF-
β1 promotes accumulation of the monomeric GTPase, RhoB by antagonising its 
normal proteolytic destruction by the 26S proteasome. RhoB appears to be a 
negative regulator of TGF-β signal transduction, since it antagonises TGF-β 
mediated transcriptional activation298. Furthermore, TGF-β1 induced activation 
of PI3K/Akt signalling promotes the epithelial to mesenchymal transition of 
NMuMG mammary epithelial cells and the migration of 4T1 and EMT6 breast 
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tumour cells299. In addition, TGF-β1 ligation of the type I receptor ALK-5 leads to 
Smad-independent activation of protein phosphatase-2A (PP2A) which in turn 
dephosphorylates p70s6k kinase, thereby leading to G1 cell cycle arrest of 
EpH4 epithelial cells300. 
 
 
 
 
 
Figure 14: TGF-β superfamily receptor signalling through Smad and non-Smad 
dependent pathways. The TGF-β superfamily signals through R-Smads and non-Smad 
signalling pathways, such as TAK1/MEKK1, MAPK, RhoA and PP2A/p70S6K 274. 
 
1.4.4. Physiological roles of the TGF-β superfamily 
TGF-β superfamily members regulate many biological processes from 
tissue development to tissue homeostasis. Processes that TGF-β superfamily 
members modulate include DNA replication, cell differentiation, cell adhesion, 
extracellular matrix composition and remodelling.  
TGF-β superfamily members play crucial roles in the early development 
of mouse embryos. Mice that are deficient for functional BMP-4, Nodal, lefty-2, 
ALK-2, ALK-3, ALK-4, BMPR-II, Smad2 or Smad4, either fail to initiate 
gastrulation or have defects in mesoderm differentiation301-303. Bmpr-II KO 
embryos stop developing at around E9.5 before gastrulation is complete and 
have a similar phenotype to Alk-3 deficient embryos301. In addition, double null 
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mutants for Bmp-5 and Bmp-7 display deficits in chorio-allantoic fusion and 
abnormalities in heart, branchial arch, somite and forebrain development, 
leading to embryonic lethality304. In the developing mouse embryo, 
morphological asymmetry of the left-right axis starts to occur at around E8. The 
TGF-β superfamily members, lefty-1 and lefty-2 are expressed on the left side 
of developing mouse embryos and are involved in the formation of the left-right 
axis. In the absence of lefty-1, mouse embryos display positional defects in 
visceral organs302.  
 
Heart development is regulated by TGF-β superfamily members at 
multiple developmental stages. Bmp-6/Bmp-7 double null mutants die from 
cardiac insufficiency during embryonic development due to multiple defects in 
heart formation, such as abnormal valve morphogenesis and a delay in cardiac 
cushion (the precursor of mature valves and septa in the heart) f formation305. 
The use of a conditional KO strategy in mice has demonstrated that ALK-3 
plays a crucial role in the normal formation of cardiac cushions, septa and 
valves306. Moreover, heterozygous mutations in BMPR-II appear to underlie 
familial primary pulmonary hypertension307. TGF-β superfamily signalling also 
plays an important role in vascular development and angiogenesis, particularly 
in the differentiation of arteries and veins and the maintenance of vessel wall 
integrity. Transgenic mice lacking functional endoglin308 or ALK-1309 show 
deficits in angiogenesis, and mutations in these genes commonly occur in 
patients with hereditary hemorrhagic telangiectasia, a disease characterised by 
vascular malformations310. 
 
TGF-β superfamily members also regulate aspects of craniofacial 
development, in particular tooth and eye development. For example, blocking 
BMP-4 signalling with Noggin induces an incisor to molar transformation 
demonstrating that BMP-4 is a key factor in the regulation of odontogenic gene 
expression311. BMP-4 also plays a role in the development of the eye being a 
critical factor for lens development. On a mixed genetic background, 
approximately 30% of mice with a homozygous null mutation in the Bmp-4 gene 
survive until E10.5312. At E10.5, the lens placode containing cells that will give 
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rise to the lens is not formed in mutant mice, although it is present in wild type 
littermates. Explant culture of placode primordia from wild type mice leads to the 
in vitro formation of lens, retina and pigmented epithelium after 4 days, but 
these structure are absent from 4 day explant cultures of placode primordia 
established from Bmp-4 null embryos. Significantly, Exogenous BMP-4 ligand 
rescues lens induction in explant cultures of Bmp-4 deficient mice, defining a 
requirement for BMP-4 in lens induction312. 
 
 TGF-β superfamily members also regulate skeletal morphogenesis by 
participating in skeletal patterning and the differentiation and maintenance of 
chondrocytes, osteoblasts and osteoclasts. For example, TGF-β2 participates in 
many steps of skeletal morphogenesis. Tgf-β2 null mutant mice die almost 
immediately after birth due to collapsed airways in the lungs. E18.5 mutants 
display many skeletal abnormalities, such a reduction in the size of limbs, 
abnormal limb and rib morphology and a failure of the neural arches of the 
spinal column to fuse313. In addition, GDF-11 regulates segmental skeletal 
pattern along the anterior/posterior axis. Homozygous mutant mice for Gdf-11 
show an increased number of thoracic and lumbar vertebrae and ribs, and a 
posterior displacement of the hindlimbs314. The important roles that GDF-5 
plays in regulating skeletal patterning and morphogenesis will be discussed in 
detail in Chapter 5. 
   
Many TGF-β superfamily ligands, such as BMP-8b, BMP-2, GDF-9 and 
activins, have been shown regulate aspects of sexual differentiation, particularly 
germ cell and gonadal development258. In addition, TGF-β has been implicated 
in modulating tissue repair and inflammation. In an experimental rat model of 
wound healing, daily injection of TGF-β has been shown to increase fibroblast 
proliferation, promote the influx of mononuclear cells and enhance the formation 
of collagen, thereby accelerating wound healing248,315. 
Deregulation of TGF-β superfamily signalling can cause developmental 
abnormalities and directly lead to cardiovascular, fibrotic, reproductive and 
skeletal disorders303. Hereditary or sporadic mutations in genes encoding TGF-
β superfamily ligands or receptors can also result in oncogenesis316. For 
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example, Juvenile Polyposis syndrome (JPS) predisposes young individuals to 
gastrointestinal tract cancers. Germ-line mutations in Smad4, Alk-3 and 
endoglin genes have been identified in JPS patients. Moreover, TGF-β1 
polymorphisms or sporadic Tgf-βRII mutations appear to underlie breast, colon, 
lung, pancreatic and prostate cancers316. 
 
1.4.5. TGF-β superfamily in the nervous system 
Members of the TGF-β superfamily are widely expressed both in the 
developing and adult peripheral and central nervous systems, reflecting their 
essential functions in neuronal development, survival, morphogenesis and 
maintenance258. Importantly, an increasing amount of data has emerged to 
suggest that certain TGF-β superfamily members may potentially be 
neuroprotective against some neurological diseases. 
Some members of the TGF-β superfamily family play important roles in 
regulating the induction of neural tissue and the determination of neural 
phenotypes during embryogenesis. In vertebrates, the dorsal ectoderm of the 
embryo forms neural tissue following induction by factors secreted by the dorsal 
mesoderm. Dorsal mesoderm-derived Noggin has been shown to induce 
anterior neural tissue317 by suppressing the activity of epidermal inducer, BMP-
4318. TGF-β superfamily members can also regulate the fate of neural crest 
cells, determining whether they become PNS neurons, melanocytes or cranial 
skeletal elements. For instance, BMP-4 and BMP-7 induce the expression of 
the adrenergic marker enzyme, tyrosine hydroxylase in neural crest cell cultures 
reflecting the differentiation of sympathetic neurons319. Moreover, TGF-β1 
stimulates the proliferation of astrocytes320 and regulates oligodendrocyte 
differentiation321. Loss of function studies, using siRNA against Smad4, have 
shown that TGF-β/BMP signalling is required to regulate neuronal specification, 
pattern formation and progenitor cell proliferation within the developing chick 
dorsal neural tube. TGF-β/BMPs regulate progenitor cell proliferation indirectly 
by promoting the expression of members of the Wnt family that act as mitogens 
for neural progenitor cells322. The regulation of neural tube progenitor cell 
proliferation and subsequent progenitor differentiation appears to be dependent 
on the identity of the BMPR-I receptor that is expressed by progenitors323. 
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Mouse CNS progenitors initially express BMPR-Ia and respond to BMPs with 
enhanced proliferation. However, BMP induced activation of BMPR-Ia induces 
the expression of BMPR-Ib. When BMPR-Ib expression levels become high, 
proliferating progenitors respond to BMPs by ceasing proliferation. During the 
early embryonic period, mitotically arrested progenitors are removed by 
apoptosis, but as development proceeds the cessation of proliferation results in 
neuronal differentiation323.  
 
TGF-β3 potentiates the survival promoting effects of the neurotrophins, 
NT-3 and NT-4 on cultured E8 chick DRG neurons and a blocking antibody to 
TGF-β reduces NT-3 and NT-4 promoted survival of these neurons, suggesting 
that endogenous TGF-β3 normally acts in an autocrine/paracrine manner to 
enhance the actions of these neurotrophins on cultured chick DRG neurons324. 
GDNF, a divergent member of the TGF-β superfamily, is a well-established 
neurotrophic factor for developing PNS and CNS neurons in vitro and in vivo93. 
GDNF was initially characterised as a neurotrophic factor based on its ability to 
promote the survival and morphological differentiation of dopaminergic neurons 
in cultures established from rat embryonic midbrain325. Administration of GDNF 
prior to nigrostriatal lesion has been shown to be neuroprotective in a mouse 
MPTP lesion model of Parkinson’s disease, reducing the loss of substantia 
nigra dopaminergic neurons and ameliorating the reduction in dopaminergic 
innervation of the striatum. Moreover, the administration of GDNF following 
MPTP lesion promotes re-innervation of the striatum by nigral dopaminergic 
neurons, raising the prospect that GDNF may have therapeutic potential in 
Parkinson’s disease326. The neurotrophic effects of GDNF on developing 
sympathetic, sensory and dopaminergic midbrain neurons, at least in culture, 
appear to be dependent on a synergistic interaction between neuron-derived 
TGF-β and exogenous recombinant GDNF327. The GDNF subfamily of the TGF-
β superfamily includes neurturin and artemin, both of which have been shown to 
play important roles in regulating the development of enteric, sympathetic and 
parasympathetic autonomic neurons and some subgroups of sensory 
neurons93.  
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Several studies have shown that members of the TGF-β superfamily 
have an important role in axon guidance by providing neurons with chemotactic 
cues. For example, GDF-7 and BMP-7 are both expressed in the roof plate of 
the developing spinal cord and GDF-7 heterodimers act as a chemo-repellent to 
drive the initial ventral trajectory of commissural axons. In support of this, many 
commissural axons are misrouted in E11.5 Gdf-7/Bmp-7 double null mutant 
mouse embryos328. TGF-β superfamily members have also been shown to 
regulate neuritic process outgrowth. TGF-β1 and TGF-β2 promote neurite 
sprouting and enhance axon elongation in cultures of embryonic rat 
hippocampal neurons329. BMP-7 induces dendritogenesis in sympathetic, 
cortical and hippocampal neuron cultures330-332. In the case of cortical neurons, 
dendritogenesis is mediated in a Smad-independent manner by the binding of 
LIM kinase 1 (LIMK1) to the BMPR-II receptor. LIMK1 is a downstream effector 
of Rho GTPases that regulates actin dynamics by phosphorylating and 
inactivating cofilin, an actin depolymerizing factor333. The importance of LIMK1 
in regulating dendrite formation, spine morphology and synaptic plasticity has 
been demonstrated in Limk1 null mice, which display abnormal dendritic spines 
and enhanced LTP compared to wild type mice334.  
Several studies have suggested that members of the TGF-β superfamily 
may be neuroprotective following neuronal damage and may ameliorate the 
development of damage-associated neuropathology. For example, TGF-β1 
protects motor neurons from axotomy and glutamate induced apoptosis and can 
restore motor function in a mouse model of amyotrophic lateral sclerosis 
(ALS)335. Moreover, TGF-β1 administration before induction of focal ischemia in 
mice reduces lesion size and the extent of cell death, and TGF-β1 limits 
apoptosis in cultures of embryonic rat hippocampal neurons following trophic 
factor deprivation336. Perhaps more importantly, TGF-β1 ameliorates Aβ 
induced apoptosis in cultures of rat cortical neurons by a signalling mechanism 
that involves activation of the PI3K pathway337. More recently, TGF-β1 has been 
shown to protect cultured mouse hippocampal neurons against Aβ-induced 
apoptosis, in a similar manner to NGF, by inducing the expression of the 
transcription factor, Hes1175. 
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TGF-β family members regulate the development of many cell and tissue 
types and play important roles in disease modulation in the adult. TGF-β family 
members have also been shown to play vital roles in the developing and adult 
nervous system including regulating neurogenesis and gliogenesis, modulating 
neuritic process outgrowth, promoting the establishment of functional synaptic 
connections, protecting against neuronal trauma and the onset of neurological 
diseases. However, several members of the TGF-β superfamily have yet to be 
fully investigated to determine whether they have neuroregulatory and/or 
neurotrophic roles in the developing or adult nervous system, leaving important 
questions unanswered.  
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1.5. Aims  
1.5.1. Hypothesis 
In this project, it was hypothesised that APRIL and GDF-5, members of 
the TNF-α and TGF-β superfamilies, respectively, and their cognate receptors 
are expressed in developing hippocampal pyramidal neurons and that APRIL 
and GDF-5 dependent signalling regulate some aspects of hippocampal neuron 
development. The characterised expression patterns of APRIL, GDF-5 and their 
receptors suggested that APRIL may play a role in regulating axonal elongation 
and GDF-5 may play a role in regulating dendrite growth.  
 
1.5.2. Specific aims 
1. Characterise the expression of APRIL and GDF-5 in developing 
hippocampal neurons at the mRNA and protein levels. 
2. Determine the cellular location of APRIL, GDF-5 and their respective 
receptors in cultured hippocampal neurons and in the developing 
hippocampus. 
3. Evaluate the morphological changes of axons and dendrites in cultures 
of developing hippocampal neurons following exposure to recombinant 
APRIL and GDF-5. 
4. Determine the receptors by which the ligands exert their effects. 
5. Investigate the intracellular signalling pathways that transduce the 
morphological changes of APRIL and GDF-5 on hippocampal neurons.  
6. Validate the physiological relevance of in vitro findings using in vivo 
models.  
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2.1. Animal husbandry 
All animals in this study were handled and kept under conditions that 
respected the guidelines of the Home Office Animals (Scientific Procedures) 
Act, ASPA, 1986. Embryonic and postnatal CD1 wild type mice and transgenic 
strains were obtained from timed overnight matings. Breeding was confirmed by 
the presence of a vaginal plug. The fertilization day was considered as 
embryonic day one (E1) and the day of birth as postnatal day zero (P0).  
April and Alk-6 transgenic mice, were genotyped using conventional 
polymerase chain reaction (PCR) (see Appendix II). Gdf-5bp-J (Growth 
differentiation factor 5, brachypodism-Jackson), obtained from The Jackson 
Laboratory), which will be referred to as Gdf-5bp below and carry a spontaneous 
point mutation. Since homozygous Gdf-5bp mice have shorter limbs than wild 
type or heterozygous mice, they were identified by their phenotype. All animals 
were fed rodent global diet pellets (Harlan) and given water ad libitum. 
 
2.2. Cell culture 
 Cell culture was used to grow neurons under controlled conditions in 
order to study the effect of different recombinant ligands, mutated forms of 
proteins and chemical compounds on the normal physiology and biochemistry 
of neurons.  
 
2.2.1. Preparation of Tungsten needles  
 Tungsten needles were made from pieces of 0.5mm diameter, 5cm long 
tungsten wire held in needle holders (InterFocus). The tip of each wire was bent 
into a 90 angle and placed vertically in a solution of 2M NaOH. The tip was 
electrolytically sharpened with a 3-12V AC current passing though the NaOH 
solution. Sharpened needles were sterilized using 70% ethanol and a Bunsen 
burner flame before and after each use.  
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2.2.2. Preparation of culture dishes  
Neurons were cultured on a poly-L-lysine hydrobromide substratum. 
Four-well dishes or 35mm dishes (Greiner bio-one) were coated with 2ml of 
0.5mg/ml poly-L-lysine (Sigma-Aldrich) and incubated at 37C overnight (see 
Appendix II for preparation details of Poly-L-lysine solution). The dishes were 
then washed twice with autoclaved milli-Q water and left to dry in a laminar flow 
hood.  
 
2.2.3. Preparation of culture media 
 Hippocampal cultures were maintained in Neurobasal-A culture media 
containing 2% B-27 Supplement, 500M of Glutamax and 1% Penicillin-
Streptomycin (Life technologies). 
 
2.2.4. Hippocampal dissection 
 Dissection tools (InterFocus) were flamed in 70% ethanol before and 
after use. All dissections were performed in a sterile environment within a 
laminar flow hood that had been previously cleaned with 70% ethanol.  
Postnatal mice at P0, P5 and P10 were killed by decapitation, whilst 
pregnant females were sacrificed by cervical dislocation to obtain E18 embryos. 
In the latter case, the female abdomen was rinsed with 70% ethanol before 
removing the embryonic sac by laparotomy and placing it in a Petri dish 
containing PBS. Next, embryos were removed from the embryonic sac, washed 
in PBS and placed in a fresh Petri dish containing PBS. The correct stage of 
development was determined according to Theiler’s criteria338. 
Brains were gently harvested from E18 mouse embryos using a 
dissecting microscope (Nikon) and a fibre-optic light source (Schott). With the 
ventral side of the brain facing up, the cerebral hemispheres were separated by 
moving the forceps through the midline and making a saggital cut. Next, the 
meninges and the choroid plexus were carefully removed from both 
hemispheres. Each hemisphere was placed with its inner surface facing upward 
and the hippocampus was identified as a thicker portion lining the curved medial 
edge of the cortex. The hippocampus was separated from the cortex using 
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sharp forceps and, finally, tungsten needles were used to remove the fimbria 
and the remaining cortex339 (Fig.15).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Hippocampus dissection at E16.5. 
(a) The mouse brain was removed and (b) cut along the medial saggital plane (c). For each half 
(d) the meninges were removed and (e) the cortex clipped off the midbrain. (f) The 
hippocampus was identified on the inner surface of the forebrain (g) and dissected from the 
cortex. (h) Cortex (cx) and Hippocampus (hip). (i) The fimbria was removed (j) and 
hippocampus collected339.  
 
2.2.4.1. Hippocampal primary cultures 
 For each culture, up to 12 hippocampi were collected and placed into a 
15ml tube (Greiner bio-one) containing 1800l of 1X HBSS without Ca2+ and 
Mg2+ (Life technologies). For enzymatic dissociation of the hippocampi, trypsin 
(Worthington) (see Appendix II for details of stock solution) was added to the 
HBSS to give a final concentration of 1mg/ml. The mixture was next incubated 
in a 37°C water bath for 20min. To quench trypsin activity, trypsin inhibitor 
(Sigma-Aldrich) (see Appendix II for stock solution preparation) was added to a 
final concentration of 1mg/ml and the hippocampi were then mechanically 
dissociated into single cells by gentle pipetting through a 1ml tip. Finally, DNase 
I (Roche) (see Appendix II for stock solution) solution was gently mixed into the 
cell suspension, to a final concentration of 0.05mg/ml, to digest DNA liberated 
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from damaged cells and avoid clumping of tissue. Subsequently, the cell 
suspension was centrifuged for 10min at 700rpm to pellet cells. After careful 
removal of the supernatant, the cell pellet was gently resuspended in 1ml of 
hippocampal neuron complete culture medium.  
 To assess the number of viable cells in the cell suspension, 20l of the 
suspension was diluted in 20l of trypan blue solution (0.4%) (Sigma-Aldrich) 
and viable cells that excluded trypan blue were counted using a Neubauer 
hemacytometer. The number of cells plated onto Poly-L-lysine coated tissue 
culture dishes varied according to the purpose of individual experiments, and 
hence the type of culture dishes used (from 40,000 cells up to 500,000 cells).  
Up to 2ml of the cell suspension was plated in 35mm dishes, whereas only 55l 
of cell suspension was plated into each well of 4-well dishes. In the latter case, 
2ml of culture medium was added to 4-well dishes after allowing 2 hours for 
plated cells to attach to the substratum. 
 Cells were incubated at 37C, with 5% CO2, for 3 or 7DIVs according to 
the purpose of the experiment. Recombinant ligands or compounds were added 
after either 2DIVs or 6DIVs (Table 2). 
 
2.2.4.2. Explants in 3D Matrigel cultures 
 Explants in 3D Matrigel cultures were use to mimic in vivo conditions. 
Using the technique described above, 350m thick hippocampal sections were 
obtained using a tissue chopper. Next, the region of interest (for example CA1) 
was carefully isolated from each slice using tungsten needles.  
Matrigel (BD Biosciences) was kept on ice prior to use to avoid 
polymerization. 20l of Matrigel was pipetted into the bottom of each well of a 4-
well dish, which was subsequently placed in a 37°C incubator for 15min until the 
gel had become polymerized. After each hippocampal explant had been 
transferred onto a Matrigel base in the 4-well dishes, a further 20l of Matrigel 
was pipetted on top of it. Dishes were then incubated at 37°C for a further 
15min until the Matrigel covering the explants had become polymerized. Finally, 
2ml of complete neurobasal medium was added to each dish and the dishes 
were incubated at 37°C, in 5% CO2, until further use340. 
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2.2.5. Cell lines cultures  
 Frozen cell lines were obtained from a commercial collection (the 
American Type Culture Collection - ATCC, Manassas, VA, USA). The BHK-21 
cell line was originally derived from baby hamster kidneys while 293T cell line 
was derived from human embryonic kidney. Frozen cells were thawed on ice, 
resuspended in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% heat-inactivated foetal bovine serum (FBS), 2mM GlutaMAX I, 
100units/ml penicillin and 100μg/ml streptomycin (Life technologies) and 
cultured in Corning cell culture flasks (Thermo Scientific), at 37C, in an 
humidified atmosphere containing 5% CO2 and 20% O2. After 3DIVs, the culture 
medium was removed and replaced with 5ml of Trypsin-EDTA (Life 
technologies). After 5min incubation at 37C, the BHK-21 or 293T cells had 
become detached from the bottom of the tissue culture flask, allowing them to 
be aspirated into fresh culture medium. Following centrifugation of the cell 
suspension, for 5min at 1000rpm, the supernatant was removed from the cell 
pellet and the cells were resuspended in fresh culture medium and used to seed 
two new tissue culture flasks.  
The IM-9 cell line was derived from human B lymphoblasts, while the 
Jurkat cell line was derived from human acute T cell leukaemia.  In the case of 
both these non-adherent cell lines, frozen cells were thawed on ice, 
resuspended in RPMI-1640 medium (Life technologies) containing 10% FBS 
and 1% Penicillin-Streptomycin and cultured in Corning cell culture flasks, at 
37C, in an humidified atmosphere containing 5% CO2 and 20% O2. After 
3DIVs, the culture medium containing suspended cells was removed and 
centrifuged, for 5min at 1000rpm, to pellet the cells. The cell pellet was 
resuspended in fresh culture medium and used to seed two new tissue culture 
flasks.  
Cells from different cells lines were collected for RNA or protein 
extraction. In addition, 2x106 cells of each cell line were resuspended in 
complete growth medium and 5% DMSO and frozen at -80C. 
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Table 2: Recombinant ligands and compounds.  
Ligands/Compounds Company Concentration 
Recombinant APRIL (human) Enzo Life Sciences 10ng/ml, 100ng/ml, 1g/ml 
Recombinant APRIL (mouse) Enzo Life Sciences 10ng/ml, 100ng/ml, 1g/ml 
PD98059 Sigma-Aldrich 10M 
LY294002 Sigma-Aldrich 10M 
AKT1/2 kinase inhibitor Sigma-Aldrich 5M 
LPA (Oleoyl-L-α-lysophosphatidic acid 
sodium salt) 
Sigma-Aldrich 10M 
Recombinant GFD5/BMP-14 (mouse) R and D systems 10ng/ml, 100ng/ml, 1g/ml 
 
2.3. Transfection  
 Transfection is the process of introducing a nucleic acid into a cell. 
Hippocampal neurons have to be cultured at a very high density to support their 
survival, thereby confounding the morphological analysis of individual neurons 
within cultures. To circumvent this problem, transfection of cDNA expression 
constructs was used to direct the expression of fluorescent proteins to individual 
neurons, thus allowing the morphology of individual hippocampal neurons to be 
analysed with fluorescence microscopy.  
 
2.3.1. Transfection vectors 
The vector expressing copGFP (pCDH-CMV-MCS-EF1-copGFP) (Fig.16) 
was provided from System Bioscience (see Appendix II). Flag-hAPRIL-A88 
vector was kindly provided by Pascal Schneider341. The flag tagged hAPRIL 
sequence was cloned into the HindIII and EcoRI sites of the expression vector 
pCDNA3.1 (Life technologies). Following this, pCDH-CMV-hAPRIL-A88-EF1-
copGFP was generated by excising the flag tagged hAPRIL sequence from 
pCDNA3.1 and inserting it into the NheI and NotI sites of the pCDH-CMV-MCS-
EF1-copGFP vector. 
Vectors encoding murine (m) BCMA and mBCMA ∆C83 were kindly 
provided by Adrian T. Ting342. mBCMA and mBCMA ∆C83 sequences were 
cloned into the HindIII and NotI sites of the vector pCDNA3.1. pCDH-CMV-
mBCMA-EF1-copGFP and pCDH-CMV-mBCMA ∆C83-EF1-copGFP were 
made by excising the respective cDNA encoding sequences from pCDNA3.1 
and inserting them into the NheI and NotI sites of the vector pCDH-CMV-MCS-
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EF1-copGFP.  
 
 A constitutively active (CA), BMPR-Ib-Q203D, and dominant negative 
(DN), BMPR-Ib-Q203D/D265A, form of BMPR-Ib were kindly provided by Daniel 
J. Bernard343. The vector pCDH-CMV-MCS-EF1-copGFP was modified to allow 
the subcloning of these mutants BMPR-Ib cDNAs into it by creating additional 
restriction sites. Double stranded DNA was generated by annealing the 
following oligos: 5’-GCT AGC CGA GCT CGG ATC CGA ATT CCT CGA GGG 
GCC CTT CGA ATG AGC GGC CGC-3’ and 5’-GGC CGC TCA TTC GAA 
GGG CCC CTC GAG GAA TTC GGA TCC GAG CTC GG-3’. This double 
stranded DNA product, containing terminal NheI and NotI sites and internal 
EcoR1 and BstB1 sites, was subcloned into pCDH-CMV-MCS-EF1-copGFP, 
thereby generating pCDH-CMV-MCS-EF1-copGFP version 1. Following this, 
pCDH-CMV-BMPR-Ib-Q203D-EF1-copGFP and pCDH-CMV-BMPR-Ib-
Q203D/D265A-EF1-copGFP were made by inserting the respective BMPR-Ib 
cDNA encoding sequences into the EcoRI and BstBI sites of pCDH-CMV-MCS-
EF1-copGFP version 1. 
Vectors encoding pGFP-N1 BMPR-II-WT and pGFP-N1 BMPR-II-D485G 
(DN) were kindly provided by Nicholas W. Morrell344. The vector expressing 
EGFP (pEGFP-N1) was obtained from Clontech. pCDH-CMV-MCS-EF1-
copGFP was modified a second time, by creating additional restriction sites, to 
allow the cloning of the BMPR-II cDNAs into it. Double stranded DNA was 
generated by annealing the following oligos: 5’- CTA GAG CTA GCG AAT TCG 
AAT TTA AAT GGA TCC ATG AGC-3’ and 5’- GGC CGC TCA TGG ATC CAT 
TTA AAT TCG AAT TCG CTA GCT-3’. The double stranded DNA product, 
flanked by XbaI and NotI sites and internal EcoR1 and BamH1 sites, was 
subcloned into pCDH-CMV-MCS-EF1-copGFP, thereby generating pCDH-
CMV-MCS-EF1-copGFP version 2. Finally, pCDH-CMV-BMPR-II-WT-EF1-
copGFP and pCDH-CMV-BMPR-II D(485)G-EF1-copGFP were made by 
inserting the respective BMPR-II cDNA encoding sequences into the EcoRI and 
BamHI sites of pCDH-CMV-MCS-EF1-copGFP version 2. 
 
 The reporter plasmid pGL3-BRE-Luciferase was kindly provided by Xiao-
Fan Wang345. pGL3-BRE-Luciferase contains the BMP responsive elements of 
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the mouse Id1 gene cloned into the pGL3 firefly luciferase vector. Reporter 
plasmids pHes5-pGL3-Luc and pHes5SM-pGL3-Luc were kindly provided by 
Tetsuya Taga346. pHes5-pGL3-Luc contains a fragment of the Hes-5 promoter 
(nucleotides ±179 to +72) cloned into the pGL3 firefly luciferase vector. 
pHes5SM-pGL3-Luc was constructed by introducing mutations (taaatcgcc) into 
a Smad-binding site (SBS) (±161 to ±153: gcccgcgcc) of the Hes5 promoter in 
pHes5-pGL3-Luc .  
 
The vector pIRES-Hes6 was kindly provided by Phil Jones347. A Myc-
tagged form of Hes6 was generated by inserting the Hes6 cDNA encoding 
sequence from pIRES-Hes6 into the NcoI/StuI sites of pCS2 (addgene). pRK-
DPC4-deltaC-Flag, encoding a C-terminal truncated form of Smad4 (aa 1-511), 
pCS2-Flag-Smad6, encoding Smad6, and pCMV5-Smad7-HA, encoding 
Smad7, were obtained from addgene (Addgene plasmid 12628348, Addgene 
plasmid 14960284 and Addgene plasmid 11733349 respectively).  
 
Vector encoding WT form of Hes5 (pCLIG-Hes5) was kindly provided by 
Ryoichiro Kageyama350. To obtain pCDH-CMV-Hes5-EF1-copGFP, 
corresponding cDNA encoding sequence was subcloned into the EcoRI site of 
pCDH-CMV-MCS-EF1-copGFP. To obtain pCDH-CMV-t-Hes5-EF1-copGFP, 
the first 28 amino-terminal amino acids of the molecule, containing the DNA-
binding domain, were deleted by PCR, using pCLIG-hes5 as template and the 
following primers: 5’-AAA TCT AGA TGG AAC AAA AAC TTA TTT CTG AAG 
AAG ATC TGG ACC GCA TCA ACA GCA GCA T-3’ and 5’-ATT CGA ATT 
CGG TCG AGG CAT-3’. The resultant cDNA was subcloned into the XbaI and 
EcoRI sites of pCDH-CMV-MCS-EF1-copGFP.  
For shRNA experiments, the vector pGFP-VRS was obtained from 
Origene Technologies (Rockville, MD, USA). For pGFP-VRS shRNA Hes5 
construction, the targeting sequence 5’- GAC ACG CAG ATG AAG CTG CTT 
TAC CAC TT-3’ was inserted into BamHI/HindIII sites of pGFP-VRS. For the 
scramble construction, the 5’-GCA CTA CCA GAG CTA ACT CAG ATA GTA 
CT-3’ was used. 
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 Subcloning of cDNA fragments between vectors was performed using 
standard molecular biology procedures. After digestion with appropriate 
restriction enzymes, DNA fragments were separated by running them in a 1% 
low-melting point agarose gel (Sigma-Aldrich). Following electrophoretic 
separation, desired DNA fragments were cut from the gel under UV light and 
purified using a QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instructions. Vector DNA fragments were dephosphorylated by 
Alkaline Phosphotase (Roche) to promote efficient ligation with cDNA encoding 
fragment. Finally, DNA fragments were ligated using the Rapid DNA ligation kit 
(Roche).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Schematic representation of pCDH-CMV-MCS-EF1-copGFP dual-expression 
vector. Of interest: CMV promoter (constitutive human cytomegalovirus promoter), MCS- 
multiple cloning site for cloning the coding sequence of interest into the vector downstream of 
the CMV promoter, EF-1 promoter (constitutive elongation factor 1α promoter) drives the 
expression of copGFP (copepod green fluorescent protein) as a reporter for transfected cells 
(see Appendix II).  
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Table 3: Plasmid description.  
Plasmid Company Resistance Gene Sequence of interest 
pCDH-CMV-MCS-EF1-
copGFP 
SBI – System 
Biosciences 
Ampicillin _______________ 
pCDH-CMV-hAPRIL-
A88-EF1-copGFP 
see section 2.3.1. Ampicillin human APRIL 
pCDH-CMV-mBCMA-
EF1-copGFP 
see section 2.3.1. Ampicillin mouse BCMA 
 
pCDH-CMV-mBCMA 
∆C83-EF1-copGFP 
see section 2.3.1. Ampicillin mouse BCMA ∆C83 
(truncated mutant) 
pCDH-CMV-mBMPR-Ib-
QD-EF1-copGFP 
see section 2.3.1. Ampicillin mouse BMPR-Ib-QD 
(constitutively active) 
pCDH-CMV-m BMPR-
Ib-QD D265A-EF1-
copGFP 
see section 2.3.1. Ampicillin mouse BMPR-Ib-QD 
D265A 
(dominant negative) 
pCDH-CMV-BMPR-II 
WT-EF1-copGFP 
see section 2.3.1. Ampicillin BMPR-II WT 
pCDH-CMV-BMPR-II 
D(485)G -EF1-copGFP 
see section 2.3.1. Ampicillin BMPR-II D(485)G 
(dominant negative) 
pRK-DPC4-deltaC-Flag addgene Ampicillin DPC4 
CS2-Flag-Smad6 addgene Ampicillin Smad6 
pCMV5-Smad7-HA addgene Ampicillin Smad7 
pGL3-BRE-Luc Gift from Professor 
Xiao-Fan Wang 
Ampicillin BMP responsive 
element 
pHes5-pGL3-Luc Gift from Professor 
Tetsuya Taga 
Ampicillin Hes5 promoter 
pHes5SM-pGL3-Luc Gift from Professor 
Tetsuya Taga 
Ampicillin Smad binding site 
mutation  
phRL-TK-Luc Promega Ampicillin Renilla luciferase 
pCS2 addgene Ampicillin _______________ 
pIRES-Hes6 Gift from Professor 
Phil Jones  
Ampicillin Hes6 
pGFP-scramble-VRS  see section 2.3.1. Ampicillin scramble shRNA 
pGFP-shRNA-Hes5-
VRS 
see section 2.3.1. Ampicillin Hes5 shRNA 
pCDH-CMV-Hes5-EF1-
copGFP 
see section 2.3.1. Ampicillin Hes5 WT 
pCDH-CMV-t-Hes5-
EF1-copGFP 
see section 2.3.1. Ampicillin t-Hes5  
(truncated mutant) 
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2.3.2. Plasmid preparation 
2.3.2.1. Transformation 
E.coli JM109 Competent Cells (Promega) were thawed on ice and 100l 
of the bacteria were transferred into a 1.5ml microfuge tube. Sequentially, 50ng 
of plasmid or 20l of ligation mixture was added to the bacteria and, following 
gentle mixing, the bacteria were incubated on ice for 30min. After this, bacteria 
were heat-shocked, at 42C for 90sec, and then immediately incubated on ice 
for 5min. Following this incubation, 900l of LB (Luria Bertani) medium (Fisher 
scientific) without antibiotics was added to the mixture and incubated, at 37C 
for 1h, with agitation. LB agar (Fisher scientific) plates containing either 
100g/ml Ampicillin (Sigma-Aldrich) or 50g/ml Kanamycin (Sigma-Aldrich) 
were prepared previously. In accordance with the resistance gene of the 
plasmid, 100l of the mixture was spread onto a selective agar plate and the 
remainder was centrifuged, resuspended in 100µl of LB medium and spread 
onto a second agar plate. Agar plates were incubated overnight at 37C.  
 
2.3.2.2. Mini and Midi plasmid preps 
 The next day, 10 bacterial colonies were randomly selected from agar 
plates containing bacteria that had been transformed with the products of 
ligation reactions. Each colony was grown overnight, at 37C with agitation, in 
10ml of LB medium containing the appropriate antibiotic (LB selection medium). 
The following day, each overnight culture was centrifuged to pellet the bacteria 
and plasmid DNA was extracted from the bacterial pellet using the QIAprep 
Spin Miniprep Kit (Qiagen) according to the manufacture’s protocol. Each 
plasmid was sequenced and the vector with the correct DNA sequence was 
selected to be used in further experiments.  
 Colonies derived from bacteria transformed with either commercially 
obtained plasmids or sequenced verified newly constructed plasmids were 
incubated in 3ml of LB selection medium, at 37C with agitation, during the day. 
Then, 1ml of the culture was added to 200ml of LB selection medium and was 
incubated, at 37C with agitation, overnight. The next day, plasmid DNA was 
extracted from overnight bacterial cultures using the Hipure Plasmid filter 
Purification kit Midiprep (Life technologies) according to the manufacture’s 
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protocol. Briefly, cells were centrifuged, and the bacterial pellet was 
resuspended in Resuspension buffer containing 20mg/ml of RNase A. Next, 
cells were lysed under alkaline conditions (sodium hydroxide/SDS), followed 
by neutralization and precipitation of proteins and cellular debris with a high salt 
concentration buffer (potassium acetate). The mixture was then passed through 
a column that contained a membrane that selectively binds plasmid DNA. 
Plasmid DNA was eluted from the membrane in a low-salt buffer (sodium 
chloride and Tris-HCl), before being precipitated with isopropanol. Precipitated 
plasmid DNA was recovered by 30min of centrifugation, at 13,000 rpm and at 
4C. Following aspiration of the supernatant, the DNA pellet was washed for 
5min with 70% ethanol, left to air dry, and finally resuspended in 100µl of 
nuclease free water. The concentration and purity of the plasmid DNA was 
measured using a Nanodrop spectrophotometer (Thermo Scientific).  
 
2.3.3. Liposome-mediated transfection 
 For each 4-well dish to be transfected, 1.2g of plasmid was mixed with 
250l of Opti-MEM (Life technologies) in a microfuge tube. In a separate 
microfuge tube, 4l of Lipofectamine 2000 transfection reagent (Life 
technologies) was added to 250l of Opti-MEM. The two mixtures were 
incubated for 5min at room temperature (RT) before combining them, mixing, 
and incubating for 30min at RT. During this incubation, spheroid liposomes 
interact with DNA, encapsulating it and allowing its delivery to cells by 
endocytosis when in contact with a cell membrane.  
  Meanwhile, neurons cultured for either 2DIVs or 6DIVs were washed with 
pre-warmed Opti-MEM reduced serum medium and were added a final volume 
of 2ml of Opti-MEM. After, 500l of the lipofectamine mixture was added drop 
wise to each 4-well dish, and dishes were gently agitated, to allow a uniform 
distribution of the liposomes, before being incubated, for 3 hours, at 37C. After 
incubation, neurons were washed twice with neurobasal complete medium and 
incubated in this medium overnight, either with or without compounds or 
cytokines. The next day, neurons were fixed with 4% paraformaldehyde (PFA) 
(see Appendix II), for 30min at RT, washed twice in PBS and stored at 4C until 
further use.  
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2.3.4. Non-liposomal-mediated transfection 
 For each 4-well dish to be transfected, 1.2g of plasmid was mixed with 
120l of EC buffer or DNA condensation buffer followed by 3.2l of Enhancer. 
The mixture was vortexed for 1sec before being incubated for 5min at RT. This 
step allows Enhancer promoted DNA condensation. Next, 10l of Effectene 
Transfection Reagent (Qiagen) was added and the mixture was vortexed for 
10sec before being incubated for 20min at RT. Effectene reagent 
spontaneously forms micelle structures that coat the highly condensed DNA. 
Meanwhile, 400l of medium was removed from neurons that had been cultured 
for 6DIVs in 4-well dishes. Following the 20min RT incubation, 635l of 
neurobasal medium without antibiotics was added to the Effectene/micelle 
coated DNA mixture and 710l of the resultant mixture was added drop wise 
per 4-well dish. Following gently agitation, to allow a uniform distribution of the 
micelles, neurons were incubated for 3 hours at 37C. Finally, neurons were 
washed twice with neurobasal complete medium and incubated in this medium 
overnight, either with or without compounds or cytokines. The next day, neurons 
were fixed with 4% PFA, for 30min at RT, washed twice in PBS and stored at 
4C until further use.  
 
2.3.5. Imaging   
 Hippocampal neurons transfected with GFP-plasmids were imaged at 20x 
magnification with an inverted microscope (Zeiss) to analyze axonal length. 
Neurons transfected with GFP-plasmids to analyze dendritic outgrowth were 
imaged with a 63x water immersion objective of a confocal microscope (Zeiss). 
Explants were imaged at 10x magnification using a confocal microscope. 
 
2.4. Luciferase assays 
Luciferase assays were carried out using the Dual-Luciferase® Reporter 
Assay kit (Promega). Briefly, a 12-well plate was seeded with 200,000 cells/well 
and transfected after 6DIVs with 1.25ug of the firefly luciferase reporter plasmid 
and 125ng of the control renilla luciferase reporter plasmid, phRL-TKluc. 
Following transfection, the neurons in some wells were incubated with 100ng/ml 
of GDF-5 for 16h, whereas control wells contained no GDF-5. At 7DIVs the 
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plate was washed with 1X PBS followed by the addition of 100µl of 1X passive 
lysis buffer to each well. The plate was placed on an orbital shaker, for 15min at 
RT, to allow cell lysis. Cell lysates were centrifuged, to remove debris, and the 
supernatant was collected and maintained on ice. Finally, a GloMax® 20/20 
manual luminometer (Promega) was used to measure luciferase activity in the 
lysates. For each sample, 20µl of lysate was mixed with 100µl of LAR II reagent 
prior to measuring firefly luciferase activity. Then, 100µl of Stop and Glo reagent 
was added to the mixture and the renilla luciferase activity was measured. 
 
2.5. Quantification of neurite outgrowth  
Hippocampal neurons were transfected with GFP-plasmids at 2DIVs or 
6DIVs and fixed, with 4% PFA for 20min, at 3DIVs and 7DIVs respectively. 
Next, 50 images were randomly taken per condition using the 20x objective of 
an inverted fluorescent microscope (Zeiss) for axonal analysis and a 63x water 
immersion objective of a confocal microscope (Zeiss) for dendritic analysis. 
Axonal length was measured using ImageJ software and dendritic outgrowth 
and complexity was analysed with Adobe Photoshop software. Briefly, a 50μm 
radius was projected from the cell soma of a transfected neuron. The dendrite 
length was expressed as the percentage of the ratio between the number of 
dendrites longer than 50μm and the total number of dendrites.  
To analyse dendrite outgrowth in Golgi preparations, approximately 50 
neurons were randomly imaged, using a 2x objective, by bright light microscopy 
(Zeiss) and analysed by Sholl simplified method. Briefly, a simple Matlab script 
takes in account the relative position of terminal and branching points relative to 
the cell soma351. 
 
2.6. Quantification of hippocampal area and neuron survival  
Serial 5m frozen sections from P10 Gdf5bp-J and C57/Black6 mice were 
stained with MAP-2 and nuclear marker 4',6-diamidino-2-phenylindole (DAPI) as 
described in sections 2.9.3. and 2.9.3.1. The hippocampal, CA fields and DG 
areas were obtained through ImageJ software. To calculate the cell number per 
CA field, 40x amplification images were obtain for each field, and cells stained 
with DAPI and positive for MAP-2 were counted, using ImageJ Cell Counter 
Plugin, within an area of 20,000m2. 
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2.7. Reverse transcription 
2.7.1. Principle  
 The reverse transcriptase-polymerase chain reaction (RT-PCR) is a rapid 
and sensitive method for analysing gene expression that combines the 
production of a single-stranded complementary DNA copy (cDNA) of the RNA 
through the reverse transcriptase with PCR amplification of the cDNA. 
 cDNA can be synthesized using random hexamers, oligo dT or target 
specific primers. Random primers hybridize in multiple origins along the RNA 
template allowing the enzyme reverse transcriptase to attach, generating 
multiple single stranded cDNA molecules. This enzyme is also a DNA-
dependent DNA-polymerase therefore can synthesize a second strand of cDNA 
using the first cDNA molecule as a template after degrading the original mRNA 
with its RNaseH activity (Fig.17).  
 
 
 
Figure 17: Reverse Transcription.  
Random primers bind to mRNA allowing the reverse transcriptase to synthesize the 1st cDNA 
strand.  After, the enzyme can produce a second strand of cDNA using the first cDNA molecule 
as a template. 
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2.7.2. Total RNA extraction 
 RNA from cells or tissue samples was extracted using the RNeasy Mini 
kit (Qiagen) and the RNeasy Lipid Tissue Mini kit (Qiagen), respectively. Briefly, 
cells or tissue were homogenized in RLT buffer containing 1% -
mercaptoethanol. One volume of 70% ethanol was added to each sample and 
mixed by pipetting up and down several times. Up to 700l of the sample was 
transferred to an RNeasy spin column placed in a 2ml collection tube (both 
provided by the kit). The RNeasy columns contain a nucleic acid binding 
membrane that preferentially binds RNA as opposed to DNA. The columns 
were centrifuged at 13,000rpm for 15sec and the flow-through discarded. Next, 
80µl of DNaseI, in DNaseI reaction buffer, (Qiagen) was added to the nucleic 
acid binding membrane of the columns and the columns were incubated for 
15min at RT. Following this, columns were washed sequentially, by 
centrifugation, with 350µl of buffer RW1 and 500µl of buffer RPE. After a 
second wash with buffer RPE, RNA was eluted from the columns by the 
addition of 50-100µl of RNase-free water followed by centrifugation, at 
13,000rpm for 1min. RNA was quantified as described below and stored at           
-80C until further use. 
 
2.7.3. RNA quantification 
 After purification, the RNA samples were kept on ice whilst the 
concentration of RNA and its purity were measured using a Nanodrop ND-1000 
Spectrophotometer (LabTech international). The Nanodrop measures the RNA 
concentration (ng/ml) per 1l of sample and calculates the 260/280nm ratio. If 
this ratio is between 1.8 and 2.0 this suggests that the RNA is free from protein 
contamination. Samples outside this interval were discarded.  
 
2.7.4. cDNA synthesis  
 Total extracted RNA (400ng-1g) was reverse transcribed using the 
Affinity Script Multiple temperature Reverse Transcriptase kit (Agilent 
Technologies). Briefly, for a 40l reaction, 26.4l of RNA (of a defined quantity) 
was mixed with 2l of 10mM Random Hexamer Primers (Fermentas), 4l of 
Affinity script 10x Buffer, 4l of 100mM DTT, 1.6l of 100mM of dNTPs (Roche) 
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and 2l of Reverse Transcriptase. The mixture was incubated in a thermocycler 
for 90min at 42oC. Negative controls (reaction mix with RNase-free water 
instead of RNA) were also performed. Samples were stored at -20oC until 
further use. 
 
2.8. Real-time PCR 
2.8.1. Principle 
 The Polymerase Chain Reaction (PCR), invented by Kary Mullis in 1983, 
entails the logarithmic amplification of a specific DNA sequence in vitro. The 
starting template of a PCR reaction is either DNA or cDNA from reverse 
transcribed RNA. PCR is a sensitive and specific method that can discriminate 
between closely related mRNAs.  
 To amplify the target DNA sequence it is necessary to perform multiple 
cycles of 3 defined steps at different temperatures: denaturation (separation of 
double stranded DNA into single strands), primer annealing and primer 
extension (Fig.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Polymerase Chain Reaction. 
Taq polymerase allows extension of primers during repeated cycles of heat denaturation, primer 
annealing and primer extension. 
Chapter 2                                                                                                  Material and Methods 
 
  79
PCR starts with a 95oC denaturation step. The high temperature induces 
the separation of complementary DNA strands by disrupting the hydrogen 
bonds holding them together (Step 1: Denaturation). Next, cooling the 
temperature of the PCR reaction mix to 49-60oC allows sequence specific 
primers to anneal to the single stranded DNA template (Step 2: Annealing). The 
annealing temperature (Ta) is usually 5-10oC bellow the melting temperature 
(Tm) of the primer. Specific primers anneal to complementary sequences on the 
template strand, thereby defining the DNA fragment that is going to be amplified 
by the PCR process. The annealing of primers to the template allows a 
thermostable DNA Polymerase to attach to its 3’ end and, by increasing the 
temperature to 72oC, a copy of the DNA template is made, synthesizing new 
DNA in a 5’ to 3’ direction (Step 3: Extension) (Fig.18).  
 PCR is an exponential process, since newly generated double stranded 
DNA serves as a template for the next amplification cycle. Consequently, there 
is an exponential increase of copies of the target DNA template throughout 
time. Both original DNA strands serve as a template for synthesis of 
complementary strands. Therefore, if the reaction starts with 1 DNA template 
molecule, after the first cycle there will be 2 template copies, then after the next 
cycle 4 and after the third cycle 8. The degree of amplification of specific target 
DNA molecules can be simplified to 2n where n is the number of cycles. After 
the target sequence has been amplified for between 20 to 40 cycles, depending 
on the original number of target template copies, it is possible to visualize the 
targeted PCR product on an ethidium bromide stained gel under UV light. 
Products appear as a single band with the size of the amplified sequence.  
 
 In Real-time PCR or quantitative-PCR (Q-PCR), the amplification of the 
target DNA is quantified whilst the PCR reaction is running by employing 
fluorescent detection methods. The fluorescence accumulation during 
thermocycling is directly proportional and reflects the amount of target DNA 
product present after each cycle. Real-time PCR uses the exponential phase of 
the PCR reaction for quantification. Quantitative analysis is based on the cycle 
number where accumulated fluorescence increases above a threshold level (Ct 
value) that is itself determined by the point where the accumulation of 
fluorescent PCR products at successive cycles becomes exponential. The lower 
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the Ct value of a sample is, the higher the number of copies of target 
DNA/cDNA that were present before PCR amplification. Figure 19 shows a 
representative amplification plot of a real-time PCR reaction.  
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Real-time PCR Amplification Plot on a Stratagene Mx3000P Thermocycler. 
Amplification plot of five-fold serially diluted cDNA using the SYBR Green fluorescence 
detection method. 
 
In this thesis, two different fluorescence detection methods were used to 
quantify PCR products: SYBR Green and Taqman probes.  
 SYBR Green is an intercalating dye that fluoresces once bound to 
double-stranded DNA. The amount of dye incorporated, and hence the level of 
fluorescence, is proportional to the amount of amplified product. However, this 
dye can bind to both specific target DNA amplification products and non-specific 
PCR products. Non-specific PCR products are generated either as a result of 
PCR primers binding to incorrect templates or due to self-amplification of 
primers (primer artefacts). The generation of high levels of non-specific PCR 
products in SYBR Green real-time PCR can confound the accurate 
quantification of correct PCR products. To overcome this problem, the purity of 
generated PCR products can be measured by incorporating a melting curve 
analysis step after the final PCR cycle. In melting curve analysis, the PCR 
reaction is heated up from 65°C at a rate of 1 degree per minute whilst 
continuously monitoring the fluorescence level of each sample. At 65°C, the 
vast majority of DNA in each sample is double-stranded and the fluorescence 
level of the sample is high. As the temperature is slowly increased, there is little 
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change in fluorescence levels until the melting temperature of the PCR products 
is reached. At this point, the individual DNA strands of the PCR products 
separate, thereby leading to a rapid and dramatic loss of fluorescence. A plot of 
rate of change of fluorescence against temperature reveals the melting 
temperature of the PCR products (Fig.20). Each PCR product has a unique 
dissociation temperature that can be calculated based on its length and 
sequence. For a SYBR Green real-time PCR assay to be valid, each sample 
must display a single, defined melting peak of the correct temperature. The 
presence of a peak at the wrong temperature and/or an ill-defined peak with a 
shoulder indicates the presence of incorrect PCR products and signals that the 
data from the sample cannot be used.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Graph showing the melting temperature of GAPDH real-time PCR products on 
a Stratagene Mx3000P Thermocycler. The clean, well-defined peak at 79°C demonstrates 
that the real-time PCR products correspond to GAPDH and contain insignificant amounts of 
non-specific amplification products. 
 
The use of Taqman probes or double dye Probes entails using a third 
oligonucleotide, a fluorogenic probe, in the PCR reaction. A reporter fluorescent 
dye (ex: FAM or 6-carboxyfluorescein) is attached to the 5’ end of the probe and 
a quencher dye (ex: TAMRA or tetramethylrhodamine) on the 3’ end. While the 
probe is intact, FAM does not fluoresce as it passes its energy onto TAMRA by 
fluorescence resonance energy transfer (FRET). The sequence specific probe 
Chapter 2                                                                                                  Material and Methods 
 
  82
binds to the DNA template in the annealing step of the PCR, downstream from 
one of the primer sites. When Taq polymerase extends from the primers, it 
displaces the 5’ end of the probe which is subsequently degraded by the 5’-3’ 
exonuclease activity of the Taq polymerase. This process allows primer 
extension to continue to the end of the DNA template and separates the 
reporter dye from the quencher dye, leading to an irreversible increase in 
fluorescence from FAM (Fig.21). As in the case of SYBR Green, the increase in 
fluorescence intensity as the real-time PCR reaction progresses is proportional 
to the amount of amplified product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Taqman probe mechanism. 
Taq polymerase allows the release of the reporter dye from the quencher dye, following the 
cleavage of the dual-labeled probe due to 5´–3´nuclease activity of Taq DNA polymerase. 
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2.8.2. Design of primers and probes 
 Primers are single stranded oligonucleotides that serve as a starting 
point for DNA amplification. Primers are designed to have a sequence that is 
the reverse complement of the template region. Probes are also small 
oligonucleotides that hybridize within the region flanked by the Forward (Fwd) 
and Reverse (Rev) primers. A good design of primers and probes allows real-
time PCR to be a sensitive and specific method to quantify gene expression. 
There are several criteria that one must consider while designing small 
oligonucleotides to be used as primers and probes.  
 Primers and probes should have between 18-30bp length and the 
optimal Tm of primer and probes with template DNA is 55-60C. Furthermore, 
the difference in Tm between the Fwd and Rev primers should be 4C. Probes 
should have a Tm that is 8-10C higher than the primers. Given the fact GC 
base paring (Guanine and Cytosine) involves 3 hydrogen bonds a higher GC 
content requires more energy for disruption than AT base paring. Consequently, 
the GC content of primers and probes should be around 40-60%. It is also 
important to avoid base paring complementarities between the Fwd and Rev 
primers, or between the primers and the probe, to prevent primer/primer and 
primer/probe dimers that can severely reduce the efficiency of real-time PCR 
reactions. Base paring complementarities within individual primers and probes 
will lead to the formation of stable hairpins that will reduce the efficiency of the 
real-time PCR reaction, and therefore should be avoided. Interactions between 
primers and probes, and secondary structures within primers and probes, are 
measured by the -G (change in Gibbs free energy) parameter. The -G value 
should be high (close to zero) because low (more negative) -G values mean 
that it takes more energy to dissociate secondary structures and prevent 
primer/primer and primer/probe interactions.  
 The probe should be placed as close as possible to one of the primers 
without overlapping it and the Fwd and Rev primers should be either intron 
spanning or intron flanking, when possible, to prevent amplification of any 
contaminating genomic DNA. Furthermore, the amplicon lengths should be 
between 80 and 150bp. Finally, to determine that primers and probes are 
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unique and specific for their target DNA, they should be checked for off target 
interactions using BLAST software.  
 
 To design primers and probes for this thesis (Table 4 and 5), sequences 
for the various genes were obtained from the Ensembl database: 
http://www.ensembl.org/index.html. Sequences were then copied into Primer3 
software: http://frodo.wi.mit.edu/primer3/, and oligos that matched the criteria 
above were selected. Primers dimers, secondary structures and -G values 
were analyzed using the Oligo Analyzer software: 
http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/. Primers with -G 
value greater than -1 were selected. Finally, to check if designed primers and 
probes were unique and specific for their target DNA, each sequence was 
checked using a BLAST search: www.ncbi.nlm.nih.gov/BLAST/. 
 
Table 4. Syber Green QPCR amplification. Primer set for each gene and corresponding optimal 
annealing temperature.  
Gene Oligo Sequence (5’ to 3’) Annealing 
Temperature (C) 
GAPDH Forward  
Reverse 
TCCCACTCTTCCACCTTC 
CTGTAGCCGTATTCATTGTC 
51 
 
Table 5: Taqman probe real-time PCR amplification. Primer and probe set for each gene and 
corresponding optimal annealing temperature.  
Gene Oligo Sequence (5’ to 3’) Annealing 
Temperature (C) 
TNFSF13 
(APRIL) 
Forward 
Reverse 
Probe 
CTGTCCTTCCTAGATAATG 
CTAGTGACACTCTGACAC 
CACCAAATTCTCCTGAGGCT 
 
55 
TNFRSF17 
(BCMA) 
Forward 
Reverse 
Probe 
TGACCAGTTCAGTGAAAGG 
GGGTTCATCTTCCTCAGC 
CGTACACGGTGCTCTGGATCTTCTT
 
57 
TNFRSF13B 
(TACI) 
Forward 
Reverse 
Probe 
CTCAAGGAAATCCTGTGT 
GAATTTGCAGAAGTCTGTAC 
CGCTGGCTCCTCTGGCTG 
 
56 
GDF-5 
(BMP-14) 
Forward 
Reverse 
Probe 
TAATGAACTCTATGGACC 
GATGAAGAGGATGCTAAT 
TGAATCCACACCACCCACTTG 
 
51 
BMPR-Ib 
(Alk-6) 
Forward 
Reverse 
Probe 
AGTGTAATA AAGACCTCCA 
AACTACAGACAGTCACAG 
CCACTCTGCCTCCTCTCAAG 
 
51 
BMPR-II Forward 
Reverse 
Probe 
ACTAGAGGACTGGCTTAT 
CCAAAGTCACTGATAACAC 
CACAGAATTACCACGAGGAGA 
 
49 
SDHA Forward 
Reverse 
Probe 
GGAACACTCCAAAAACAG 
CCACAGCATCAAATTCAT 
CCTGCGGCTTTCACTTCTCT 
 
57 
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2.8.3. Real-time PCR procedure 
Standard curves were generated for every real-time PCR run by using 
serial five-fold dilutions of reverse transcribed RNA from spleen (for TNF- 
superfamily members) or from total adult brain (for all the other genes) (Fig.22). 
All values obtained were normalized to the geometric mean of the reference 
genes GAPDH and SDHA. Four separate samples were analyzed for each age. 
Real-time PCR was used to amplify 2.5μl of the reverse transcription 
reaction in a 25µl reaction. To amplify GAPDH FastStart Universal SYBR Green 
Master (Rox) (Roche) was used and the PCR was followed by melting curve 
analysis. For the amplification of other genes (Table 5) FastStart Universal 
Probe Master (Rox) (Roche) and Taqman probes were used. Primers and 
probes were acquired from Eurofins – MWG-Operon and used at a final 
concentration of 200nM each. Primers and probes for Hes1 and Hes5 were 
purchased from Applied Biosystems. 
PCR was performed using a Stratagene Mx3000P thermocycler with an 
initial step at 95oC for 10min, to activate the Taq polymerase, followed by 45 
cycles consisting of the denaturation step of 95oC for 1min, the annealing step 
at 49-60oC, depending on the gene, for 1min, and the extension step at 72oC for 
30sec. TaqMan probes and primers for Hes1 and Hes5 and the housekeeping 
gene ribosomal (r)RNA 18S were selected as the Assay-on-Demand gene 
expression products (Applied-Biosystem-Invitrogen Life Technologies, Paisley, 
UK). 
 
2.8.4. Data analysis  
The real-time PCR data were analysed using an absolute quantification 
assay. The value for each gene in each sample was determined by placing its 
Ct value on the standard curve (Fig.22). GAPDH and SDHA were used as 
reference genes (stable throughout the different samples) and the geometric 
mean of these genes was calculated and used as a normalisation factor. The 
raw values of each gene of interest were then standardised to the normalisation 
factor. 
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Figure 22: Standard curve. 
Example of a 5 times-serially diluted cDNA standard curve for GAPDH. Amplification was 
performed using SYBR Green reagents and a Stratagene Mx3000P thermocycler. 
 
2.9. Immunohistochemistry 
2.9.1. Principle   
Immunohistochemistry is a technique that allows the visualization of a 
specific protein or proteins in cells or tissues by using an antibody. The 
antibody-antigen complex is then observed using either chromogenic detection, 
in which an enzyme conjugated to the antibody cleaves a substrate to produce 
coloured deposits at the sites of antibody-antigen binding, or fluorescent 
detection, in which a fluorophore is conjugated to the antibody and can be 
visualized using fluorescence microscopy. 
 
2.9.2. Immunocytofluorescence of dissociated cultures 
 Dissociated cultures were prepared in 4-well dishes as described in 
section 2.2.4.1. Cultures at 7DIVs were fixed with 4% PFA, for 30min, at RT. 
After this, they were washed twice with PBS and permeabilised for 15min with 
0.5% Triton X-100/PBS. Cells were washed three times, for 5min each, with 
0.1% Triton X-100/PBS before being incubated for 1 hour with blocking buffer 
(10% Goat serum in 0.1% Triton X-100/PBS). Cells were then incubated with 
the primary antibody in blocking buffer (see dilution and incubation time in table 
7). Subsequently, cells were washed three times, incubated with the appropriate 
secondary antibodies in blocking buffer for 1h at RT (see dilution and incubation 
time in table 8), and then washed three times with PBS. In all cases, 
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counterstaining off the nuclei was performed using either DNA stain 4',6-
diamidino-2-phenylindole (DAPI, 1:10000, Invitrogen) or TOTO®-3 Iodide 
staining (1:10000 Invitrogen). Negative controls (no primary antibody staining) 
were also set up.   
 
2.9.3. Preparation of brain frozen sections  
 Mouse brains were collected at different ages (E18, P0, P5 and P10) and 
fixed in 4% PFA, at 4C (Table 6). Next, brains were cryo-protected in 30% 
sucrose, at 4°C, either overnight or until they sank. Each brain was then 
washed in water, dried and embedded in Tissue-Tek O.C.T. compound 
(Sakura) in a disposable mold (Polysciences, Inc.). The molds were placed in 
an ice cold 2-methylbutan/iso-Pentan (Fisher scientific) holder surrounded by 
dry ice, and were slowly frozen. Once frozen, the molds were stored at -80C. 
Frozen sections 15μm thick were obtained with a cryostat (Leica) and placed 
directly into X-tra adhesive slides (Leica). After the sections had been allowed 
to dry, they were stored at -80C until further use.  
 
       Table 6: Incubation time in 4% PFA for mouse brains. 
Age 4% PFA incubation time 
E18 1 hour 
P0 2 hours 
P5 4 hours 
P10 4 hours, after perfusion 
 
2.9.3.1. Immunohistofluoroscence staining of frozen sections 
 Frozen sections were incubated at RT with PBS for 5min, followed by 1 
hour incubation with blocking buffer (10% Goat serum/0.1% Triton X-100/PBS). 
Sections were then incubated, at 4°C overnight, with the primary antibody in 2% 
Goat serum/PBS (see antibody dilutions in table 7). To avoid sections drying 
out, they were covered by a piece of Parafilm during incubation. Subsequently, 
sections were washed three times in PBS, and incubated with the appropriate 
secondary antibodies, in 2% Goat serum/PBS, for 1 hour at RT (see antibody 
dilutions in table 8) covered with a piece of parafilm. Finally, sections were 
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washed three times with PBS and mounted with Hydromount (National 
Diagnosis).  
 
2.9.4. Golgi staining 
Modified Golgi-Cox impregnation of neurons was performed using the FD 
Rapid GolgiStain kit (FD NeuroTechnologies, Ellicott City,MD) according to the 
manufacturer’s instructions. Briefly, P10 mouse brains from Gdf-5 WT, Gdf-5 
Het and Gdf-5bp, mice were incubated in impregnation solution (solution A + 
solution B) for 2 weeks at RT in the dark.  Brains were transferred to solution C 
for 1 week at 4°C in the dark, and cut at 80m on the cryostat. Sections were 
mounted on polylisine-coated slides with solution C and dried before staining 
with silver nitrate solution (solution D + solution E). Sections were dehydrated in 
increasing ethanol solutions, cleared in xylene and mounted with DPX mounting 
medium (VWR Scientific, West Chester, PA). 
2.9.5. Imaging 
Cells and sections were imaged using an inverted or confocal 
microscope (Zeiss). In some experiments 10x, 20x or 40x objectives were used, 
whereas for in other experiments a 63x water immersion objective was used for 
confocal microscopy.  
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Table 7: Primary antibodies used in the study.  
Primary 
Antibody 
Antibody 
Type 
Company Concentration Incubation time 
GFP polyclonal abcam 1:500 4C overnight 
copGFP polyclonal evrogen 1:500 1 hour at RT 
TNFSF13 
(APRIL) 
polyclonal abcam 1:100 4C overnight 
TNFRSF17 
(BCMA) 
polyclonal abcam 1:100 4C overnight 
TNFRSF13B 
(TACI) 
polyclonal abcam 1:100 4C overnight 
TAU monoclonal abcam 1:500 4C overnight 
GDF-5 polyclonal abcam 1:100 4C overnight 
BMPR-Ib polyclonal abcam 1:100 4C overnight 
BMPR-II polyclonal abcam 1:100 4C overnight 
MAP2 (2a+2b) monoclonal Sigma 1:500 4C overnight 
-III Tubulin monoclonal R and D Systems 1:500 4C overnight 
 
Table 8: Secondary antibodies used in the study.  
Secondary 
Antibody 
Company Concentration Incubation time
Alexa Fluor 488 anti-mouse IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 488 anti-rabbit IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 488 anti-chicken IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 546 anti-mouse IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 546 anti-rabbit  IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 633 anti-mouse IgG Invitrogen 1:1000 1 hour at RT 
Alexa Fluor 633 anti-rabbit IgG Invitrogen 1:1000 1 hour at RT 
 
2.10. Western blotting          
2.10.1. Principle  
 Western blotting, or immunoblotting, is a widely used technique to detect 
and quantify specific proteins in a complex protein mixture.  This is achieved by 
using high-quality antibodies directed against the proteins of interest. Initially, 
proteins are separated by their size through SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Next, the negatively charged, separated proteins 
are transferred by electric current from the SDS-gel to a positively charged 
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nitrocellulose or polyvinylidene fluoride (PVDF) membrane. Finally, the 
transferred protein is detected on the membrane by using a specific primary 
antibody, followed by a secondary enzyme-conjugated antibody (e.g., 
horseradish peroxidase (HRP)) that is used to visualize the protein.  
 
2.10.2. Protein extraction  
 Neurons were plated in 24-well plate or 35mm dishes and incubated for 
3DIVs or 7DIVs. Two hours before neuron stimulation by trophic factors, the 
culture medium was replaced by Neurobasal A medium without additives. After 
neuron stimulation, the medium was removed before adding 30l of RIPA lysis 
buffer (see Appendix II) containing a 1:100 dilution of Protease Inhibitor Cocktail 
and 1mM of sodium orthovanadate (Sigma-Aldrich). Using a cell scraper, 
neurons were removed from each well, collected in a microfuge tube, and 
incubated on ice for 30min. Following this, insoluble debris was removed from 
the lysates by centrifuging the samples, for 5min at 12,000g, in a pre-cooled 
(4oC) centrifuge. Supernatants were stored at -80C in a microfuge tube whilst 
awaiting further analysis. 
 Tissue samples (spleen, midbrain, thymus and aorta) were minced and 
homogenized in 100l of complete RIPA lysis buffer using a pellet pestle motor 
(VWR international). The lysates were centrifuged, for 5min at 12,000g, in a 
pre-cooled (4oC) centrifuge and the supernatants were collected and stored on 
ice. Protein levels in the lysates were quantified, as described below, and used 
for Western blotting on the same day.  
 
2.10.3. Protein quantification  
 Protein was quantified using the Bradford protein assay. The Bradford 
assay is a colorimetric method based on an absorbance shift of the dye 
Coomassie Brilliant Blue G-250. Under acidic conditions, the dye is 
predominantly in the double-protonated, red cationic form (maximum 
absorbance at 470nm). However, when the dye binds to protein, it is converted 
to a stable non-protonated blue form (maximum absorbance at 595nm). A 
commercially available version of the Bradford assay, the Bio-Rad Protein 
Assay (Bio-Rad), was used to determine protein concentrations in cell lysates, 
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and BSA (Sigma-Aldrich) was used to generate a protein standard curve. Prior 
to performing the assay, a standard curve was prepared according to table 9 
and samples of lysate were diluted 1:100 in distilled water. The Bio-Rad Protein 
Assay reagent was diluted 5-fold in water to its working concentration. After, 
200l of each standard and each unknown sample were pipetted, in triplicate, 
into a 96-well plate. Following this, 50l of diluted Bio-Rad reagent was added 
to each well and, following thorough mixing, The absorbance of each sample 
was measured at 595nm using a microplate reader. The protein concentration 
in each diluted lysate sample was quantified using the standard curve. 
 
      Table 9: Standard curve dilutions for Bradford assay.  
Curve standards Concentration BSA (0.1mg/ml) distilled H2O 
1 0g/ml 0l 200l 
2 2g/ml 5l 195l 
3 4g/ml 10l 190l 
4 6g/ml 15l 185l 
5 8g/ml 20l 180l 
6 10g/ml 25l 175l 
 
2.10.4. Western blotting procedure 
 Protein extracts were boiled for 5min with Laemmli buffer (see Appendix 
II) to denature the proteins. Protein extracts were then allowed to cool on ice 
before equal amounts of each sample were loaded into the wells of a 10% SDS-
polyacrylamide mini gel with a 5% stacking gel (see Appendix II). A molecular 
weight marker was loaded into one well of each gel to confirm the molecular 
weights of unidentified proteins. The gels were assembled (Mini-Protean Tetra 
Cell (Bio Rad)), submerged in running buffer (see Appendix II) and run for 
20min at 80V, followed by 50min at 130V. Laemmli buffer also served as an 
indicator dye to observe the migration front that runs ahead of the proteins in 
the gel.  
 Following electrophoresis, proteins in the gel were electrophoretically 
transferred onto a PVDF membrane (Millipore), for 1 hour at 100V, whilst 
submerged in transfer buffer (see Appendix II). To confirm the transfer of 
proteins, the membrane was stained with Ponceau S (see Appendix II). 
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Subsequently, the membrane was washed with PBS containing 0.1% Tween 20 
(PBS-T) and incubated, for 1 hour at RT, with blocking solution (3% (w/v) BSA 
and 5% (w/v) milk (Bio Rad) in PBS-T) whilst being gently agitated on an orbital 
shaker. The membrane was then rinsed in PBS-T and incubated with the 
primary antibody in 3% BSA/PBS-T (see dilution and incubation time in table 
10). 
 Next, the membrane was washed three times, for 10min each, in PBS-T 
followed by 1 hour incubation, at RT with gentle agitation, on an orbital shaker 
with the appropriate peroxidase-linked secondary antibody that had been 
diluted in blocking solution (see dilution and incubation time in table 11). 
Membranes were washed after the incubation with secondary antibodies and 
protein complexes were visualized with Western blot Luminol Reagent (Santa 
Cruz). Membranes were incubated with luminol for 1min and then were put in 
contact with a chemiluminescence film (GE Helthcare) in an autoradiography 
cassette. The film was developed and fixed (Kodak GBX developing and fixing 
solution Sigma-Aldrich), and the membrane was then stripped of antibodies by 
15min incubation, at RT, with stripping buffer (Thermo Scientific). The 
membrane was then washed before being re-probed with antibodies to detect 
other proteins. 
 
2.10.5. Protein densitometry 
Chemiluminescence films were scanned and GelPro Analyzer software 
was used to perform densitometry and quantify the amount of protein in bands.  
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Table 10: Primary antibodies used in the study.  
Primary 
Antibody 
Antibody 
Type 
Company Concentration Incubation 
time 
TNFSF13 (APRIL) polyclonal abcam 1:500 4C overnight 
TNFRSF17 (BCMA) polyclonal abcam 1:500 4C overnight 
TNFRSF13B (TACI) polyclonal ProSci 
Incorporated 
1:400 4C overnight 
Phospho-p44/p42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
 
monoclonal 
 
Cell Signaling 
 
1:2000 
 
4C overnight 
p44/p42 MAPK 
(Erk1/2) 
monoclonal Cell Signaling 1:2000 4C overnight 
Phospho-Akt 
(Ser473) 
monoclonal Cell Signaling 1:1000 4C overnight 
Akt monoclonal Cell Signaling 1:1000 4C overnight 
Phospho-GSK-3/ 
(Ser21/9) 
polyclonal Cell Signaling 1:2000 4C overnight 
GSK-3 monoclonal BD Transduction 
Laboratories 
1:3000 4C overnight 
GDF-5 polyclonal abcam 1:50 4C overnight 
BMPR-Ib polyclonal Thermo Scientific 1:50 4C overnight 
BMPR-II polyclonal Thermo Scientific 1:50 4C overnight 
Phospho-Smad1 
(Ser463/465)/ 
Smad5(Ser463/465)/ 
Smad8(Ser426/428) 
 
polyclonal 
 
Cell Signaling 
 
1:1000 
 
4C overnight 
Smad1 polyclonal Cell Signaling 1:1000 4C overnight 
Hes5 polyclonal abcam 1:200 4C overnight 
copGFP polyclonal evrogen 1:500 1 hour at RT 
GAPDH polyclonal abcam 1:2500 1 hour at RT 
-actin polyclonal abcam 1:2500 4C overnight 
-III Tubulin monoclonal R and D systems 1:5000 1h at RT 
 
Table 11: Secondary antibodies used in the study.  
Secondary 
Antibody 
Company Concentration Incubation time 
anti-rabbit IgG HRP conjugate Promega 1:5000 1 hour at RT 
anti-mouse IgG HRP conjugate Promega 1:5000 1 hour at RT 
anti-chicken IgG HRP conjugate Abcam 1:2000 1 hour at RT 
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2.11. Elisa 
2.11.1. Principle  
The ELISA (Enzyme-Linked Immunosorbent Assay) assay is a specific 
and highly sensitive method for quantitative measurements of proteins, in 
particular cytokines. This assay is usually performed in a 96-well plate that is 
coated with a specific monoclonal antibody able to capture the cytokine of 
interest. A detection enzyme or other tag can be either linked directly to the 
primary antibody, or introduced through a secondary antibody that recognizes 
the primary antibody. Detection is accomplished by assessing the conjugated 
enzyme activity via incubation with a chromogenic substrate to produce a 
coloured product whose concentration can be measured on a plate reader.  
 
2.11.2. Sample collection 
 Hippocampal cultures were plated in 6 wells of a 96-well plate with a 
density of 75,000 cells per well. After 3DIVs, the supernatant was collected, 
centrifuged to remove debris, and stored at -80C until further use. Cells were 
collected in distilled water, centrifuged to remove debris, and stored at -80C 
until further use. 
 
2.11.3. Procedure 
Standards and samples (100l) were added to a microtiter plate pre-
coated with an antibody specific for APRIL (Uscn Life Science inc.). The plate 
was covered with a plate sealer and incubated, for 2 hours, at 37C. Next, the 
liquid was removed from each well and 100l of a biotin-conjugated antibody 
specific for APRIL was added to each well, followed by incubation, for 1 hour, at 
37C. After this, the plate was washed three times with wash solution and 100l 
of avidin conjugated to HRP was added to each well. Following incubation, for 
30min at 37C, the plate was washed three times with wash solution and 90l of 
TMB (3,3’5’5’-tetramethylbenzidine base) substrate solution was added to the 
wells. TMB was incubated with the avidin-HRP in the dark, for 25min at 37C, 
prior to the addition of 50l of Stop solution (a sulphuric acid solution) to 
terminate the colorimetric reaction. The absorbance of each well was 
immediately read in a plate reader at a wavelength of 450nm. The concentration 
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of APRIL in each well was then determined by comparison with a standard 
curve set up in the same plate with known concentrations of APRIL (0ng/ml, 
0.625ng/ml, 1.25ng/ml, 2.5ng/ml, 5ng/ml, 10ng/ml, 20ng/ml and 40ng/ml).  
 
2.12. Statistical analysis 
To determine whether or not data was normally distributed, the 
D´Agostino-Person test was used. To determine whether or not data had equal 
or different variances an F-test test was used. For normal distributed data, 
statistical significance was determined by the Student´s t test. If the data was 
not normally distributed, statistical significance was calculated using the Mann–
Whitney U test. The minimum level of significance accepted for all tests was 
p<0.01.  
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3.1. Introduction  
 APRIL is a type II membrane protein cytoplasmic domain, a hydrophobic 
transmembrane region and an extracellular domain of 201 amino acids. To be 
biologically active, APRIL needs to be processed by a furin convertase in the 
Golgi apparatus prior to its secretion352. Although APRIL was initially 
characterised as a new member of the TNFSF with tumourigenic activity, it has 
since been shown to be expressed predominantly in cells of the immune 
system, namely monocytes, macrophages, dendritic cells and T cells353-355. 
Several cytokines, such as IFNα, IFN and CD40L, can stimulate the production 
of APRIL by macrophages and dendritic cells355. APRIL is also expressed in 
osteoclasts356, various tumour derived cell lines, human thyroid and colorectal 
carcinomas and lymphomas353. The two APRIL receptors, BCMA and TACI, are 
predominantly expressed in mature B cells and activated T cells357,358. BCMA is 
also expressed by germinal centre B cells and plays a role in later stages of B 
cell maturation and survival359. Additionally, BCMA mRNA is detectable in 
malignant T cell lymphoma358 and myeloma360. Intriguingly, Bcma deficient mice 
do not display an abnormal B cell phenotype361, although they show impairment 
in the survival of bone marrow plasma cells compared to wild type mice362.  
Within the spleen and lymph nodes of mice, TACI is expressed by marginal 
zone B cells and activated B cells, but not by germinal centre B cells359. Taci 
deficient mice show normal B cell maturation and T-dependent antibody 
production, but the responses to T-independent type II antigens are impaired, 
with a significant reduction in secretion of both immunoglobulin M (IgM) and IgG 
compared to wild type mice363. Taci null mice also display increased B cell 
accumulation and splenomegaly364.  
 
 APRIL has been reported to be important in immune regulation by 
stimulating IgM production by peripheral blood B cells365, as well as enhancing 
the proliferation of primary B and T cells in vitro354. APRIL binding to BCMA also 
induces the expression of co-stimulatory molecules on splenic B cells, thereby 
enhancing their capacity to present antigen to T cells342. In vivo injection of 
recombinant APRIL results in splenomegaly due to the expansion of the B cell 
population and increased T cell activation354. Moreover, transgenic mice 
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specifically overexpressing APRIL in T cells, display enhanced T cell survival 
both in vitro and in vivo that correlates with elevated levels of Bcl-2366. Two 
groups have generated April deficient mice with different results. The first group 
reported normal lymphoid development and normal B and T cell proliferation367. 
Whilst the second group also reported normal B and T cell development and 
proliferation, their mice had an increased number of effector memory T cells 
and enlarged germinal centres368.  
 
 APRIL has been linked to the establishment and maintenance of 
autoimmune diseases. For example, patients with systemic lupus 
erythematosus (SLE) have higher levels of APRIL in their serum compared to 
healthy control patients369. This observation raises the possibility that APRIL 
could play a role in the aetiology of the disease. In support of this, an APRIL 
polymorphism, APRIL 67G, has been found to be correlated with susceptibility 
to SLE in humans370. Importantly, APRIL blockade in a SLE mouse model 
delays the development of the disease as well as ameliorating some of its 
symptoms371. APRIL and its related ligand, BAFF, have also been detected in 
the synovial fluid of patients with inflammatory arthritis372. These ligands are 
thought to be produced locally in the inflamed joints, thereby aiding the survival 
and/or expansion of B cells that produce pathogenic autoantibodies, and 
potentially promoting local T cell activation, actions that can both consequently 
promote joint destruction372. In a mouse model of rheumatoid arthritis, TACI-Fc 
treatment significantly reduces joint inflammation, bone and cartilage 
destruction and inhibits disease progression224. Increased levels of APRIL have 
also been found in the plasma and cerebrospinal fluid of patients with multiple 
sclerosis373. 
 
 In addition to potential roles in the aetiology of autoimmune disease, 
APRIL has emerged as a potent enhancer of tumourigenesis. APRIL is 
produced in large quantities within malignant tumours and stimulates the 
survival and proliferation of transformed cells353. For example, APRIL increases 
the proliferation of cultured glioblastoma cell lines, an effect that can be blocked 
by the addition of a soluble BCMA-Fc fusion protein to cultures374. In addition, 
multiple myeloma cell lines and primary myeloma cells from patients express 
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APRIL and its receptors, and exogenous APRIL can rescue myeloma cells lines 
from IL-6 withdrawal induced apoptosis and prevent dexamethasone induced 
apoptosis of primary myeloma cells360 rather than by the transformed cells 
themselves375. High levels of APRIL are found in the serum of patients with B-
cell chronic lymphocytic leukaemia (B-CLL)376. Moreover, patients with B-CLL 
express APRIL within leukemic B cells and there is an inverse relationship 
between the percentage of leukemic B cells expressing APRIL and patient 
survival377. Together, this suggests that inhibiting APRIL or its receptors may 
present a valuable therapeutic approach for B-CLL and related B cell 
lymphomas. In support of this, the addition of either a BCMA-Fc fusion protein 
or anti-APRIL antibodies enhances apoptosis in cultures of leukemic B cells378, 
and neutralization of endogenous APRIL (or BAFF) by soluble TACI and BCMA 
decoy receptors reduces the survival of cultured, patient-derived non-Hodgkin’s 
lymphoma B cells379.  
 
Prior to this current study, there has been little evidence showing that 
APRIL and its receptors are either expressed in the nervous system or play a 
role in regulating nervous system development or function. APRIL has 
previously been shown to be expressed in a number of glioblastoma cell 
lines374. In addition, flow cytometry has suggested that specific APRIL receptors 
are expressed by glioblastomas, human embryonic neural progenitors and 
human embryonic and adult astrocytes. In accordance with this, recombinant 
APRIL increases the proliferation of cultured human adult astrocytes and 
glioblastoma cells, an effect that can be blocked by the addition of soluble 
BCMA-Fc to cultures374. Likewise, APRIL is expressed by adult human 
astrocytes and, multiple sclerosis patients show increased expression of APRIL 
within reactive astrocytes380. This chapter provides novel data on the 
expression of APRIL and its receptors in the nervous system, in particular in the 
developing hippocampus.  
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3.2. Aims 
The aims of this chapter were to characterise the expression levels of 
APRIL and its receptors at the mRNA and protein levels in the developing 
hippocampus and to determine which cell types within the hippocampus 
predominantly express these molecules.  
 
3.3. Results  
3.3.1. Stage specific development of cultured hippocampal neurons  
E18 hippocampal neurons were cultured as described in Chapter 2 and 
fixed after 0.25, 0.5, 1.5, 4 and 7DIVs. Following fixation, -III tubulin 
immunofluorescence staining was performed to visualise the neurons and 
axonal and dendritic processes. Because later stage cultures become complex 
due to precocious axonal and dendritic outgrowth, cultures were transfected 
with pCDH-CMV-MCS-EF1-copGFP at 3DIVs and 6DIVs and fixed 24h later to 
allow the visualisation of single neurons at 4DIVs (stage 4) and 7DIVs (stage 5). 
In accordance with previously published data22, hippocampal cultures 
show 5 distinct stages of development (Fig.23). At stage 1 (0.25DIVs), it is 
possible to observe growing lamellipodia around neuronal cell bodies that are 
organized in patches where the first neurites will arise. Stage 2 (0.5DIVs) is 
characterized by the transformation of lamellipodia into minor processes. By 
1.5DIVs (stage 3), neurons have few processes, but it is possible to identify one 
major process forming which is the axon. At 4DIVs (stage 4), dendrites become 
discernible. The final stage of hippocampal neuron development, stage 5, 
corresponds to 7 or more DIVs and is characterised by neuronal maturation 
(Fig.23). 
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Figure 23: The stages of hippocampal neuron development in vitro.  
E18 hippocampal pyramidal neurons were cultured and fixed at 0.25, 0.5, 1.5, 4 and 7DIVs, 
time points that correspond to Dotti
22
 stages 1 to 5 of hippocampal neuron development.  
Neurons were stained for -III tubulin (red). Cultures were transfected with pCDH-CMV-MCS-
EF1-copGFP (green) at 3DIVs and 6DIVs and fixed 24h later to allow clear visualisation of 
single neurons at stages 4 and 5. Stages 1, 2 and 3; scale bar 10µm. Stages 4 and 5; scale bar 
50µm. 
 
 
 
 
 
 
Chapter 3              Expression of APRIL and its receptors in the developing hippocampus 
 
 102 
3.3.2. The expression of APRIL, BCMA and TACI mRNAs in the developing 
hippocampus and in hippocampal cultures  
In order to study the relative expression of transcripts encoding APRIL 
and its receptors in the developing hippocampus, reverse transcriptase real-
time PCR was performed on total RNA extracted from hippocampi of different 
developmental ages from E18 to adult. The levels of APRIL, BCMA and TACI 
transcripts were normalised to the expression levels of the reference mRNAs, 
GAPDH and SDHA. As shown in Fig.24.A, APRIL mRNA levels in the 
developing hippocampus remain relatively constant from E18 to adult. In 
contrast, BCMA mRNA expression levels increase 2.5 fold between E18 and 
P10, before dropping by a similar amount between P10 and adult (Fig.24.B). 
Real-time PCR was not able to reliably quantify the very low levels of TACI 
mRNA expressed in the developing and adult hippocampus. The levels of 
APRIL and BCMA mRNAs were also quantified in total RNA extracted from 
adult mouse thymus and spleen, reservoirs of T and B cells, respectively, in 
order to calibrate the levels of hippocampal APRIL and BCMA transcript 
expression with tissues that are known to express very high, functional levels of 
these mRNAs190,353,358,359,381. Not surprisingly, both APRIL and BCMA mRNA 
expression levels are significantly higher in the thymus and spleen compared to 
the adult hippocampus (Fig.24.C and D).  
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Figure 24: The relative expression levels of APRIL and BCMA mRNAs in the developing 
and adult mouse hippocampus and adult mouse thymus and spleen. Total RNA was 
extracted from E18, P0, P5, P10 hippocampus and adult hippocampus, thymus and spleen. The 
expression of APRIL and BCMA mRNAs were analysed by reverse transcriptase real-time PCR 
and quantified relative to the expression levels of mRNAs for the reference genes, GAPDH and 
SDHA. The data represents mean and SEM of four separate experiments. Graphs show: (A) 
APRIL and (B) BCMA mRNA levels in the hippocampus at different developmental ages and (C) 
APRIL and (D) BCMA mRNA levels in adult hippocampus compared with thymus and spleen. 
Data represent the mean and sem of four separate experiments. 
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Reverse transcriptase real-time PCR was also used to examine the 
expression of APRIL, BCMA and TACI mRNAs in E18 hippocampal cultures 
after 2 hours (0DIVs), 2, 5 and 7DIVs. APRIL mRNA levels fall by 50% during 
the first two days in culture. Thereafter, APRIL transcript levels remain 
unaltered from 2DIVs to 7DIVs (Fig.25.A). BCMA mRNA levels are maintained 
over the first two days in culture, but decrease by 50% between day 2 and day 
5 to reach a level that is maintained until day 7 (Fig.25.B). TACI transcript levels 
increase 3-fold from 2 hours in culture to reach a peak at 2DIVs, before falling 
4-fold to reach a lower level by 5DIVs that is maintained until 7DIVs (Fig.25.C). 
During the whole culture period, TACI mRNA levels are at the lower limit of 
reliable quantification by real-time PCR. 
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Figure 25: The relative expression levels of APRIL, BCMA and TACI mRNAs at different 
time points in E18 hippocampal cultures. Total RNA was extracted from E18 hippocampal 
cultures after 2 hours (0DIV) and 2, 5 and 7DIVs. The levels of (A) APRIL, (B) BCMA, and (C) 
TACI mRNAs were determined by reverse transcriptase real-time PCR and are relative to 
mRNAs for the reference genes, GAPDH and SDHA. Data represent the mean and sem of four 
separate experiments. 
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3.3.3. Expression of APRIL, BCMA and TACI proteins in 7DIVs hippocampal 
cultures 
Western blotting was used to assess the levels of APRIL, BCMA and 
TACI proteins in E18 hippocampal neurons that had been cultured for 7DIVs. 
The levels of these three proteins were also analysed by Western Blotting in 
protein extracts from spleen and thymus, tissues that are known to express high 
levels of these proteins190,353,358,359,381. In addition, the expression of APRIL, 
BCMA and TACI proteins were analysed in the BHK cell line. Western blots 
were also probed with antibodies against β-III tubulin (a neuronal marker) and 
β-actin (a protein expressed in all cell types). As shown in Fig.26.A, two 
immunoreactive bands of approximately 17KDa and 32KDa, corresponding to 
mature and precursor (pro) forms of APRIL, respectively, are detected in lysates 
from hippocampal cultures, thymus, spleen and BHK cells. Relative to the pro 
form, the mature form of APRIL is expressed at lower levels in hippocampal 
neurons than it is in the other tissues analysed. BCMA protein, with a molecular 
weight of 35KDa, is also expressed in all the tissues analysed (Fig.26.B). 
Similarly, a 45KDa band corresponding to TACI is detectable in the lysates of all 
tissues (Fig.26.C). It is notable that hippocampal neurons express similar or 
higher levels of BCMA, relative to β-actin, compared to the other tissues tested, 
whereas hippocampal neurons express low levels of TACI compared to spleen, 
thymus and BHK cells.  
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Figure 26: Western blots showing APRIL, BCMA and TACI protein expression in 7DIVs 
hippocampal neurons. -III tubulin was used as a neuronal marker and -actin as an 
endogenous control. Protein extracts from spleen, thymus and BHK cells were used as positive 
controls. (A) 17KDa mature and 32KDa pro forms of APRIL are expressed in all tissues 
analysed. Similarly, the lysates of all tissues contain (B) 35KDa BCMA and (C) 45KDa TACI 
proteins. 50KDa -III tubulin expression in restricted to hippocampal neurons, whereas 37KDa 
-actin is expressed in all tissues (A, B and C).  
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3.3.4. Cellular localisation of APRIL, BCMA and TACI proteins in 
hippocampal neurons 
To investigate the cellular distribution of APRIL and its receptors in 
hippocampal neurons, E18 neurons were transfected with a GFP expression 
plasmid after 6DIVs, fixed 24 hours later and labelled using antibodies that 
recognise either APRIL, BCMA or TACI. Antibodies that recognise TAU were 
also used to identify the axons of hippocampal neurons. Photomicrographs of 
stained neurons reveal that APRIL is expressed in the cell soma as well as in 
the axon of cultured hippocampal neurons (Fig.27.A). BCMA immunoreactivity 
is distributed over the soma and processes, although it is more evident in axons 
rather than dendrites (Fig.27.B). TACI is expressed at very low levels in the 
soma of hippocampal neurons and is not detectable in the processes 
(Fig.27.C). Although E18 hippocampal cultures contain very few non-neuronal 
cells after 7DIVs, occasionally non-neuronal cells expressing APRIL or BCMA 
were observed (data not shown). 
 
Macrophages and lymphocytes were used as positive control cells for the 
APRIL antibody (Fig.28 and 29) and lymphocytes were used as a positive 
control for BCMA and TACI antibodies (Fig.29). Macrophages and lymphocytes 
were kindly provided by Luke Davies from the Department of Infection, 
Immunity and Biochemistry at Cardiff University School of Medicine. 
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Figure 27: The cellular localisation of APRIL, BCMA and TACI proteins in 7DIVs 
hippocampal neurons. Hippocampal neurons were transfected with pCDH-CMV-MCS-EF1-
copGFP (green) after 6DIVs and fixed 24h later. Fixed neurons were stained with antibodies 
against (A) APRIL, (B) BCMA, (C) TACI (all red) or (D) no primary antibody. Fixed neurons were 
also stained using an antibody against the axonal marker, TAU (purple in A, B and C) and with 
the nuclear marker DAPI (blue in A, B, C and D). Scale bar: 20m. 
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Figure 28: APRIL expression in macrophages.  
Fixed macrophages were stained with antibodies recognising (A) APRIL (red) or (B) no primary 
antibody and nuclear marker DAPI (blue). Scale bar: 50m. 
 
 
Figure 29: APRIL, BCMA and TACI expression in lymphocytes.  
Fixed lymphocytes were stained with antibodies recognising (A) APRIL, (B) BCMA, (C) TACI 
(red) or (D) no primary antibody and nuclear marker DAPI (blue). Scale bar: 50m. 
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3.3.5. Localisation of APRIL, BCMA and TACI proteins in the hippocampus 
Immunohistochemistry was used to investigate the distribution of APRIL, 
BCMA and TACI in the developing mouse hippocampus at E18, P0, P5 and 
P10. At E18, there is diffuse, low level APRIL staining in the developing 
hippocampus, but BCMA staining is absent (Fig.30). By P0, APRIL and BCMA 
are beginning to be localised to the stratum pyramidale and the granule layer of 
the DG and the expression of both proteins is more prominent in these cell 
layers at P5 and P10. In accordance with the data from 7DIVs E18 hippocampal 
cultures (Fig.27 above), TACI protein is not detectable at any age examined in 
the developing hippocampus (Fig.30 below).  
 
Figure 30: Localisation of APRIL, BCMA and TACI proteins in the developing mouse 
hippocampus. E18, P0, P5 and P10 hippocampal sections were stained with antibodies 
against APRIL, BCMA, and TACI (green). The column of panels on the right shows staining in 
the absence of primary antibodies. Scale bar: 200m. (DG: dentate gyrus, CA1 and CA3 layer). 
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3.3.6. APRIL is secreted by cultured hippocampal neurons 
 To determine if cultured hippocampal neurons release soluble APRIL into 
the culture medium, an APRIL ELISA was performed on culture medium after 
E18 neurons had been in culture for 3 days. To allow a comparison between the 
levels of secreted APRIL and the total amount of APRIL expressed by cultured 
hippocampal neurons, protein extracts of 3DIVs cultures were also analysed by 
an APRIL ELISA alongside culture medium samples. Medium samples and 
protein extracts were obtained from both high (100,000cells/cm2) and low-
density (20,000cells/cm2) hippocampal cultures. Soluble APRIL was clearly 
present in the culture medium from 3DIVs hippocampal cultures and the level of 
APRIL was higher in medium from high-density cultures (1.9ng/ml) compared to 
low-density cultures (1.5ng/ml). In high-density cultures, the culture medium 
contained more APRIL than cell lysates, a situation that was reversed in low-
density cultures (Fig.31). The high levels of APRIL in culture medium suggest 
that APRIL is actively released from hippocampal neurons rather than being a 
consequence of leakage following neuronal death. 
 
 
Figure 31: Hippocampal neurons secrete APRIL. 
The amount of APRIL in culture medium and cell lysates of high (100,000cells/cm
2
) and low 
density (20,000cells/cm
2
), 3DIVs E18 hippocampal cultures was quantified by ELISA. 
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3.4. Discussion  
In order to lay the ground work for the research presented in Chapters 4 
and 6, E18 hippocampal neuron cultures needed to be established and 
confirmed they progressed clearly through the 5 stages of development that 
have previously been documented22. This was important so analyses on axons 
(stage 3) and dendrites (stage 4-5) could be performed. Figure 23 shows that 
Dotti stages 1-5 were all clearly identifiable these cultures.  
 
 As the expression of APRIL, BCMA and TACI have not previously been 
reported in the developing or adult hippocampus, a wide range of techniques 
was used to examine the expression of these TNFSF and TNFRSF members at 
the mRNA and protein level. Reverse transcriptase real-time PCR was utilised 
to quantify the levels of APRIL, BCMA and TACI transcripts in the developing 
hippocampus and in E18 hippocampal neurons cultured for between 0 and 
7DIVs. Since APRIL and its receptors are mainly expressed by cells of the 
immune system190,353,358,359,381, the transcripts encoding these proteins were 
also quantified in adult mouse thymus (where thymocytes mature into T cells) 
and spleen (reservoir of monocytes, B and T lymphocytes), both to act as a 
positive control for the real-time PCR and to allow a judgement to be made 
regarding the physiological relevance of APRIL, BCMA and TACI transcript 
levels in the developing hippocampus. Both APRIL and BCMA mRNAs are 
readily detectable and quantifiable throughout hippocampal development. 
Whilst APRIL mRNA expression levels are fairly constant during hippocampal 
development, BCMA transcript levels increase linearly from E18 to reach a peak 
at P10, before decreasing 2.5-fold between P10 and adult (Fig.24). This 
expression pattern suggests a possible role for BCMA in the early stages of 
neuronal maturation and hippocampal circuit development. In contrast to APRIL 
and BCMA, TACI mRNA levels are too low to be reliable quantified in the 
developing hippocampus, suggesting that it is unlikely to be a functional 
receptor for APRIL in the developing hippocampus. APRIL and BCMA mRNAs 
are readily detectable and quantifiable in cultures of E18 hippocampus, but 
TACI mRNA, although just about quantifiable, is expressed at very low levels in 
these cultures (Fig.25). 
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As future work it would be interesting to analyse the expression levels of 
BCMA mRNA at ages between P10 and adult, to determine whether the 
decrease in BCMA transcript levels between P10 and adult is gradual or 
whether a pronounced drop in expression occurs at a specific postnatal age. If 
the latter is the case, the drop in expression may be correlated with a specific 
developmental/maturation process.   
 The analysis of mRNA expression in hippocampal cultures aimed to 
understand how the expression of BCMA and APRIL transcripts varied during 
the culture periods when hippocampal neurons were projecting their first minor 
processes, specifying a single axon and undergoing axon elongation. High 
levels of APRIL and BCMA transcripts at 0DIVs (2hrs after plating) might reflect 
a transcriptional reaction to hippocampal dissociation and the new culture 
environment. Alternatively, it may reflect the levels of these mRNAs in the intact 
hippocampus in vivo. This could be addressed by analysing the expression of 
BCMA and APRIL mRNAs in RNA extracted from freshly dissected hippocampi 
and comparing expression levels to those in RNA extracted from hippocampal 
neurons that had been cultured for 2 hours.  Importantly, BCMA transcript levels 
remain elevated in hippocampal neurons at 2 DIVs, a period of axonal 
extension, and are reduced at 7DIVs, a period characterised by the beginning of 
dendrite maturation (Fig.25). This suggests that APRIL/BCMA signalling may 
play a role in regulating axon elongation and is less likely to play a role in 
modulating dendrite outgrowth and branching. 
 
Western blotting of lysates from E18 hippocampal cultures after 7DIVs 
revealed that hippocampal neurons express BCMA and APRIL proteins. Two 
isoforms of APRIL are evident in Western blots of hippocampal neurons, spleen 
and thymus lysates: one of 17KDa corresponding to mature APRIL and the 
other, 32KDa, corresponding to precursor APRIL. Whilst the ratio of mature to 
precursor protein is lower in hippocampal neurons than in thymus and spleen, 
mature APRIL is clearly detectable in hippocampal neurons. The expression 
levels of BCMA protein relative to β-actin appears to be higher in cultured 
hippocampal neurons compared to the thymus and spleen. In contrast, the 
levels of TACI are much lower in hippocampal neurons than in thymus and 
spleen (Fig.26). Once again this suggests that BCMA may play an important 
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role in hippocampal neuron development and that TACI is unlikely to be a 
receptor for APRIL in the developing hippocampus. 
 
Immunocytochemistry has revealed that 7DIVs cultured hippocampal 
neurons express the ligand APRIL and the receptor BCMA, but not the 
alternative APRIL receptor, TACI. Double staining for APRIL and the axonal 
marker TAU has shown that the ligand is expressed in the soma and axon of 
hippocampal neurons. Likewise, BCMA is detected in the cell soma and co-
localises with TAU in axons. In addition BCMA is also expressed in the initial 
segments of dendritic processes (Fig.27). These observations suggest a 
possible role for APRIL/BCMA signalling in promoting initial neurite formation 
and potentially enhancing axon elongation. The expression of both APRIL and 
its receptor, BCMA, in neurons raises the possibility that APRIL/BCMA 
signalling may act in an autocrine manner to regulate some aspect of 
hippocampal neuron development. Whilst E18 hippocampal cultures contain 
few glia by 7DIV, some non-neuronal cells in the cultures express APRIL and 
BCMA as previously reported380. Given that hippocampal non-neuronal cells 
also express APRIL, there is a possibility that paracrine signalling between 
neurons and glia could modulate neuronal development in the hippocampus.  
 
Immunohistochemistry for APRIL, BCMA and TACI in the hippocampus 
at different developmental ages, validated the expression data obtained from 
real-time PCR, Western Blotting and immunocytochemistry. Whilst APRIL is 
detectable in sections of E18 hippocampus, expression is diffuse. By P0, APRIL 
expression appears to become localised to the DG granule cell layer and the 
stratum pyramidale, and these structures become more clearly delineated by 
APRIL expression as development proceeds. BCMA protein is not detectable in 
sections of E18 hippocampus, but from P0 onwards BCMA staining co-localises 
with APRIL staining in the stratum pyramidale and granule cell layer of the DG 
(Fig.30). DG granule cells are not present in hippocampal cultures established 
from E18 mouse embryos, because at E18 putative granule cells are still 
migrating towards the hippocampus4. As may be expected from real-time PCR, 
Western blot and immunocytochemistry data, TACI is not detectable in the 
hippocampus by immunohistochemistry at any developmental stage. BCMA 
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protein levels increase from E18 to P10 and this observation correlates with the 
mRNA expression data. However, the same is not observed for APRIL. APRIL 
protein levels increase from E18 to P10, but mRNA levels remain constant, or 
even slightly decrease over this developmental period. This may reflect an 
increase in the efficiency of translation of the APRIL message as hippocampal 
development proceeds and/or an increase in the stability of the APRIL protein 
over this time period. 
 
The fact that Western blot analyses of cultured hippocampal neurons 
detect both the mature and pro forms of APRIL suggests that APRIL might be 
synthesised and processed by hippocampal neurons before secretion as the 
mature form. A specific ELISA for APRIL detects the protein in both cell lysates 
and culture medium of low and high-density hippocampal neuron cultures 
(Fig.31). This result demonstrates that hippocampal neurons not only express 
APRIL, as shown by the expression of its mRNA and protein in the developing 
hippocampus and in hippocampal cultures, but are also able to process it in 
their Golgi apparatus and release it exogenously in a mature and functional 
form to the culture environment in vitro, and presumably the extracellular matrix 
in vivo. 
 
In summary, the data presented in this chapter provides the first 
demonstration that APRIL and one of its receptors, BCMA, are expressed by 
neurons in the developing mouse hippocampus. TACI, the alternative cognate 
TNF superfamily receptor for APRIL, is detected at significantly lower levels 
than BCMA in developing hippocampal neurons, suggesting that it does not 
mediate potential trophic effects of APRIL on these neurons. Since APRIL and 
BCMA are both expressed by neurons, and APRIL is secreted from cultured 
hippocampal neurons, it is possible that APRIL regulates some aspect of 
hippocampal neuron development via an autocrine route. The data provided the 
bases for further studies that aimed to determine if APRIL was a novel 
neurotrophic factor for developing hippocampal pyramidal neurons.  
 
 117 
Chapter 4 
 
 
 
 
 
 
APRIL promotes the growth of hippocampal 
axons through MAPK and PI3K/Akt/GSK-3 
signalling pathways  
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4.1. Introduction  
The April gene encodes a 250 amino acids protein that is most closely 
related to BAFF amongst TNFSF members, sharing 30% amino acid sequence 
identity and a similar tertiary structure382. APRIL and another TNFSF member, 
TWEAK, are both mapped in close proximity on the same chromosome 
(chromosome 17 in humans and 11 in mice) and alternative splicing of the locus 
leads to the generation of TWE-PRIL, a protein that comprises APRIL exons 2-6 
fused with TWEAK exons 1-6. TWE-PRIL is a membrane bound protein sharing 
the cytoplasmic and transmembrane domains of TWEAK and the extracellular 
portion of APRIL383,384. APRIL can also form heterotrimers with the TNFSF 
member, BAFF that is detected in the serum of patients with systemic immune-
based rheumatic diseases385.  
 
 In addition to forming heterotrimers, APRIL and BAFF both signal 
through BCMA and TACI, although the affinity of BCMA for BAFF is significantly 
lower than that for APRIL365,386.  BAFF, but not APRIL, also binds to and signals 
through BAFF-R387. Curiously, contrary to the majority of TNF receptors, BCMA 
and TACI only have a single CRD that contact APRIL or BAFF388. TWE-PRIL is 
hypothesized to bind to BCMA and TACI383,384 while APRIL/BAFF heterodimers 
appear to bind more efficiently to TACI385. Interestingly, neither BCMA nor TACI 
appear to be involved in the tumour promoting effects of APRIL on some cell 
types. For example, whilst APRIL induces the proliferation of Jurkat T 
leukaemia, HT29 colon carcinoma and A549 lung epithelial cells, these tumour 
cells do not express BCMA or TACI357. Therefore, it was suggested that a third 
specific APRIL receptor, that was responsible for the tumour promoting effects 
of APRIL, existed in these cell lines357. A consensus motif in the N-terminal 
basic region of mature APRIL that is important for the binding of heparan 
sulphate proteoglycans (HSPG) has been identified389. As this region is different 
from the one that APRIL uses to bind to TNF receptors, APRIL is able to bind to 
HSPG and BCMA or TACI at the same time. It is possible that HSPG may 
mediate APRIL/BCMA or APRIL/TACI interactions in some cell types; however, 
it seems likely that APRIL can signal directly through proteoglycans in some 
tumour cell lines389. 
Chapter 4                 APRIL promotes axonal growth through MAPK and PI3K/Akt/GSK-3  
 
 119 
 The signalling pathways that are initiated by APRIL binding to its 
receptors differ between BCMA and TACI. Immunoprecipitation studies have 
shown that BCMA associates with TRAF1, 2 and 3390. Overexpression of BCMA 
in human embryonic kidney (HEK) 293 cells results in the activation of MAPK, 
JNK, p38 kinase, NF-B and Elk-1. Moreover, a 25 amino acid sequence in the 
cytoplasmic domain of BCMA is crucial for its association with TRAFs and the 
subsequent activation of NF-B, Elk-1 and JNK390. Ligand bound TACI 
associates with TRAFs 2, 5 and 6 in B cells, leading to the promotion of NF-B 
and JNK activity391. TACI has also been shown to activate the nuclear factor of 
activated T cells transcription factor (NF-AT) in T lymphocytes392.  
 
4.2. Aims  
The previous chapter revealed that APRIL and BCMA are both 
expressed by developing hippocampal neurons in vitro and in vivo, suggesting 
that APRIL/BCMA signalling regulates some aspect of hippocampal neuron 
development. This chapter aimed to identify and clarify the role of APRIL/BCMA 
signalling in developing hippocampal neurons. After establishing that APRIL 
enhances axonal elongation from cultured hippocampal neurons, further work 
identified BCMA as the receptor that mediates this effect and revealed the 
signalling pathways downstream of BCMA that lead to increased axonal growth.   
 
4.3. Results  
4.3.1. APRIL increases hippocampal neuron axon length  
 To determine whether APRIL regulates the extent of axon outgrowth 
from cultured E18 hippocampal neurons, neurons were cultured for 2DIVs 
before being transfected with pCDH-CMV-MCS-EF1-copGFP and 
supplemented with different concentrations of recombinant APRIL for a further 
16 hours. Cultured neurons were fixed, stained with an antibody against GFP 
and analysed at 3DIVs, a time point that precedes the growth of dendrites22 
(3.3.1. above). Figures 32 and 33 show that recombinant APRIL significantly 
increases the length of axons projecting from 3DIVs hippocampal neurons 
compared to control cultures. The enhancement of axonal growth is highly 
significant at 10ng/ml APRIL and the degree of enhancement is slightly 
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increased at 100ng/ml and 1000ng/ml APRIL. In addition to dissociated cultures 
of hippocampal neurons, P0 explants of the hippocampal CA area were cultured 
for 2 days in the presence or absence of 100ng/ml of APRIL to investigate the 
effects of APRIL on axon outgrowth. Figure 32.B clearly demonstrates that 
APRIL promotes axonal outgrowth from P0 hippocampus explants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: APRIL promotes axonal outgrowth from cultured hippocampal neurons. 
(A) Representative photomicrographs of typical cultured hippocampal neurons that were grown 
for 2DIVs before being transfected with pCDH-CMV-MCS-EF1-copGFP and cultured for a 
further 16 hours, either with no factors or with 100ng/ml recombinant APRIL, and then fixed and 
stained for GFP. Scale bar: 100µm. (B) Representative photomicrographs of P0 hippocampal 
explants that were cultured for 2 days, either in the absence of factors or with 100ng/ml APRIL, 
before being stained with Calcein AM. Scale bar: 200µm.  
 
 
 
 
control APRIL 100 ng/ml 
A 
control APRIL 100 ng/ml 
B 
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Figure 33: APRIL promotes axonal outgrowth from cultured hippocampal neurons.  
E18 hippocampal neurons were cultured for 2DIVs before being transfected with pCDH-CMV-
MCS-EF1-copGFP, and cultured for a further 16 hours in medium containing no factors (control) 
or medium containing either 10ng/ml, 100ng/ml or 1000ng/ml recombinant APRIL. Cultures 
were fixed at 3DIVs and stained with an anti-GFP antibody, before being imaged using a 
fluorescence microscope. Images were analysed using ImageJ software. Graph corresponds to 
mean of total axonal length. Data represent the mean and sem of 150 neurons for each 
condition from 3 separate experiments. ***indicates p<0.0001, statistical comparison with 
control, (Mann–Whitney U test). 
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4.3.2. APRIL does not increase hippocampal dendritic outgrowth 
 To evaluate whether APRIL could enhance dendrite outgrowth in addition 
to axon elongation, 6DIVs E18 hippocampal neuron cultures were transfected 
with pCDH-CMV-MCS-EF1-copGFP and cultured for a further 16 hours in 
medium containing, either no factors (control) or 10ng/ml, 100ng/ml or 
1000ng/ml APRIL. After fixation and staining for GFP, neurons were imaged 
using a fluorescence microscope and the images analysed with Photoshop. The 
addition of APRIL to cultures does not increase the number of dendrites 
projecting from GFP stained neurons that are greater than 50µm in length 
compared to control cultures (Fig.34.A and B) Similarly, APRIL does not 
increase the mean number of primary dendrites arising from GFP stained 
neurons above that of control cultures (Fig.34.A and C).  
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Figure 34: APRIL does not promote dendritic outgrowth from cultured hippocampal 
neurons. 6DIVs E18 hippocampal neurons were transfected with pCDH-CMV-MCS-EF1-
copGFP, and cultured for a further 16h in medium containing, either no factors (control) or 
10ng/ml, 100ng/ml or 1000ng/ml recombinant APRIL. Cultures were fixed at 7DIVs, stained with 
an anti-GFP antibody and imaged on a fluorescence microscope. Images were analysed using 
Photoshop. (A) Representative photomicrographs of typical hippocampal neurons cultured 
either in the absence of factors (control) or in medium containing 100ng/ml APRIL. Scale bar: 
50µm. Graphs correspond to the (B) % of dendrites > 50m and the (C) mean number of 
primary dendrites. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments.  
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A 
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4.3.3. BCMA mediates APRIL-promoted axonal elongation from cultured 
hippocampal neurons 
Transfection of bicistronic expression plasmids encoding either WT BCMA 
and GFP (pCDH-CMV-BCMA-EF1-copGFP), or GFP together with a signalling-
defective BCMA mutant lacking 83 C-terminal residues (pCDH-CMV-BCMA-
ΔC83-EF1-copGFP), were used to investigate the role of BCMA in APRIL 
promoted axon growth. Compared to control transfected neurons (transfected 
with pCDH-CMV-MCS-EF1-copGFP), the overexpression of WT BCMA 
increases axon length by the same order as magnitude as the addition of 
100ng/ml recombinant APRIL to cultures. The addition of 100ng/ml APRIL to 
cultures containing neurons transfected with WT BCMA does not further 
increase axon length compared to neurons transfected with WT BCMA cultured 
in the absence of APRIL. Conversely, the expression of truncated BCMA 
significantly decreases axon length compared to control transfect cultures and 
prevents exogenous APRIL from promoting axonal elongation (Fig.35.A and B).  
Taken together, these data demonstrates that APRIL signals via BCMA to 
mediate axonal growth in hippocampal cultures. 
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Figure 35: BCMA mediates APRIL promoted-axonal outgrowth from cultured 
hippocampal neurons. E18 hippocampal neurons that had been cultured for 2DIVs were 
transfected with either pCDH-CMV-MCS-EF1-copGFP (control), pCDH-CMV-BCMA-EF1-
copGFP or pCDH-CMV-BCMA-ΔC83-EF1-copGFP. Transfected neurons were culture for a 
further 16h in medium containing either no factors or medium containing 100ng/ml APRIL 
before being fixed, stained for GFP and imaged under a fluorescence microscope. Images were 
analysed by ImageJ software. (A) Representative photomicrographs of typical cultured neurons 
under different conditions. Scale bar: 100µm. Graph corresponds to (B) mean of total axonal 
length. Data represent the mean and sem of 150 neurons for each condition from 3 separate 
experiments. ***indicates p<0.0001, statistical comparison with control, (Mann–Whitney U test).  
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4.3.4. Heparan sulphate proteoglycans are not essential for APRIL-
promoted axon growth from cultured hippocampal neurons 
 To evaluate whether HSPGs were required for BCMA mediated 
enhancement of axon elongation by APRIL, E18 hippocampal neurons were 
transfected with pCDH-CMV-MCS-EF1-copGFP after 2DIVs and cultured for a 
further 16 hours in medium containing either no factors (control) or medium 
containing recombinant mutant APRIL (APRIL H89) that lacks the capacity to 
bind HSPGs. APRIL H89 promotes a dose-dependent increase in axonal 
growth. However, whilst the extent of axon elongation promoted by APRIL H89 
and WT APRIL are similar at APRIL concentrations of 100ng/ml and 1000ng/ml, 
10ng/ml of APRIL H89, unlike WT APRIL, is not able to significantly increase 
the length of hippocampal neuron axons compared to control cultures (Fig.36.A 
and B). This data suggests that although APRIL H89 promotes axon elongation 
from cultured hippocampal neurons, it may be slightly less potent than WT 
APRIL.  
 
The efficacy of APRIL H89 in enhancing axon growth was further 
investigated in a second series of experiments. Hippocampal neurons that had 
been cultured for 2DIVs were transfected either with a control plasmid 
expressing GFP alone (pCDH-CMV-MCS-EF1-copGFP) or a plasmid 
expressing GFP together with WT APRIL (pCDH-CMV-APRIL-EF1-copGFP). 
Following transfection, control transfected neurons were cultured for a further 
16 hours either in the absence of factors (control) or in medium containing 
100ng/ml of either WT APRIL or APRIL H89. Figure 37.A and B demonstrates 
that overexpressing WT APRIL is as effective as the addition of 100ng/ml 
APRIL to cultures in terms of enhancing axon elongation from hippocampal 
neurons. Interestingly, 100ng/ml APRIL H89 appears to be more potent than 
100ng/ml WT APRIL in promoting axon growth. Taken together, the data 
indicate that the binding of APRIL to HSPGs is not required to mediate axon 
elongation from cultured hippocampal neurons.  
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Figure 36: APRIL does not require HSPGs to promote axonal outgrowth from cultured 
hippocampal neurons. E18 hippocampal neurons were cultured for 2DIVs before being 
transfected with pCDH-CMV-MCS-EF1-copGFP, and cultured for a further 16h in medium 
containing no factors (control) or medium containing either 10ng/ml, 100ng/ml or 1000ng/ml 
recombinant APRIL H89. Cultures were fixed at 3DIVs and stained with an anti-GFP antibody, 
before being imaged using a fluorescence microscope. Images were analysed using ImageJ 
software. (A) Representative photomicrographs of typical hippocampal neurons cultured either 
in the absence of factors (control) or in medium containing 100ng/ml APRIL H89. Scale bar: 
100µm. Graph corresponds to (B) mean of total axonal length. Data represent the mean and 
sem of 150 neurons for each condition from 3 separate experiments. ***indicates p<0.0001, 
statistical comparison with control, (Mann–Whitney U test). 
APRIL H89  
100 ng/ml 
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Figure 37: APRIL does not require HSPGs to promote axonal outgrowth from cultured 
hippocampal neurons. E18 hippocampal neurons were cultured for 2DIVs before being 
transfected with either pCDH-CMV-MCS-EF1-copGFP (control) or pCDH-CMV-APRIL-EF1-
copGFP. Control transfected neurons were cultured for a further 16h in medium containing no 
factors (control) or medium containing either 100ng/ml of WT APRIL or APRILH89. Neurons 
transfected with pCDH-CMV-APRIL-EF1-copGFP were cultured for a further 16h in the absence 
of trophic factors. Cultures were fixed at 3DIVs and stained with an anti-GFP antibody, before 
being imaged using a fluorescence microscope. Images were analysed using ImageJ software. 
(A) Representative photomicrographs of typical hippocampal neurons transfected with either 
pCDH-CMV-MCS-EF1-copGFP (control) or pCDH-CMV-APRIL-EF1-copGFP and cultured for a 
further 16h in the absence of factors. Scale bar: 100µm. Graph corresponds to (B) mean of total 
axonal length. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments. ***indicates p<0.0001, statistical comparison with control, (Mann–
Whitney U test). 
APRIL over 
expression plasmid 
control 
A 
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4.3.5. Signalling transduction induced by APRIL in hippocampal 
neurons: activation of MAPK and PI3K/Akt-PKB/GSK-3β pathways 
To elucidate the molecular mechanism underlying the selective influence 
of APRIL on promoting axonal growth from hippocampal neurons, potential 
common links in intracellular signalling were explored. To assess the 
importance of ERK1/2 activation on APRIL-promoted axonal growth, 
PD98059, a selective MEK1 and MEK2 inhibitor that prevents the 
phosphorylation, and hence activation, of ERK1/2393, was added to 
hippocampal neuron cultures. Hippocampal neurons that had been cultured 
for 2DIVs were transfected with pCDH-CMV-MCS-EF1-copGFP and cultured 
for a further 2 hours either in the absence or presence of 10µM PD98059. 
After, cultures were incubated for a further 16 hours either in the presence or 
absence of 100ng/ml APRIL. Whilst PD98059 does not reduce the length of 
axons compared to control cultures when hippocampal neurons are cultured 
without APRIL, it totally blocks the axon growth promoting ability of APRIL 
(Fig.38.A and B). Further evidence that ERK1/2 activation forms part of the 
signalling mechanism that mediates APRIL promoted axonal elongation can 
be seen in figure 39. The addition of 100ng/ml APRIL to 3DIVs hippocampal 
cultures results in a rapid and sustained increase in the levels of phospho-
ERK1/2 (phosphorylation of residues Thr202 and Tyr204 in ERK1 and 2, 
respectively) in hippocampal neurons, as determined by Western blotting.  
 
 
 
 
 
 
 
 
 
 
  
Chapter 4             APRIL promotes axonal growth through MAPK and PI3K/Akt/GSK-3β   
 
  130 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38:  ERK activation is required for APRIL-promoted axonal growth. 
E18 hippocampal neurons that had been cultured for 2DIVs were transfected with pCDH-
CMV-MCS-EF1-copGFP prior to 2h incubation either in the presence or absence of 10µM 
PD98059. Following this, neurons were cultured for a further 16h, either in the presence or 
absence of 100ng/ml of recombinant APRIL, before being fixed at 3DIVs, stained with an 
antibody against GFP and imaged under a fluorescence microscope. Images were analysed 
with ImageJ. (A) Representative photomicrographs of typical hippocampal neurons cultured 
under the stated conditions. Scale bar: 100µm. Graph corresponds to (B) mean of total 
axonal length. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments. ***indicates p≤0.0001, statistical comparison with control, n.s. non-
significant (Mann-Whitney U test).  
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Figure 39: APRIL increases ERK phosphorylation. 
E18 hippocampal neurons that had been cultured for 3DIVs were treated with 100ng/ml of 
recombinant APRIL for 15, 30 or 60min before being lysed. Western blots of lysates were 
probed with antibodies against ERK1/2, phospho-ERK1/2 and β-III tubulin. (A) Representative 
scans of Western blots. Graphs correspond to densitometry measurements from films and 
show (B) P-Erk/Erk and (C) P-Erk/β-III tubulin ratios. Data represent the mean and sem of 3 
separate experiments. ***indicates p<0.0001, statistical comparison with control and refers to 
both Erk1 and Erk2 (Mann-Whitney U test).  
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Having established that the addition of recombinant APRIL to cultures of 
hippocampal neurons leads to the phosphorylation of ERK1/2, and that 
inhibiting ERK1/2 phosphorylation abolishes APRIL promoted axonal growth, 
the roles that PI3K and Akt play in mediating APRIL promoted axon 
elongation were examined. LY294002 is a selective pharmacological blocker 
of PI3K activity that prevents the phosphorylation and activation of Akt1/2394. 
Hippocampal neurons that had been cultured for 2DIVs were transfected with 
pCDH-CMV-MCS-EF1-copGFP and cultured for a further 2 hours either in the 
absence or presence of 10µM LY294002. After, cultures were incubated for a 
further 16 hours either in the presence or absence of 100ng/ml APRIL. Whilst 
LY294002 does not reduce the length of axons compared to control cultures 
in the absence of APRIL, it totally prevents APRIL from enhancing the growth 
of hippocampal neuron axons (Fig.40.A and B).  
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Figure 40:  PI3K activity is required for APRIL-promoted axonal growth.  
E18 hippocampal neurons that had been cultured for 2DIVs were transfected with pCDH-
CMV-MCS-EF1-copGFP prior to 2h incubation either in the presence or absence of 10µM 
LY294002. Following this, neurons were cultured for a further 16h, either in the presence or 
absence of 100ng/ml of recombinant APRIL, before being fixed at 3DIVs, stained with an 
antibody against GFP and imaged under a fluorescence microscope. Images were analysed 
with ImageJ. (A) Representative photomicrographs of typical hippocampal neurons cultured 
under the stated conditions. Scale bar: 100µm. Graph corresponds to (B) mean of total 
axonal length. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments. ***indicates p<0.0001, statistical comparison with control, n.s. non-
significant (Mann-Whitney U test).  
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Blocking the activity of PI3K, and potentially the subsequent 
phosphorylation and activation of Akt1/2, clearly prevents APRIL from 
promoting the elongation of hippocampal axons. To address whether Akt1/2 
activity is essential for APRIL promoted axonal growth, an Akt1/2 inhibitor was 
added to cultures using a similar experimental paradigm to that used for 
MEK1/2 and PI3K inhibitors. In the absence of exogenous APRIL, the Akt 
inhibitor does not change mean axon length compared to control cultures. 
However, the inhibitor abolishes APRIL-mediated axonal growth (Fig.41.A and 
B). The role of activated Akt in transducing APRIL promoted axon outgrowth 
was further investigated by examining the phosphorylation status of Akt after 
the addition of 100ng/ml APRIL to hippocampal neurons that had been in 
culture for three days. The addition of APRIL induces a rapid and sustained 
phosphorylation of Akt serine residue 473, and hence activation of Akt 
(Fig.42). 
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Figure 41:  Akt activity is required for APRIL-promoted axonal growth. 
Hippocampal neurons that had been cultured for 2DIVs neurons were transfected with pCDH-
CMV-MCS-EF1-copGFP prior to 2h incubation either in the presence or absence of 5µM of 
Akt1/2 inhibitor. Following this, neurons were cultured for a further 16h, either in the presence 
or absence of 100ng/ml of recombinant APRIL, before being fixed at 3DIVs, stained with an 
antibody against GFP and imaged under a fluorescence microscope. Images were analysed 
with ImageJ. (A) Representative photomicrographs of typical hippocampal neurons cultured 
under the stated conditions. Scale bar: 100µm. Graph corresponds to (B) mean of total 
axonal length. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments. ***indicates p≤0.0001, statistical comparison with control, n.s. non-
significant (Mann-Whitney U test).  
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Figure 42: APRIL enhances the phosphorylation of Akt. 
E18 hippocampal neurons that had been cultured for 3DIVs were treated with 100ng/ml of 
recombinant APRIL for 15, 30 or 60min before being lysed. Western blots of lysates were 
probed with antibodies against Akt, phospho-Akt and β-III tubulin. (A) Representative scans of 
Western blots. Graphs correspond to densitometry measurements from films and show (B) P-
Akt/Akt and (C) P-Akt/β-III tubulin ratios. Data represent the mean and sem of 3 separate 
experiments. ***indicates p<0.0001, statistical comparison with control (Mann-Whitney U 
test).  
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One of the downstream targets of activated Akt is GSK-3β, a protein 
kinase that acts to inhibit axon growth in its non-phosphorylated, kinase active 
state. Phosphorylation of GSK-3β abolishes its kinase activity, thereby 
removing its ability to inhibit axon growth395. To try to ascertain whether the 
modulation of GSK-3β activity is part of the signalling cascade that leads to 
APRIL-induced axonal extension, hippocampal neurons were cultured in the 
presence or absence of APRIL and/or lysophosphatidic acid (LPA), a known 
activator of GSK-3β activity396, using a similar experimental paradigm to that 
used above for MEK, PI3K and Akt inhibitors. In the absence of exogenous 
APRIL, LPA does not change mean axon length compared to control cultures. 
The addition of LPA to cultures, and hence the promotion of GSK-3β kinase 
activity, does, however, prevent APRIL from enhancing axonal outgrowth 
(Fig.43). Moreover, Western blotting reveals that the addition of 100ng/ml 
recombinant APRIL to E18 hippocampal neurons that had been in culture for 
3 days leads to a rapid and sustained increase in the phosphorylation of GSK-
3β (Fig.44).  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Figure 43: Enhancing GSK-3β kinase activity prevents APRIL-promoted axonal growth. 
E18 hippocampal neurons that had been cultured for 2DIVs were transfected with pCDH-
CMV-MCS-EF1-copGFP prior to 2h incubation either in the presence or absence of 10µM 
LPA. Following this, neurons were cultured for a further 16h, either in the presence or 
absence of 100ng/ml of recombinant APRIL, before being fixed at 3DIVs, stained with an 
antibody against GFP and imaged under a fluorescence microscope. Images were analysed 
with ImageJ. (A) Representative photomicrographs of typical hippocampal neurons cultured 
under the stated conditions. Scale bar: 100µm. Graph corresponds to (B) mean of total 
axonal length. Data represent the mean and sem of 150 neurons for each condition from 3 
separate experiments. ***indicates p<0.0001, statistical comparison with control, n.s. non-
significant (Mann-Whitney U test).  
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Figure 44: APRIL enhances the phosphorylation of GSK-3β. 
E18 hippocampal neurons that had been cultured for 3DIVs were treated with 100ng/ml of 
recombinant APRIL for 15, 30 or 60min before being lysed. Western blots of lysates were 
probed with antibodies against GSK-3β, phospho-GSK-3 (recognises phosphorylated GSK-
3α and GSK-3β) and β-III tubulin. (A) Representative scans of Western blots. Graphs 
correspond to densitometry measurements from films and show (B) P-GSK-3β/GSK-3β and 
(C) P-GSK-3β/β-III tubulin ratios. Data represent the mean and sem of 3 separate 
experiments. ***indicates p<0.0001, statistical comparison with control (Mann-Whitney U 
test).   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4.4. Discussion 
Novel roles for TNFSF members in the developing nervous system 
have recently been characterised. In particular, TNFSF members have been 
shown to regulate the elongation and branching of the processes of 
developing neurons from peripheral sensory and sympathetic ganglia176-
178,397. TNFSF members have also been shown to either promote or inhibit 
neurite outgrowth from developing hippocampal and cortical neurons166,240.  
 
This chapter describes a novel role for APRIL in promoting axonal 
growth from cultured embryonic mouse hippocampal neurons. APRIL’s ability 
to promote axonal growth is mediated by BCMA dependent activation of 
MAPK and PI3K/Akt/GSK-3β signal pathways. The co-expression of APRIL 
and BCMA in hippocampal neurons described in Chapter 3, together with the 
release of APRIL into the medium in hippocampal cultures, raised the 
possibility of autocrine and/or paracrine APRIL-BCMA signalling in these 
neurons. To investigate the potential significance of this signalling, the effect 
of exogenous recombinant APRIL was examined on neurite outgrowth from 
cultured embryonic hippocampal neurons. APRIL significantly increased 
hippocampal axon length in a dose-dependent manner. In addition to 
enhancing axonal outgrowth from E18 dissociated cultures of hippocampal 
neurons, APRIL also induced profuse axonal outgrowth from P0 explants of 
the hippocampal CA region (Fig.32 and 33). In contrast to its efficacy in 
promoting axonal growth, APRIL had no effect on the length or number of 
primary dendrites projecting from the soma of hippocampal neurons (Fig.34). 
 
Since Chapter 3 demonstrated that the APRIL receptor, BCMA is 
expressed at much higher levels in the developing hippocampus than the 
alternative APRIL receptor, TACI, the role of BCMA was examined in 
mediating the axon growth enhancing effects of APRIL. BCMA 
overexpression mimicked the effect of adding recombinant APRIL to 
hippocampal cultures by increasing axon length, presumably by potentiating 
signalling by hippocampal neuron secreted APRIL. Adding recombinant 
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APRIL to neurons overexpressing BCMA did not further increase axonal 
length (Fig.35). 
Overexpression of signalling deficient BCMA significantly decreased 
axonal length in the absence of exogenous APRIL and totally prevented 
recombinant APRIL from promoting axonal elongation (Fig.35). The reduction 
in axonal length in the absence of exogenous APRIL, may mean that 
expression of signalling deficient BCMA interferes with endogenous 
APRIL/BCMA autocrine/paracrine signalling, either by being incorporated into 
functional BCMA signalling trimers, thereby rendering them non-functional, or 
acting as a decoy receptor. Alternatively, the possibility exists that autocrine 
BAFF/BAFFR signalling may act in hippocampal cultures to promote axon 
elongation and mutant BCMA may sequester autocrine/paracrine released 
BAFF and interfere with this putative signalling loop. Taken together, these 
data indicate that BCMA mediates APRIL induced axonal growth from 
hippocampal neurons and suggests that endogenous autocrine and/or 
paracrine signalling normally plays a role in regulating the growth of 
hippocampal axons. APRIL autocrine/paracrine signalling has previously been 
described in other cell types. For example, APRIL confers resistance to 
apoptosis in B-CLL cells via an autocrine signalling route378. APRIL, BCMA 
and TACI are expressed by B-CLL leukemic cells and the addition of APRIL to 
cultures protects these cells from spontaneous, and flavopiridol induced 
apoptosis. In contrast, neutralizing APRIL-BCMA signalling, using either a 
soluble BCMA-Fc fusion protein or a function blocking APRIL antibody 
increases B-CLL cell death378. Similarly, Hodgkin lymphoma is initiated by the 
clonal expansion of malignant Hodgkin and Reed-Sternberg cells (HRS cells). 
HRS cells express APRIL, BAFF, BCMA and TACI and exogenous BAFF or 
APRIL enhances their survival and proliferation. Conversely, siRNAs against 
APRIL, BAFF, BCMA or TACI reduce the survival and proliferation of HRS 
cells, suggesting HRS cell expansion is as a result of autocrine/paracrine 
signalling between these TNFSF members and their receptors398. APRIL can 
also act as an autocrine growth factor during megakaryocytopoiesis, a 
developmental hematopoietic process responsible for progenitor cell 
differentiation to megakaryoblasts and megakaryocytes, leading to platelet 
formation399.  APRIL, but not BCMA or TACI, is expressed in differentiating 
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megakaryocytes and cDNA driven overexpression of APRIL promotes 
increased proliferation of immature megakaryocytes in culture. In accordance 
with this, sequestering megakaryocyte produced APRIL with a TACI-Fc fusion 
protein reduces megakaryocyte expansion and reduces platelet formation in 
culture399. A similar approach of using soluble receptor-Fc fusion proteins or 
APRIL blocking antibodies would be useful in future experiments designed to 
further investigate APRIL-BCMA signalling in cultures of hippocampal 
neurons.  
 
To assess the role of HSPGs in APRIL signalling, hippocampal 
neurons were cultured in medium containing a recombinant mutant APRIL 
(APRIL H89) that lacks 10 basic amino acids preceding the TNF homology 
domain and cannot bind HSPGs341. Surprisingly, mutant APRIL promoted 
robust axonal growth demonstrating that this cytokine does not require 
HSPGs for functional signalling in hippocampal neurons. However, unlike WT 
APRIL, APRIL H89 was not able to promote axon elongation at a 
concentration of 10ng/ml, suggesting that, although not necessary for APRIL 
signalling in hippocampal neurons, HSPGs may act to potentiate APRIL 
signalling (Fig.36). HSPGs play important roles in several biological 
processes in several tissue types, such as proliferation, cell adhesion, 
differentiation and cell migration. HSPGs can either be extracellular (example: 
perlecan or agrin) or plasma membrane bound (example: syndecans or 
glypicans) and can bind to growth factors, cytokines, proteases and proteases 
inhibitors400,401. Rat primary hippocampal neuron cultures have been shown to 
express agrin, glypican, syndican-3 and perlecan402 and HSPGs have 
previously been shown to play a role in regulating the extent of process 
outgrowth from cultured hippocampal neurons402,403. For example, heparin 
promotes the polarization of cultured E18 rat hippocampal neurons and 
enhances the elongation of their axons. The Wnt signalling antagonist, Sfrp1 
prevents heparin promoted axon elongation, suggesting that heparin 
stimulates axon growth by potentiating endogenous Wnt signalling402. Whilst 
soluble GDNF does not enhance neurite outgrowth from cultured E17 rat 
hippocampal neurons, immobilised GDNF dramatically increases the 
percentage of hippocampal neurons bearing processes in these cultures 
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through a signalling mechanism that does not require an interaction with 
cognate GDNF receptors, Ret and GFRα1403. The neurite growth promoting 
effects of immobilised GDNF are significantly reduced in the presence of 
heparinase III, suggesting that immobilised GDNF promotes neurite outgrowth 
by interacting with neuron expressed HSPGs. The HSPG that mediates 
immobilised GDNF signalling appears to be syndecan-3, since immobilised 
GDNF promotes neurite outgrowth from hippocampal cultures established 
from wild type E16 mouse embryos but not syndecan-3 null mutant embryos. 
The data presented in this chapter suggest that, whilst HSPGs are not 
required for APRIL mediated promotion of axon elongation, they may enhance 
APRIL-BCMA signalling at low concentrations of APRIL. This is in line with 
previous data demonstrating that APRIL does not require HSPG binding to 
promote B-cell proliferation, but that binding to HSPGs enhances the 
multimerisation of APRIL and thereby potentiates its ability to signal through 
BCMA and TACI404. To further investigate the potential roles that HSPGs play 
in APRIL mediated promotion of axon growth, further experiments need to be 
performed to examine APRIL promoted axon elongation in cultures of 
hippocampal neurons supplemented with different heparinases.  
 
 To determine the intracellular signalling pathways that induce axon 
elongation following APRIL mediated activation of BCMA, several intracellular 
signalling pathways that have previously been linked to the regulation of 
neuronal process growth were investigated. ERKs have being widely 
described as signalling mediators that are important for regulating axonal 
growth. For instance, neurotrophins, netrin-1, Sema7A and members of the 
TNFSF induce axonal growth that is mediated by the phosphorylation, and 
hence activation, of ERKs397,405-408. ERK activation has also been directly 
linked to the regulation of axon microtubule dynamics. For example, MAP-2 is 
a substrate of ERK409. ERK signalling also regulates actin filament dynamics 
in the growth cones of sympathetic SCG neurons and blocking this signalling 
causes actin depolymerization and growth cone collapse410. Exactly how 
these processes are regulated is not yet well understood, but it is thought that 
ERK regulates local protein production within growth cones, thereby 
maintaining a balance between protein synthesis and degradation. Campbell 
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and Holt have shown that inhibiting ERK1/2 signalling blocks the synthesis of 
proteins such as netrin-1 and Sema3A that are necessary for growth cone 
guidance411. The importance of ERK signalling in regulating axon growth is 
further exemplified by the observation that specific targeting of ERK1/2 to the 
proteasome following distal axotomy or neurotrophic factor deprivation 
appears to play a role in regulating Wallerian degeneration and local axon 
pruning, respectively412. APRIL has previously been shown to activate ERK 
signalling in myeloma cells, thereby protecting them from dexamethasone 
induced apoptosis360, and the ability of APRIL to increase the proliferation of 
cultured human adipose-derived stem cells is mediated by ERK activation413. 
The data in this chapter demonstrates that APRIL induces the 
phosphorylation and activation of ERK1/2, and suggests that ERK1/2 
activation is essential for APRIL promoted growth of hippocampal neuron 
axons (Fig.38 and 39). However, one caveat of the data is that ERK1/2 
activity was inhibited pharmacologically by the compound PD98059. Although 
PD98059 is claimed to be a specific inhibitor of MEK1/2, it is likely to have at 
least some off target affects. To confirm the essential role of ERK1/2 
activation in APRIL promoted axon growth, further experiments should be 
performed using transfection of expression vectors encoding signalling 
deficient, dominant-negative ERKs. It is unclear at present how APRIL binding 
to BCMA leads to the induction of ERK1/2 signalling in hippocampal neurons. 
In a human kidney cell line, BCMA associates with TRAF1, 2 and 3 and these 
adaptor proteins mediate the activation of the p38 and JNK, but not ERK1/2, 
MAPK pathways390. The association of BCMA with TRAFs has not been 
verified in the nervous system, but the possibility clearly exists that APRIL 
binding to hippocampal neuron BCMA induces the association of TRAFs with 
BCMA and, ERK1/2 is activated as a result of this association. Further 
investigation is required to determine which, if any, TRAFs can associate with 
ligand bound BCMA in hippocampal neurons and whether TRAFs are an 
essential mediator of APRIL induced ERK1/2 activation and axonal growth. 
One way this could be addressed would be by analysing axon length in 
cultures of hippocampal neurons transfected with cDNA expression constructs 
coding for either GFP together with WT BCMA or GFP together with mutated 
versions of BCMA that lack TRAF binding sites. Transfection of hippocampal 
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neurons with expression vectors encoding either WT or DN TRAFs would also 
be informative. In addition to characterising the upstream signalling pathways 
that lead to APRIL mediated ERK1/2 activation, it would also be interesting to 
identify the downstream targets of activated ERK1/2 and determine how they 
contribute to APRIL promoted axonal elongation.  
In addition to investigating whether ERK1/2 activation mediates APRIL 
promoted axonal growth in hippocampal cultures, the experiments in this 
chapter also aimed to determine whether PI3K/Akt signalling plays a role in 
transducing the growth enhancing properties of APRIL. APRIL has previously 
been reported to activate PI3K in myeloma cells360, B-cell lymphoma414 and 
human adipose-derived stem cells413. The PI3K signalling pathway is well 
established as being crucial for nervous system development, in particular 
with respect to axonal and dendritic morphogenesis415. Neurotrophins have 
been shown to activate the PI3K signalling pathway in a number of different 
neuron types. For example, NGF-induced PI3K activity at the growth cone 
promotes rapid axon growth through the inactivation of GSK-3β in cultured 
mouse DRG neurons416.  BDNF binding to exogenously expressed TrkB in 
sympathetic neurons promotes sympathetic neuron survival and axonal 
growth by stimulating PI3K activity405. The pharmacologic inhibition of PI3K 
activity using LY294002 was shown to prevent APRIL-mediated axon 
elongation, thereby identifying PI3K as an essential signalling molecule for 
APRIL promoted axon growth (Fig.40). However, once again the data comes 
with the limitation that PI3K activity was inhibited pharmacologically by the 
compound LY294002. Although LY294002 is claimed to be a specific inhibitor 
of PI3K, it is likely to exert at least some inhibitory activity on other closely 
related kinases. To confirm the essential role of PI3K activity in APRIL 
promoted axon growth, further experiments should be performed using 
transfection of expression vectors encoding signalling deficient, dominant-
negative PI3K. 
 
 Downstream of activated PI3K, several other kinases are 
phosphorylated to regulate different aspects of axonal growth. One of these 
kinases is the serine/threonine kinase, Akt. Overexpression of Akt is sufficient 
to induce the formation of multiple axons from cultured embryonic rat 
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hippocampal neurons417 and enhance the regeneration of axotomized adult 
rat hypoglossal motor neurons418. In agreement with these observations, 
pharmacological inhibition of Akt prevented APRIL from promoting axon 
growth in cultures of E18 mouse hippocampal neurons and the addition of 
APRIL to these cultures induced a rapid and sustained phosphorylation of Akt 
(Fig.41 and 42). Curiously, the use of pharmacological inhibitors for MEK 
(PD98059), PI3K (LY294002) or AKT (Akt inhibitor) did not affect axonal 
outgrowth in the absence of exogenous APRIL. Baseline axonal growth 
should be affected by these inhibitors, given the fact, that, axonal growth 
appears to be dependent on ERK and PI3K/Akt signalling pathways (395) and 
dense cultures of hippocampal neurons are likely to be secreting a number of 
axon growth promoting trophic factors. This anomaly can perhaps be 
explained by the use of sub-optimal concentration of signalling inhibitors. 
Dose response analysis of the ability of each inhibitor to inhibit axon growth 
should have been performed. 
 
GSK-3β is one of the downstream targets of activated Akt. GSK-3β, an 
isoform of GSK-3, is a serine/threonine kinase that regulates tubulin 
polymerization and microtubule stability by phosphorylating several 
microtubule associating proteins395,416,417. A second GSK-3 isoform, GSK-3α 
appears to have a similar function to GSK-3β, and both are localized in axon 
growth cones395. Curiously, despite the wealth of data implicating GSK-3β as 
an important regulator of axon growth, Gsk-3β null mice do not display 
obvious differences in neuronal development or axonal growth, presumably 
because of a functional redundancy with GSK-3α419. However, the use of 
GSK-3 inhibitors or shRNA directed against both GSK-3α and 3β isoforms 
blocks neurotrophin-induced axonal growth from both DRG and hippocampal 
neurons109,419,420. PI3K/Akt mediated phosphorylation of GSK-3β on serine 
residue 9 has been shown to result in the inactivation of GSK-3β activity, 
increased microtubule stability and enhanced axon growth109,416,417. LPA is a 
known activator of GSK-3β activity396. The addition of LPA to hippocampal 
cultures prevents APRIL from promoting axonal growth (Fig.43), suggesting 
that the activation of PI3K/Akt signalling by APRIL increases axon elongation 
by inhibiting GSK-3β activity. Further support for this hypothesis comes from 
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the observation that the addition of APRIL to hippocampal neuron cultures 
leads to the rapid and sustained phosphorylation of GSK-3β and, therefore, its 
inactivation (Fig.44).  
 
Whilst the data in this chapter suggest that APRIL promotes axonal 
elongation by a mechanism that involves the sequential activation of PI3K and 
Akt followed by Akt mediated phosphorylation and inactivation of GSK-3β, it is 
not clear how the binding of APRIL to BCMA results in the phosphorylation 
and activation of PI3K. There are some clear avenues to explore in future 
studies. For example, activated Trk receptors recruit growth factor receptor-
bound protein 2 (Grb2) that in turn recruits PI3K, leading to its 
phosphorylation421. In the case of TNFRSF members, an interaction between 
ligand bound TNFR1 and Grb2 has been shown to be essential for the 
activation of c-Raf-1 kinase and subsequently ERK1/2422. Therefore, Grb2 
may be a possible link between ligand bound BCMA and the activation of 
either ERK1/2 or PI3K pathways. Interestingly, ERK1/2 activation appears to 
mediate the phosphorylation of GSK-3β in PC12 cells and neonatal rat SCG 
neurons423. It would be interesting to analyse whether blocking ERK1/2 
activation and/or PI3K/Akt activity, prevents the phosphorylation of GSK-3β in 
hippocampal neurons following the addition of recombinant APRIL. Although 
activating GSK-3β by the addition of LPA to cultures prevents APRIL from 
increasing axonal growth and possible phosphorylation and inactivation of 
GSK-3β, an essential role for GSK-3β inactivation in APRIL promoted 
outgrowth needs to be confirmed. Further experiments need to be performed 
to determine whether transfection of a constitutively active GSK-3β, were 
serine 9 is replaced by alanine, can prevent APRIL from increasing the length 
of cultured hippocampal neuron axons424.  
Taken together, the results presented above define a novel 
neurotrophic role for APRIL in the developing nervous system. APRIL 
promotes the elongation of cultured embryonic mouse hippocampal neuronal 
axons by a signalling mechanism that involves the activation of ERK1/2 and 
PI3K/Akt signalling pathways and the subsequent phosphorylation and 
inhibition of GSK-3β.  
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5.1. Introduction 
The TGF-β superfamily member GDF-5 initially received particular 
interest because spontaneous frameshift mutations in the Gdf-5 gene result in 
brachypodism (bp) in mice425. These mice have a normal axial skeleton (skull 
and rib cage) but have numerous alterations in the appendicular skeleton 
(lower and upper limbs). Skeletal abnormalities include shortening of limbs 
and feet, reduction of the number of bones in digits, abnormal joint formation 
within the limbs and sternum. Moreover, chromosome mapping of GDF-5 
showed a physical proximity with a locus on mouse chromosome 2 that had 
previously been linked to brachypodism. In Gdf-5bp mice, spontaneous 
frameshift mutations in the Gdf-5 gene create a translational stop codon in the 
prodomain of the peptide that prevents the translation of the mature and 
bioactive form of GDF-5425. Mutations in the human homologue of GDF-5, 
cartilage-derived morphogenetic protein (CDMP1), leads to at least three 
different skeletal displasias. Brachydactyly type C is an autosomal dominant 
condition whereby heterozygous mutations in the Cdmp1 gene are sufficient 
to cause the shortening or absence of phalanges426. Homozygous mutations 
in the Cdmp1 gene result in more severe conditions, namely Hunter-
Thompson type (CHTT) and Grebe type I (CGT) chondrodysplasias. CHTT is 
similar in appearance to the phenotype of Gdf-5bp mice and is characterized 
by under developed bones in hands, feet, ankles and wrists and joints 
dislocations427. CGT is an autosomal recessive disorder that is characterised 
by severe limb shortening. In CGT, the bones of the hands and feet are 
particularly severely affected and fingers and toes lack articulation. Whilst 
CHTT is a consequence of mutations in the Cdmp1 gene that result in 
truncation of the CDMP1 protein, CGT is caused by missense mutations in 
the Cdmp1 gene that result in a single amino acid substitution in CDMP1 and 
impaired secretion of the protein from cells428. Mice that are deficient for the 
GDF-5 type I receptor, Bmpr-Ib (also known as Alk-6) show a similar 
phenotype to Gdf-5bp mice. In addition, Bmpr-Ib null mice, display reduced 
proliferation of prechondrogenic cells in the phalanges as well as impaired 
chondrocyte differentiation429.  
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The distinct phenotypes of Gdf-5bp and Bmpr-Ib null mice are 
consistent with a role for GDF-5 in the developing appendicular skeleton. In 
situ-hybridization on embryonic mouse tissues has shown that GDF-5 mRNA 
is expressed at its highest levels within developing limbs at the sites of 
developing elbow and shoulder joints and at the site of future joints between 
the metacarpals and the proximal phalanges430. GDF-5 is involved in 
regulating cartilage formation, normal joint development and in determining 
the correct positioning of joints431. GDF-5 does this, in part, by accelerating 
the initial steps of chondrogenesis by increasing cell adhesion. In addition, 
GDF-5 regulates chondrogenic and osteogenic differentiation during later 
stages of skeletal development432, thereby inducing the formation of cartilage, 
bone433, tendon, ligaments434 and teeth435. Similarly, the GDF-5 receptors, 
BMPR-Ia (also known as ALK-3) and BMPR-Ib are expressed during early 
chondrogenesis and play important roles in chondrocyte proliferation, survival, 
and differentiation in vivo429,436. Transgenic mice with a null mutation in both 
Bmpr-Ia and Bmpr-Ib have severe chondrodysplasia with flattened thoracic 
cavities and shortened limbs. These mice display impaired chondrocyte 
differentiation, reduced proliferation and increased apoptosis of chondrocytes 
and disorganization of cartilage elements due to a lack of cartilage-specific 
extracellular matrix429,436. GDF5-induced chondrogenesis is negatively 
regulated by the tyrosine kinase, Ror2. This kinase forms a heterodimeric 
complex with BMPR-Ib that results in the suppression of Smad signalling and 
the activation of non-Smad signalling pathways437. The GDF-5 type II 
receptor, BMPR-II is required for many different aspects of embryonic 
development and mice with a germ line-null mutation of the Bmpr-II gene die 
during gastrulation301. Mutant mice lacking part of the extracellular domain of 
Bmpr-II survive to mid-gestation and display delayed ossification of bones, rib 
loss and impairment of limb development438. However, the main defects 
observed in these mutants are cardiovascular in nature and include 
abnormalities of heart septation, interruption of the aortic arch and the 
absence of semilunar valves438. BMPR-II is expressed in pulmonary artery 
endothelial cells and mutations in the human gene, Bmpr-II are the basis of 
primary pulmonary hypertension (PPH), a vascular disease that is caused by 
increased proliferation of endothelial and smooth muscle cells in the 
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pulmonary arteries439. Furthermore, GDF-5 has angiogenic activity, inducing 
the formation of capillary-like structures in collagen gels in vitro and rabbit 
cornea in vivo440. 
 
GDF-5 and its receptors are also expressed in the nervous system. 
GDF-5 enhances the survival promoting effects of NGF and NT-3 in cultures 
of DRG neurons441. Moreover, in the presence of NGF and cell adhesion 
molecules, GDF-5 synergistically increases neurite outgrowth from cultured 
chick DRG neurons442. GDF-5 is widely expressed in the developing and adult 
brain in regions such as cortex, midbrain, striatum and cerebellum443. Most 
studies on the roles of GDF-5 in the CNS have been focused on the 
therapeutic potential of GDF-5 in the midbrain, particularly in Parkinson’s 
disease. The neurotrophic potential of GDF-5 has been demonstrated by its 
ability to enhance the survival and differentiation of embryonic midbrain 
dopaminergic neurons in vitro444. Intra-striatal or intra-nigral injection of GDF-5 
preserves nigral dopaminergic cell bodies, restores dopamine levels in the 
injured striatum and significantly reverses the behavioral consequences of 6-
hydroxydomamine (6-OHDA) treatment in rats that have been subjected to 
the 6-OHDA partial lesion model of Parkinson’s disease445. GDF-5 pre-
treatment enhances the survival of mesencephalic grafts and their ability to 
compensate for 6-OHDA lesions in the same rat Parkinson’s disease model to 
the same extent as GDNF pre-treatment of graft tissue446. Moreover, 
transplantation of CHO cells that overexpress GDF-5 has a neuroprotective 
and a neurorestorative effect in a rat 6-OHDA model of Parkinson’s 
disease447. BMPR-Ia, BMPR-Ib and BMPR-II have all been shown to be 
expressed in the developing rodent nervous system and the adult rat brain448-
450. Whilst BMPR-Ia, BMPR-Ib and BMPR-II proteins are detected in many 
kinds of axons in the adult rat brain, BMPR-Ib appears to be preferentially 
expressed in dendrites and BMPR-Ia is more highly expressed in neuronal 
cell bodies. All three BMP receptors are expressed in the adult hippocampus 
and also expressed by astrocytes449,450.  
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5.2. Aims 
The experimental aim of this chapter was to quantify the expression of 
GDF-5, BMPR-Ib and BMPR-II mRNAs and proteins in the developing 
hippocampus and to localise the expression of GDF-5 and its receptors, both 
within the hippocampus as a whole and within individual hippocampal 
neurons. 
 
5.3. Results 
5.3.1. The expression of GDF-5, BMPR-Ib and BMPR-II mRNAs in the 
developing mouse hippocampus and cultured E18 hippocampal 
neurons 
Reverse transcriptase real-time PCR was used to determine the 
relative levels of GDF-5, BMPR-Ib and BMPR-II mRNAs in total RNA 
extracted from hippocampi dissected at different developmental ages from 
E18 to P10 and from adult mice. GDF-5 mRNA levels increase 2.5-fold from 
E18 to reach a peak at P0. After this peak, the levels of GDF-5 mRNA fall by 
7.5-fold between P0 and P10 and a further 15-fold between P10 and adult 
(Fig.46.A). BMPR-Ib transcript levels in the developing hippocampus increase 
5-fold from E18 to reach a maximum at P10. The amount of BMPR-Ib mRNA 
expressed in the adult hippocampus is approximately 40% lower than that at 
P10 (Fig.46.B). There is little change in the amount of BMPR-II mRNA 
expressed in the developing hippocampus between E18 and P10; however, 
there is an approximately 40% increase in BMPR-II transcript levels in the 
hippocampus between P10 and adult (Fig.46.C).  
The levels of GDF-5, BMPR-Ib and BMPR-II mRNAs expressed in the 
adult mouse hippocampus were compared to those expressed in total RNA 
extracted from E18 mouse midbrain, thymus and aorta, as these tissues have 
previously been shown to express GDF-5 and its receptors426,440,451. As 
shown in Fig.46.D, the levels of GDF-5 mRNA expressed in adult mouse 
hippocampus are approximately the same as in E18 mouse midbrain, lower 
than in the E18 mouse thymus and much higher than in E18 mouse aorta. In 
contrast, BMPR-Ib transcripts are expressed at slightly higher levels in the 
adult mouse hippocampus compared to E18 mouse midbrain. E18 mouse 
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aorta and thymus express negligible levels of BMPR-Ib mRNA (Fig.46.E). The 
comparative levels BMPR-II mRNA expressed in the adult hippocampus and 
the other tissues analysed are almost identical to BMPR-Ib mRNA (Fig.46.F). 
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Figure 46: Relative expression of GDF-5, BMPR-Ib and BMPR-II mRNAs in the 
developing and adult mouse hippocampus. Total RNA was extracted from E18, P0, P5, 
P10 and adult mouse hippocampi, E18 mouse midbrain, thymus and aorta. Reverse 
transcriptase real-time PCR was used to quantify the levels of GDF-5, BMPR-Ib and BMPR-II 
transcripts and the levels of these mRNAs are expressed relative to the mRNAs encoding the 
reference genes GAPDH and SDHA. Graphs show (A) GDF-5, (B) BMPR-Ib and (C) BMPR-II 
mRNA expression at different developmental ages. (D) GDF-5, (E) BMPR-Ib and (F) BMPR-II 
mRNA expression levels in adult mouse hippocampus compared with E18 mouse midbrain, 
thymus and aorta. Data represent the mean and sem of four separate samples. 
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Reverse transcriptase real-time PCR was also used to examine the 
expression of GDF-5, BMPR-Ib and BMPR-II mRNAs in E18 hippocampal 
cultures after 2 hours (0DIVs), 2, 5 and 7 days in culture. GDF-5 mRNA 
expression levels initially fall by approximately 50% over the first two days in 
culture, but remain constant between 2 and 7DIVs (Fig.47.A). In contrast, 
whilst BMPR-Ib transcript levels also drop by approximately 50% over the first 
two days in culture, cultured hippocampal neurons increase their expression 
of this mRNA by almost 2-fold between 2DIVs and 7DIVs (Fig.47.B). The 
levels of BMPR-II mRNA expressed by cultured E18 hippocampal neurons 
remain fairly constant throughout the 7 days culture period (Fig.47.C). 
 
Figure 47: Relative levels of GDF-5, BMPR-Ib and BMPR-II mRNAs expressed by 
cultured hippocampal neurons. Total RNA was extracted from E18 hippocampal cultures 
after 2h (0DIV) and 2, 5 and 7DIVs. The levels of (A) GDF-5, (B) BMPR-Ib, and (C) BMPR-II 
mRNAs are expressed relative to the mRNAs encoding the reference genes GAPDH and 
SDHA. Data represent the mean and sem of four separate experiments. 
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5.3.2. The expression of GDF-5, BMPR-Ib and BMPR-II proteins in the 
developing mouse hippocampus 
 To assess the levels of GDF-5, BMPR-Ib and BMPR-II protein in the 
developing hippocampus Western blotting was performed on lysates of E18, 
P0, P5 and P10 hippocampi. Lysates of E18 midbrain were used as a positive 
control, since the embryonic rodent midbrain has previously been shown to 
express GDF-5 and its receptors and GDF-5 is a neurotrophic factor for 
embryonic midbrain neurons in vitro443,444,448,450. GDF-5 protein is expressed 
at a similar level to E18 midbrain in E18, P0, P5 and P10 hippocampus. Two 
immunoreactive bands, of approximately 27KDa and 58KDa, are present in 
midbrain and hippocampal lysates corresponding to mature and precursor 
forms of GDF-5, respectively (Fig.48.A). A 57KDa immunoreactive band 
corresponding to BMPR-Ib is present in the lysates from E18 midbrain and 
E18 to P10 hippocampus. Whilst BMPR-Ib expression in the hippocampus 
appears to be lower at E18 than in the E18 midbrain, hippocampal expression 
of BMPR-Ib increases with age, so that by P10 the hippocampus expresses 
comparable levels of BMPR-Ib to the E18 midbrain (Fig.48.B). In contrast, 
BMPR-II (115KDa) is expressed at higher levels in the E18 hippocampus than 
the E18 midbrain and BMPR-II expression in the developing hippocampus 
appears to decrease slightly with age (Fig.48.C).  
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Figure 48: GDF-5, BMPR-Ib and BMPR-II protein expression in the developing 
hippocampus. Western blots of E18, P0, P5 and P10 hippocampus and E18 midbrain 
lysates were probed with antibodies against GDF-5, BMPR-Ib and BMPR-II. Panels show (A) 
mature (27kDa) and pro- (58KDa) GDF-5, (B) 57KDa BMPR-Ib and (C) 115KDa BMPR-II. 
GAPDH (36KDa) was used as an endogenous loading control.  
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5.3.3. Cellular localisation of GDF-5, BMPR-Ib and BMPR-II proteins in 
cultured pyramidal neurons 
 To determine the cellular location of GDF-5 and its receptors, E18 
hippocampal neurons that had been cultured for 6DIVs were transfected with 
pCDH-CMV-MCS-EF1-copGFP, cultured for a further 24 hours and then fixed. 
Fixed neurons were labeled with antibodies that recognize either GDF-5, 
BMPR-Ib or BMPR-II. Neurons were also double-labelled with an antibody 
against MAP-2452 and nuclei were stained with DAPI. GDF-5 is mainly present 
in the cell soma of pyramidal neurons but weak staining is also observed the 
dendrites (Fig.49.A). Both GDF-5 receptors were distributed in the cell soma 
as well as in the dendrites (Fig.49.B and C). Negative controls are shown in 
Fig.49.D. 
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Figure 49: The cellular location of GDF-5, BMPR-Ib and BMPR-II proteins in 7DIVs 
hippocampal neurons. Hippocampal neurons were transfected with pCDH-CMV-MCS-EF1-
copGFP (green) at 6DIVs and fixed 24h later. Fixed neurons were stained with antibodies 
against (A) GDF-5, (B) BMPR-Ib, (C) BMPR-II (all red) or (D) no primary antibody, as well as 
antibodies for the dendritic marker MAP-2 (purple) and nuclear marker DAPI (blue). Scale 
bar: 20m. 
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5.3.4. Localisation of GDF-5, BMPR-Ib and BMPR-II proteins in the 
developing hippocampus 
 To study the distribution of GDF-5, BMPR-Ib and BMPR-II proteins in 
the developing hippocampus immunohistochemistry was performed on frozen 
sections cut from E18, P0, P5 and P10 mouse brains. Hippocampal sections 
were triple stained with the nuclear marker TOTO-3, the dendrite marker anti-
MAP-2 and either anti-GDF-5, anti-BMPR-Ib or anti-BMPR-II. 
 GDF-5 expression is distributed in the CA area of the hippocampus 
and in the granule cell layer of the DG. Immunoreactivity is weak at E18, but 
increases as the hippocampus matures between P0 and P10. GDF-5 protein 
is detected in both CA1 and CA3 areas and localises mainly within cell soma 
in the stratum pyramidale (Fig.50). Like GDF-5, BMPR-Ib and BMPR-II are 
both expressed at all ages in the developing hippocampus and expression 
increases with age (Fig.51 and 52). However, compared to GDF-5, BMPR-Ib 
and BMPR-II are only expressed at low levels in the granule cell layer of the 
DG and mostly in the suprapyramidal blade.  Both receptors are expressed in 
the cell soma within the stratum pyramidale but, unlike GDF-5, they also 
colocalise with MAP-2 staining, and hence the dendrites of pyramidal 
neurons.  
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Figure 50: GDF-5 distribution in the developing hippocampus.  
E18, P0, P5 and P10 hippocampal sections were stained for GDF-5 (green), MAP-2 (red) and 
TOTO-3 Iodide (blue). (DG: dentate gyrus; CA1 and CA3 layer). Last panel shows staining in 
the absence of primary antibodies. Scale bar: low magnification 200µm and high 
magnification 50µm.  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Figure 51: BMPR-Ib distribution in the developing hippocampus.  
E18, P0, P5 and P10 hippocampal sections were stained for BMPR-Ib (green), MAP-2 (red) 
and TOTO-3 Iodide (blue). (DG: dentate gyrus; CA1 and CA3 layer). Last panel shows 
staining in the absence of primary antibodies. Scale bar: low magnification 200µm and high 
magnification 50µm.  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Figure 52: BMPR-II distribution in the developing hippocampus.  
E18, P0, P5 and P10 hippocampal sections were stained for BMPR-II (green), MAP-2 (red) 
and TOTO-3 Iodide (blue). (DG: dentate gyrus; CA1 and CA3 layer). Last panel shows 
staining in the absence of primary antibodies. Scale bar: low magnification 200µm and high 
magnification 50µm.  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5.4. Discussion 
In this chapter, the expression of GDF-5 and its receptors, BMPR-Ib and 
BMPR-II were analysed at the mRNA and protein level in the developing 
hippocampus. Although BMPR-Ib and BMPR-II proteins have previously been 
detected in the adult rat hippocampus449, it was important to verify that 
transcripts and protein for these two receptors are expressed in the 
developing mouse hippocampus. GDF-5 expression has previously not been 
reported in the developing or adult mouse hippocampus. Transcripts for GDF-
5 and its receptors are expressed throughout hippocampal development and 
each shows a distinct developmental expression pattern. GDF-5 mRNA levels 
peak in the developing hippocampus at P0 and thereafter fall to small levels in 
the adult hippocampus. In contrast, the levels of BMPR-Ib mRNA gradually 
rise between E18 and P10 and fall only marginally between P10 and the 
adult. BMPR-II transcripts are expressed at relatively constant levels between 
E18 and P10 as hippocampal development proceeds, but expression 
increases modestly between P10 and adult (Fig.46). Similarly to chapter 3, it 
would have been interesting to analyse the mRNA expression of ligand and 
receptors at several postnatal ages between P10 and adult. During this period 
the neurons mature, dendrites become more complex and synaptogenesis 
takes place. It would be interesting to determine whether these events are 
marked by significant changes in the levels of GDF5, BMPR-Ib and BMPR-II 
mRNAs. The developmental expression patterns of GDF-5 and its receptors 
suggest that GDF-5 may play a role in regulating some aspects of 
hippocampus development during the early postnatal period. Although GDF-5 
mRNA levels are very low in the adult hippocampus compared to the neonatal 
period, GDF-5 is expressed at similar levels in the adult hippocampus as the 
E18 mouse midbrain. Since GDF-5 is a trophic factor for embryonic rodent 
midbrain neurons444, the parity of expression levels between adult 
hippocampus and midbrain, does not rule out a functional role for GDF-5 in 
the adult hippocampus. However, the relatively high levels of BMPR-Ib and 
BMPR-II mRNAs expressed in the adult hippocampus suggests that another 
member of the BMP subfamily of the TGF-β superfamily may be the functional 
ligand for these receptors in the adult hippocampus. The analysis of GDF-5, 
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BMPR-Ib and BMPR-II mRNAs in hippocampal cultures reveals that putting 
hippocampal neurons in culture does not dramatically alter the expression 
levels of these transcripts. Importantly, transcript levels after 5-7DIVs, the time 
that functional experiments analysing the effect of GDF-5 on dendrite size 
were performed, are close to those at 0DIVs (Fig.47).  
Western blotting has revealed that mature and pro-GDF-5, BMPR-Ib 
and BMPR-II proteins are all expressed in the developing hippocampus 
(Fig.48). Whilst the changing levels of these proteins in the developing 
hippocampus do not closely follow the mRNA expression patterns, Western 
blotting is only a semi-quantitative measure of protein expression levels. 
However, the disparity between protein and transcript expression patterns 
observed may reflect a change in the efficiency of translation of GDF-5, 
BMPR-Ib and BMPR-II mRNAs as hippocampal development proceeds.  
 
Immunocytochemistry was subsequently used to localise the proteins 
detected by Western blotting in cultured embryonic hippocampal neurons. 
GDF-5 is predominantly localised in the soma of hippocampal neurons, 
including the nucleus, although some weak staining is evident in the initial 
segments of the dendrites. GDF-5, in common with other members of the 
BMP subfamily of TGF-β superfamily members, can exist as a non-cleaved 
protein, containing the proregion and a nuclear localization signal, which is 
translocated to the nucleus453. The antibody used to detect GDF-5 in this 
chapter recognises the proform of GDF-5 and, therefore, detects GDF-5 that 
has been translocated to the nucleus. In addition to being detectable in the 
neuron soma, BMPR-Ib and BMPR-II are also found in dendrites where they 
co-localise with the dendritic marker, MAP-2 (Fig.49). The dendritic 
localisation of these receptors suggests that they may play a role in 
transducing a signal that regulates the morphology and/or molecular 
phenotype of developing hippocampal neuron dendrites. The detection of 
GDF-5 and its receptors, BMPR-Ib and BMPR-II in the same neuron raises 
the possibility that GDF-5 may regulate some aspect of hippocampal neuron 
development by autocrine and/or paracrine signalling.  
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Immunohistochemistry has revealed that, in the accordance with the 
data from Western blotting, GDF-5 expression is low in the developing 
hippocampus at E18 and increases as development proceeds. At postnatal 
ages, GDF-5 is clearly expressed in the soma of pyramidal neurons in the CA 
fields of the hippocampus, as well as in the granule cell layer of the DG 
(Fig.50). These protein expression results are not in accordance with the 
GDF-5 mRNA expression data at postnatal ages. This difference might be 
due to an increase in the efficiency of GDF-5 mRNA translation as postnatal 
development proceeds and/or an increased half life of the GDF-5 protein over 
the same period. BMPR-Ib is expressed in the developing hippocampus at all 
the ages examined and, like GDF-5, its expression increases as development 
proceeds, thereby mirroring real-time PCR and Western blot data (Fig.51). 
BMPR-II expression increases significantly in the developing hippocampus 
from E18 to P10 (Fig.52). At P5 and P10, both GDF-5 receptors are clearly 
expressed in the soma of pyramidal neurons and also in the surrounding 
lamina containing MAP-2 positive apical and basal dendrites. In contrast to 
GDF-5, BMPR-Ib and BMPR-II are not highly expressed in the granule cell 
layer of the DG. Negative controls with no primary antibodies were included in 
immunocytochemistry and immunohistochemistry experiments, confirming the 
specificity of the secondary antibodies. Ideally, the staining should be 
repeated using blocking peptides and/or tissues from transgenic mice lacking 
the expression of either GDF-5, BMPR-Ib or BMPR-II to confirm primary 
antibody specificity.  
In conclusion, the data in this chapter demonstrates the expression of 
GDF-5 in the developing hippocampus for the first time. Developing 
hippocampal pyramidal neurons express GDF-5, BMPR-Ib and BMPR-II in 
vitro and in vivo. The expression of GDF-5 receptors in dendritic arbors raises 
the possibility that GDF-5 plays a role on regulating dendrite development. 
The co-expression of GDF-5 and its receptors in the same neurons may 
suggest that, if GDF-5 modulates dendrite development, it may do so by an 
autocrine and/or paracrine route. These results provide the rationale behind 
the functional studies described in Chapter 6. 
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Chapter 6 
 
 
 
 
 
 
GDF-5 promotes hippocampal dendritic 
growth by regulating Smad1/5/8 signalling 
and induction of hairy enhancer of split-1 
and -5 expression 
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6.1. Introduction 
The crystal structure of recombinant human GDF-5 has confirmed that 
functional GDF-5 is a dimer consisting of two banana-shaped monomers454. 
Like other members of the TGF- superfamily, GDF-5 is produced 
intracellularly as a large dimeric precursor that is subsequently cleaved at an 
RXXR (Arg, X, X, Arg) consensus sequence to release the biologically active 
molecule. The core of the mature dimer forms a ‘‘cysteine-knot’’ structure with 
seven disulfide bonds in total, comprising three intramolecular cysteine 
interactions per monomer and one disulfide bridge linking the GDF-5 
monomers454. 
GDF-5 preferentially binds to the BMPR-Ib type I receptor with a high 
affinity, although it has been reported that GDF-5 can bind with a 17-fold 
lower affinity to BMPR-Ia and interact very weakly with ActR-I. Regarding type 
II receptors, GDF-5 has been shown to bind efficiently to BMPR-II and ActR-II 
and less efficiently to ActR-IIB1455. GDF-5 preference for BMPR-Ib as a type I 
receptor is corroborated by the phenotypic similarities of Gdf-5bp and Bmpr-Ib 
deficient mice. However, a comprehensive analysis of the limbs of transgenic 
mice with a double inactivating mutation of Gdf-5bp and Bmpr-Ib, and a 
comparison to the limbs of mice containing a single mutation in either Gdf-5bp 
or Bmpr-Ib, has suggested that GDF-5 partially regulates limb morphogenesis 
through an alternative receptor to BMPR-Ib, and that, BMPR-Ib also binds 
other BMP ligands to modulate some aspects of limb development456. A single 
amino acid residue of GDF-5, Arg57 defines the binding specificity for BMPR-
Ib457. 
 
GDF-5 has been shown to induce the phosphorylation and nuclear 
translocation of Smad1 in cultures of smooth muscle cells derived from the 
human umbilical cord vein458. The nuclear translocation of Smad1 promotes 
the expression of the transcriptional regulator, ID1 in cultured smooth muscle 
cells and induces their migration.  Curiously, GDF-5 also activates ERK1/2 in 
cultured smooth muscle cells, although ERK1/2 activation is not required to 
promote the expression of ID1 and induce cell migration458. GDF-5 has also 
been shown to activate ERK1/2 signalling, together with p38 MAPK signalling, 
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in cultures of human ligamentum flavum (HLF) cells (a ligament that connects 
adjacent vertebrae in the spinal column). GDF-5 induced activation of these 
two MAPK pathways results in increased activity of alkaline phosphatase and 
increased expression of osteocalcin within HLF cells, suggesting that GDF-5 
is promoting their osteogenic differentiation459. 
 
6.2. Aims 
The data in Chapter 5 revealed that GDF-5, BMPR-Ib and BMPR-II are 
expressed in developing hippocampal neurons; thereby suggesting that GDF-
5 regulates some aspect of hippocampal neuron development. Since BMPR-
Ib and BMPR-II are expressed in the dendrites of developing hippocampal 
neurons, the initial aim of the experimental work presented in this chapter was 
to determine whether GDF-5 regulates the growth and complexity of 
developing hippocampal neuron dendrites in vitro. After establishing that 
GDF-5 promotes the growth of dendrites, further experiments aimed to 
identify the intracellular signalling pathways that GDF-5 uses to promote 
dendrite growth. The final aim of this chapter was to verify the physiological 
significance of in vitro data by examining hippocampal neuron dendrite 
development in Gdf-5bp mice. 
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6.3. Results 
6.3.1. GDF-5 increase dendritic but not axonal outgrowth from cultured 
hippocampal neurons 
Functional analyses were performed to evaluate whether GDF-5 could 
promote axonal and/or dendritic outgrowth from E18 mouse hippocampal 
neuron in vitro. For axonal analyses, 2DIVs hippocampal neurons were 
transfected with pCDH-CMV-MCS-EF1-copGFP and incubated for a further 
16 hours in media containing either no GDF-5 (control) or media containing 
different concentrations of recombinant GDF-5. Cultured neurons were fixed, 
stained with an antibody against GFP and analysed at 3DIVs, a time point that 
precedes the growth of dendrites22. GDF-5 did not alter the length of 
hippocampal neuron axons compared to control cultures (Fig.53 and Fig.54.A 
and B). Although 10ng/ml and 1000ng/ml GDF-5 does not alter the number of 
collaterals that hippocampal neuron axons have compared to control cultures, 
100ng/ml GDF-5 induces a small, but statistically significant, reduction in the 
mean number of axon collaterals (Fig.54.A and C).  
 
Figure 53: GDF-5 does not promote axonal outgrowth from cultured hippocampal 
neurons. Camera lucida drawings of representative control neurons and neurons treated with 
100ng/ml GDF-5. 
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Figure 54: GDF-5 does not promote axonal outgrowth from cultured E18 hippocampal 
neurons. E18 hippocampal neurons were cultured for 2DIVs before being transfected with 
pCDH-CMV-MCS-EF1-copGFP and cultured for a further 16h in medium containing no 
factors (control) or medium containing either 10ng/ml, 100ng/ml or 1000ng/ml recombinant 
GDF-5. Cultures were fixed at 3DIVs and stained with an anti-GFP antibody, before being 
imaged using a fluorescence microscope. Images were analysed using ImageJ software. (A) 
Representative photomicrographs of typical neurons cultured under the stated conditions. 
Scale bar: 100µm. Graphs correspond to (B) mean axonal length and the (C) mean number 
of axon collaterals. Data represent the mean and sem of 150 neurons for each condition from 
3 separate experiments. **indicates p<0.001, statistical comparison with control, (Mann–
Whitney U test).   
 
Chapter 6         GDF-5 promotes hippocampal dendritic growth by Smad/Hes signalling  
 
 178 
To determine whether GDF-5 regulates dendritic outgrowth from 
cultured embryonic hippocampal neurons, 6DIVs E18 hippocampal neuron 
cultures were transfected with pCDH-CMV-MCS-EF1-copGFP and cultured 
for a further 16 hours in medium containing either no factors (control) or 
10ng/ml, 100ng/ml or 1000ng/ml GDF-5. After fixation and staining for GFP, 
neurons were imaged using a fluorescence microscope and the images 
analysed with Photoshop. Fig.55 and Fig.56.A and B demonstrate that GDF-5 
increases the number of dendrites that are greater than 50µm in length in a 
dose dependent manner. The most effective concentration of GDF-5, 
100ng/ml, increases the number of dendrites that are over 50µm in length by 
almost 2-fold compared to control cultures. Representative camera lucida 
drawing of typical neurons cultured in the absence or presence of 100ng/ml 
GDF-5 are shown in Figure 55. Interestingly, in addition to promoting an 
increase in the number of dendrites greater than 50µm in length, 100ng/ml 
GDF-5 significantly decreases the mean number of primary dendrites (Fig.55, 
Fig.56.A and C).  
 
A 
 
 
 
Figure 55: GDF-5 promotes dendritic outgrowth from cultured E18 hippocampal 
neurons. Camera lucida drawings of representative control neurons and neurons treated with 
100ng/ml GDF-5. 
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Figure 56: GDF-5 promotes dendritic outgrowth from cultured E18 hippocampal 
neurons. 6DIVs E18 hippocampal neurons were transfected with pCDH-CMV-MCS-EF1-
copGFP and cultured for a further 16h in medium containing either no factors (control) or 
10ng/ml, 100ng/ml or 1000ng/ml recombinant GDF-5. Cultures were fixed at 7DIVs, stained 
with an anti-GFP antibody and imaged on a fluorescence microscope. Images were analysed 
using Photoshop. (A) Representative photomicrographs of typical neurons cultured under the 
stated conditions. Scale bar: 50µm. Graphs correspond to the (A) % of dendrites > 50µm and 
the (B) mean number of primary dendrites. Data represent the mean and sem of 150 neurons 
for each condition from 3 separate experiments. **indicates p<0.001, ***indicates p<0.0001, 
statistical comparison with control, (Mann–Whitney U test).  
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6.3.2. BMPR-Ib and BMPR-II receptors mediate GDF-5 promoted 
dendrite growth  
Next, the roles that BMPR-Ib and BMPR-II receptors play in GDF-5 
promoted dendritic growth were evaluated. E18 Hippocampal neurons that 
had been cultured for 6DIVs were transfected with either pCDH-CMV-MCS-
EF1-copGFP (control), or pCDH-CMV-MCS-EF1-copGFP containing an insert 
encoding either a constitutively active (CA) form of BMPR-Ib (pCDH-CMV-
mAlk6QD-EF1-copGFP) or a dominant-negative (DN) form of BMPR-Ib 
(pCDH-CMV-mAlk6QD-D265A-EF1-copGFP). Transfected neurons were 
cultured for a further 16 hours in the presence or absence of 100ng/ml 
recombinant GDF-5. After fixation at 7DIVs, neurons were stained with an 
antibody that recognises GFP and imaged under a fluorescence microscope. 
Images were analysed using Photoshop.  
 
In accordance with figure 56, 100ng/ml GDF-5 significantly increases 
the number of dendrites that are longer than 50µm and significantly 
decreases the number of primary dendrites compared to control cultures 
(Fig.57). Expression of constitutively active BMPR-Ib in hippocampal neurons 
increases the length of dendrites, compared to control cultures, in the 
absence of recombinant GDF-5, but does not alter the number of primary 
dendrites. The addition of 100ng/ml GDF-5 to cultures containing neurons that 
express constitutively active BMPR-Ib does not further increase the number of 
dendrites that are longer than 50µm, but it does significantly reduce the 
number of primary dendrites. Whilst the expression of the dominant-negative 
form of BMPR-Ib does not affect the length of dendrites in the absence of 
exogenous GDF-5, it totally prevents 100ng/ml GDF-5 from promoting the 
elongation of hippocampal neuron dendrites (Fig.57). 
 
To confirm that BMPR-Ib is required to mediate the dendrite growth 
promoting effects of GDF-5, E18 hippocampal cultures were established from 
Bmpr-Ib (Alk6-/-) deficient embryos, WT embryos (Alk6+/+) and embryos that 
were heterozygous for functional Alk-6 deletion (Alk6+/-). After 6DIVs, cultures 
were transfected with pCDH-CMV-MCS-EF1-copGFP and cultured for a 
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further 16 hours, either in the presence or absence of 100ng/ml GDF-5. As 
expected, GDF-5 increases the number of dendrites longer than 50µm and 
reduces the number of primary dendrites, compared to controls, in cultures 
established from Alk6+/+ embryos (Fig.58). Very similar data was obtained 
from cultures established from Alk6+/- embryos. In contrast, 100ng/ml GDF-5 
does not increase dendrite length compared to control cultures in cultures 
established from Alk6-/- embryos (Fig.58.A and B). Curiously, the complete 
loss of functional Alk-6 reduces the number of primary dendrites associated 
with cultured hippocampal neurons in the absence of exogenous GDF-5 and 
the addition of 100ng/ml recombinant GDF-5 to cultures of Alk6-/- hippocampal 
neurons does not further decrease the number of primary dendrites (Fig.58.A 
and C). 
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Figure 57: BMPR-Ib mediates GDF-5-promoted dendrite growth. E18 hippocampal 
neurons that had been cultured for 6DIVs were transfected with either pCDH-CMV-MCS-EF1-
copGFP (control), pCDH-CMV-mAlk6QD-EF1-copGFP (BMPR-Ib-CA) or pCDH-CMV-
mAlk6QD-D265A-EF1-copGFP (BMPR-Ib-DN). Transfected neurons were culture for a 
further 16h in medium containing either no factors or medium containing 100ng/ml GDF-5 
before being fixed, stained for GFP and imaged under a fluorescence microscope. Images 
were analysed using Photoshop. (A) Representative photomicrographs of typical neurons 
cultured under the stated conditions. Scale bar: 50µm. Graphs correspond to the (B) % of 
dendrites >50µm and the (C) mean number of primary dendrites. Data represent the mean 
and sem of 150 neurons for each condition from 3 separate experiments. ***indicates 
p<0.0001, statistical comparison with control, n.s. non-significant (Mann–Whitney U test). 
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Figure 58: BMPR-Ib is required for GDF-5-promoted dendrite growth. Cultures were 
established from Alk6
+/+
, Alk6
+/-
 and Alk6
-/-
 E18 mouse embryos. After 6DIVs, cultured were 
transfected with pCDH-CMV-MCS-EF1-copGFP, and cultured for a further 16h in medium 
containing either no factors (control) or 100ng/ml recombinant GDF-5. Neurons were fixed at 
7DIVs, stained with an anti-GFP antibody and imaged on a fluorescence microscope. Images 
were analysed using Photoshop. (A) Representative photomicrographs of typical cultured 
neurons established from Alk6
+/+
, Alk6
+/-
 and Alk6
-/-
 embryos and cultured with or without 
GDF-5. Scale bar: 50µm. Graphs correspond to the (B) % of dendrites > 50m and the (C) 
mean number of primary dendrites. Data represent the mean and sem of 150 neurons for 
each condition from 3 separate experiments. **indicates p<0.001, ***indicates p<0.0001, 
statistical comparison with control, n.s. non-significant (Mann–Whitney U test).  
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To assess the role of the BMPR-II receptor in GDF-5 promoted 
dendrite growth, hippocampal neurons that had been in culture for 6DIVs 
were transfected with either pCDH-CMV-MCS-EF1-copGFP (control), or 
pCDH-CMV-MCS-EF1-copGFP containing an insert encoding either a WT 
form of BMPR-II (pCDH-CMV-BMPR-II WT-EF1-copGFP) or a DN form of 
BMPR-II (pCDH-CMV-BMPR-II-D(485)G-EF1-copGFP). Transfected neurons 
were cultured for a further 16 hours, either in the presence or absence of 
100ng/ml GDF-5. After this period, neurons were fixed, stained with an 
antibody against GFP and imaged with a fluorescence microscope. Images 
were analysed with Photoshop.  
Overexpression of WT BMPR-II mimics the effect of adding 100ng/ml 
of recombinant GDF-5 by increasing the percentage of hippocampal neurons 
with dendrites greater than 50µm in length, compared to control cultures 
Adding GDF-5 to neurons overexpressing WT BMPR-II does not further 
increase the length of dendrites. Expression of DN BMPR-II does not reduce 
the percentage of hippocampal neurons with dendrites greater than 50µm in 
length, compared to control transfected neurons, but it totally prevents GDF-5 
promoted dendrite growth (Fig.59.A and B). The addition of exogenous GDF-5 
to cultures and transfection of WT or DN BMPR-II, either in the presence or 
absence of 100ng/ml GDF-5, significantly reduces the number of hippocampal 
neuron primary dendrites compared to control cultures (Fig.59.A and C). 
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Figure 59: BMPR-II mediates GDF-5-promoted dendrite growth.  
E18 hippocampal neurons that had been cultured for 6DIVs were transfected with either 
pCDH-CMV-MCS-EF1-copGFP (control), pCDH-CMV-BMPR-II-WT-EF1-copGFP (BMPR-II 
WT) or pCDH-CMV-BMPR-II-D(485)G-EF1-copGFP (BMPR-II-DN). Transfected neurons 
were culture for a further 16h in medium containing either no factors or medium containing 
100ng/ml GDF-5 before being fixed, stained for GFP and imaged under a fluorescence 
microscope. Images were analysed using Photoshop. (A) Representative photomicrographs 
of typical neurons cultured under the stated conditions. Scale bar: 50µm. Graphs correspond 
to the (B) % of dendrites >50µm and the (C) mean number of primary dendrites. Data 
represent the mean and sem of 150 neurons for each condition from 3 separate experiments. 
**indicates p<0.001, ***indicates p<0.0001, statistical comparison with control, n.s. non-
significant (Mann–Whitney U test). 
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6.3.3. Signalling pathways induced by GDF-5 in hippocampal neurons: 
activation of Smad1/5/8 transcription factors  
To begin to elucidate the molecular mechanisms underlying GDF-5 
promoted dendritic outgrowth, E18 hippocampal neurons that had been in 
culture for 6DIVs were treated with 100ng/ml of recombinant GDF-5 for 15, 30 
and 60 minutes and lysed. Control cultures did not have recombinant GDF-5 
added. Lysates were analysed by Western Blotting using antibodies against 
phospho-Smads 1/5/8 (that recognises the phosphorylation of ser463/465 of 
Smads1 and 5 and ser426/428 of Smad8), non-phosphorylated Smad1 and β-
III tubulin. The addition of GDF-5 to cultures results in an increase in the 
levels of phospho-Smad1/5/8 within 15 minutes that is maintained until 60 
minutes (Fig.60.A, B and C).  
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Figure 60: GDF-5 promotes the phosphorylation and activation of Smads1/5/8. 
E18 hippocampal neurons that had been cultured for 6 days were exposed to 100ng/ml of 
recombinant GDF-5 for 15, 30 and 60min before being lysed. Control cultures were lysed 
without the addition of GDF-5. Lysates were analysed by Western blotting using antibodies 
against phospho-Smads 1/5/8, non-phosphorylated Smad1 and β-III-tubulin. (A) 
Representative scan of a Western blot. Graphs correspond to densitometry measured ratios 
of (B) P-Smad1/5/8 /Smad1 and (C) P-Smad1/5/8 /β-III tubulin. Data represent the mean and 
sem of 3 separate experiments. *indicates p<0.01, **indicates p<0.001, ***indicates 
p<0.0001, statistical comparison with control (Mann–Whitney U test).  
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To determine the importance of Smad signalling in GDF-5-promoted 
dendrite growth, 6DIVs hippocampal neurons were co-transfected with pCDH-
CMV-MCS-EF1-copGFP together with either a plasmid that expresses an 
inhibitor of Smad signalling or an empty control plasmid that consisted of the 
expression vector that the Smad signalling inhibitors were cloned into. To 
inhibit Smad signalling, neurons were transfected with expression vectors 
encoding the inhibitory Smads, Smad6 (pCS2-Flag-Smad6) or Smad7 
(pCMV5-Smad7-HA) or with a DN version of Smad4 (pRK-DPC4-deltaC-
Flag). Transfected neurons were cultured for a further 16 hours, either in the 
presence or absence of 100ng/ml recombinant GDF-5, fixed, stained for GFP 
and imaged under a fluorescence microscope. Images were analysed using 
Photoshop.  
Dendrite growth from neurons transfected with a plasmid expressing 
DN Smad4 is significantly less than that from control-transfected neurons in 
the absence of GDF-5, and expression of DN Smad4 completely eliminates 
GDF-5-promoted dendrite growth (Fig.61.A and B). In accordance with 
previous experiments, the number of primary dendrites is significantly reduced 
in control transfected neurons cultured in the presence of 100ng/ml GDF-5 
compared to control transfected neurons cultured in the absence of GDF-5. 
The expression of DN Smad4 prevents GDF-5 from reducing the number of 
primary dendrites (Fig.61.A and C).  As expected, the expression of inhibitory 
Smads6 and 7 prevents GDF-5 from promoting dendrite growth and reducing 
the primary number of dendrites (Fig.62.A, B and C).  
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Figure 61: Dominant-negative Smad4 inhibits GDF-5 promoted dendritic growth.  
E18 hippocampal neurons that had been in culture for 6 days were co-transfected with pCDH-
CMV-MCS-EF1-copGFP together with either pRK-DPC4-deltaC-Flag (Smad4_DN) or pRK-
Flag (control). Transfected neurons were cultured for a further 16h, either in the presence or 
absence of 100ng/ml recombinant GDF-5, before being fixed, stained for GFP and imaged 
under a fluorescence microscope. Images were analysed using Photoshop. (A) 
Representative photomicrographs of typical cultured neurons under the stated conditions. 
Scale bar: 50µm. Graphs correspond to the (B) % of dendrites > 50m and the (C) number of 
primary dendrites. Data represent the mean and sem of 150 neurons for each condition from 
3 separate experiments. ***indicates p<0.0001, statistical comparison with control (Mann–
Whitney U test).  
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Figure 62: Smad6 and Smad7 inhibit GDF-5 promoted dendritic growth.  
E18 hippocampal neurons that had been in culture for 6 days were co-transfected with pCDH-
CMV-MCS-EF1-copGFP together with either pCS2-Flag-Smad6 (Smad_6), pCMV5-Smad7-
HA (Smad_7) or pCS2-Flag/pCMV5-HA (control). Transfected neurons were cultured for a 
further 16h, either in the presence or absence of 100ng/ml recombinant GDF-5, before being 
fixed, stained for GFP and imaged under a fluorescence microscope. Images were analysed 
using Photoshop. (A) Representative photomicrographs of typical cultured neurons under the 
stated conditions. Scale bar: 50µm. Graphs correspond to the (B) % of dendrites > 50m and 
the (C) mean number of primary dendrites. Data represent the mean and sem of 150 neurons 
for each condition from 3 separate experiments. *indicates p<0.01, **indicates p<0.001 and 
***indicates p<0.0001, statistical comparison with control (Mann–Whitney U test).  
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To determine the specificity of Smad signalling, neurons were 
transfected with a pGL3-BRE-Luc plasmid. This construct has a BMP 
responsive element sequence followed by a luciferase gene. If the BRE is 
activated by phospho-Smads the luciferase gene is transcribed. As shown in 
Fig.63.A, an increase in luciferase activity is observed when cells expressing 
BRE-Luc are treated with GDF-5. When Smad inhibitors, Smad_6 or Smad_7, 
were co-transfected in the presence of GDF-5, there was a decrease of 
luciferase activity compared to neurons co-transfected with a control plasmid 
and treated with GDF-5 (Fig.63.B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: GDF-5 enhances Smad transcriptional activation.  
(A) Hippocampal neurons that that had been in culture for 6 days were transfected with pGL3-
BRE-Luc and cultured for a further 16h either without GDF-5 (control) or with 100ng/ml GDF-
5. At 7DIVs neurons were lysed and processed for luciferase quantification. (B) Hippocampal 
neurons that that had been in culture for 6 days were co-transfected with pGL3-BRE-Luc and 
either pCDH-MCS-EF1-copGFP, pCS2-Flag-Smad6 (Smad_6) or pCMV5-Smad7-HA 
(Smad_7). Co-transfected neurons were cultured for a further 16h either without GDF-5 
(control) or with 100ng/ml GDF-5. At 7DIVs neurons were lysed and processed for luciferase 
quantification. Data represent the mean and sem of 3 separate experiments. ***indicates 
p<0.0001, statistical comparison with control ((A) t-test and (B) Mann–Whitney U test).  
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6.3.4. Signal transduction induced by GDF-5 in hippocampal neurons: 
induction of hairy and enhancer-of-split-1 (Hes1) and -5 (Hes5) 
expression 
NGF-enhanced dendrite elongation from cultured hippocampal neurons 
has previously been shown to be promoted by increasing the expression of 
Hes1 and Hes5 bHLH transcription factors that are nuclear targets of Notch 
signalling110. To investigate if GDF-5-promoted dendrite growth is mediated by 
an upregulation of Hes1 and Hes5 transcription factor expression, 7DIVs 
hippocampal neuron cultures were supplemented with 100ng/ml GDF-5 for 
either 4h or 18h. Control 7DIVs cultures were not treated with GDF-5. Rea-
time PCR analysis of total RNA extracted from hippocampal neuron cultures 
shows that 4h of GDF-5 treatment significantly increases the expression of 
Hes1 and Hes5 mRNAs (Fig.64.A and B). Although the GDF-5 induced 
increase in Hes1 transcript expression was not maintained with prolonged 
exposure to GDF-5, Hes5 mRNA levels are higher after 18h culture with GDF-
5 compared to after 4h (Fig.64.B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: GDF-5 increases the expression of Hes1 and Hes5 mRNAs. 
Total RNA was extracted from 7DIVs hippocampal cultures that had been exposed to 
100ng/ml GDF-5 for either 4h or 18h. Control cultures were not treated with GDF-5. Graphs 
show the levels of (A) Hes1 and (B) Hes5 mRNAs relative to the reference mRNA, 18s. Data 
represent the mean and sem of five separate experiments. ***indicates p<0.0001, statistical 
comparison with control (t test). 
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Having established that GDF-5 promotes the expression of Hes1 and 
Hes5 mRNAs, the next step was to try and establish a direct link between 
Smad activation and Hes5 expression (Hes5 expression was analysed 
because it is more robustly upregulated by GDF-5 than Hes1). To do this, 
6DIVs hippocampal neurons were transfected with the luciferase reporter 
constructs pHes5-pGL3-Luc or pHes5-SM-pGL3-Luc and cultured for a further 
16 hours either without GDF-5 or with 100ng/ml GDF-5. pHes5-pGL3-Luc 
contains a fragment of the Hes5 promoter containing a Smad binding site that 
can be used to drive luciferase expression, while pH5-SM-pGL3-Luc contains 
mutations in the Smad-binding site of the Hes-5 promoter. The addition of 
GDF-5 to cultures transfected with pHes5-pGL3-Luc induces a robust 
increase in luciferase reporter signal in comparison to neurons transfected 
with pHes5-pGL3-Luc and cultured without GDF-5. The GDF-5 promoted 
increase in luciferase reporter signal does not occur in neurons transfected 
with pH5-SM-pGL3-Luc (Fig.65). This data suggested that GDF-5 increases 
the expression of Hes5 mRNA by a Smad-dependent mechanism. 
 
 
 
 
 
 
 
 
 
 
 
Figure 65: Activation of Hes5 promoter activity by Smads.  
Hippocampal neurons that had been cultured for 6 days were transfected with pH5-pGL3-Luc 
or pH5-SM-pGL3-Luc. Transfected neurons were incubated for a further 16h, either in the 
presence or absence of 100ng/ml GDF-5, and lysed after 7DIVs and processed for luciferase 
activity quantification. Data represent the mean and sem of 3 separate experiments. 
***indicates p<0.0001, n.s. non-significant, statistical comparison with control (t test).  
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 To further investigate the role that Hes1 and Hes5 transcription factors 
play in mediating the dendrite growth promoting effects of GDF-5, 6DIVs 
hippocampal neurons were transfected with pCDH-CMV-MCS-EF1-copGFP 
alone (control) or pCDH-CMV-MCS-EF1-copGFP together with an expression 
plasmid encoding Hes6 (pIRES-Hes6), a transcription factor that antagonizes 
the functions of Hes1 and Hes5460,461. The overexpression of Hes6 prevents 
100ng/ml GDF-5 from both promoting dendrite growth and reducing the 
number of primary dendrites (Fig.66). Interestingly, the overexpression of 
Hes6 increases the number of primary dendrites in the absence of 
recombinant GDF-5 and the addition of GDF-5 to cultures reverses this effect 
(Fig.66.A and C). 
 
 To determine whether Hes-5 upregulation is required for GDF-5 
promoted dendrite growth, hippocampal neurons were transfected with a 
plasmid that expresses Hes5 shRNA to interfere with Hes-5 expression. The 
efficiency of Hes-5 knockdown by Hes5 shRNA was first confirmed in HEK 
293T cells. Western blot analysis of HEK 293T cell lysates 24 hours after 
transfection with either Hes5 shRNA, or a plasmid containing a scrambled 
control RNA, reveals that cells transfected with Hes5 shRNA express 
significantly lower levels of Hes5 protein compared to cells transfected with 
scrambled RNA. (Fig.67.B). The expression of Hes5 shRNA, but not 
scrambled RNA, in cultured hippocampal neurons completely prevents GDF-5 
promoted dendrite growth and prevents GDF-5 from reducing the number of 
primary dendrites (Fig.67.A, C and D). 
 
 As a final step to confirm the role that Hes5 plays in mediating GDF-5 
promoted dendrite outgrowth, 6DIVs cultures of hippocampal neurons were 
transfected with either pCDH-CMV-MCS-EF1-copGFP (control), a plasmid 
that expresses WT Hes5 (pCDH-CMV-Hes5-EF1-copGFP) or a plasmid that 
expresses a truncated Hes5 protein that dimerises with endogenous Hes5 
normally but lacks the DNA binding domain, thereby interfering with the 
transcriptional activity of endogenous Hes5 (pCDH-CMV-t-Hes5-EF1-
copGFP). Transfected neurons were cultured for a further 16 hours, either in 
the absence or presence of 100ng/ml GDF-5, before being fixed, processed 
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and imaged. The extent of dendrite growth from neurons overexpressing 
Hes5 and cultured in the absence GDF-5 is comparable to that of control 
transfected neurons treated with GDF-5.  Furthermore, GDF-5 treatment does 
not further increase the growth of dendrites from neurons overexpressing WT 
Hes5 (Fig.68.A and B). The number of primary dendrites is significantly 
reduced in the presence of GDF-5 in control transfected neurons compared to 
control transfected neurons cultured without GDF-5. Whilst, the 
overexpression of WT Hes5 decreases the number of primary dendrites 
compared to control cultures, the addition of GDF-5 to cultures transfected 
with WT Hes5 does not further reduce the number of primary dendrites 
(Fig.68.A and C). The expression of truncated Hes5 does not reduce dendrite 
length or increase the number of primary dendrite compared to control 
cultures, but it does prevent GDF-5 from promoting the growth of dendrites 
and reducing the number of primary dendrites (Fig.68). 
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Figure 66: Hes6 overexpression prevents GDF-5 promoted dendritic growth. 
Hippocampal neurons that had been cultured for 6 days were transfected with pCDH-CMV-
MCS-EF1-copGFP alone or co-transfected with pCDH-CMV-MCS-EF1-copGFP plus pIRES-
Hes6. Transfected neurons were incubated for a further 16h, either in the presence or 
absence of 100ng/ml GDF-5, fixed at 7DIVs, stained with an antibody against GFP and 
imaged using a fluorescence microscope. Images were analysed using Photoshop. (A) 
Representative photomicrographs of typical neurons cultured under the stated conditions. 
Scale bar: 50µm.  Graphs correspond to the (B) % of dendrites > 50nm and the (C) mean 
number of primary dendrites. Data represent the mean and sem of 150 neurons for each 
condition from 3 separate experiments. *indicates p<0.01 and ***indicates p<0.0001, n.s. 
non-significant, statistical comparison with control (Mann–Whitney U test).  
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Figure 67: Hes5-shRNA prevents GDF-5 promoted dendrite growth.  
Hippocampal neurons that had been cultured for 6 days were co-transfected with pCDH-
CMV-MCS-EF1-copGFP containing either Hes5 shRNA (shRNA-Hes5) or a scrambled RNA. 
Transfected neurons were incubated for a further 16h, either in the presence or absence of 
100ng/ml GDF-5, fixed at 7DIVs, stained with an antibody against GFP and imaged using a 
fluorescence microscope. Images were analysed using Photoshop. (A) Representative 
photomicrographs of typical neurons cultured under the stated conditions. Scale bar: 50µm. 
(B) Representative Western blot of lysates of HEK 293T cells co-transfected with pCDH-
CMV-MCS-EF1-copGFP expressing Hes5 shRNA (shRNA-Hes5) or a scrambled RNA. HEK 
293T cells were lysed 24h after transfection. Western blots were probed with and antibody 
against Hes5 and GFP. Graphs correspond to the (C) % of dendrites > 50m and the (D) 
mean number of primary dendrites. Data represent the mean and sem of 150 neurons for 
each condition from 3 separate experiments. ***indicates p<0.0001, statistical comparison 
with control (Mann–Whitney U test). 
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Figure 68: Hes5 regulates the growth of hippocampal neuron dendrites. 
Hippocampal neurons that had been cultured for 6 days were transfected with either pCDH-
CMV-MCS-EF1-copGFP (control), pCDH-CMV-Hes5-EF1-copGFP (Hes5-WT) or pCDH-
CMV-t-Hes5-EF1-copGFP (t-Hes5). Transfected neurons were incubated for a further 16h, 
either in the presence or absence of 100ng/ml GDF-5, fixed at 7DIVs, stained with an 
antibody against GFP and imaged using a fluorescence microscope. Images were analysed 
using Photoshop. (A) Representative photomicrographs of typical neurons cultured under the 
stated conditions. Scale bar: 50µm. Graphs correspond to the (B) % of dendrites > 50m and 
the (C) mean number of primary dendrites. Data represent the mean and sem of 150 neurons 
for each condition from 3 separate experiments. ***indicates p<0.0001, n.s. non-significant, 
statistical comparison with control (Mann–Whitney U test).  
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6.3.5. Hippocampal pyramidal dendrites are greatly reduced in size in 
brachypod mice 
 To assess the physiological and developmental significance of the 
effects of GDF-5 on dendrite growth observed in vitro, Golgi staining was 
used to visualise the dendritic arbors of pyramidal neurons in the CA1 and 
CA3 fields of the P10 hippocampus of WT mice and mice that are either 
heterozygous (Het) or homozygous (Gdf-5bp) for the brachypod null mutation 
in the Gdf-5 gene. These preparations revealed that pyramidal dendrite arbors 
of Gdf-5bp mice are dramatically reduced compared with those of WT mice in 
both CA1 (Fig.69.A) and CA3 (Fig.69.B). Because the dendrite arbors of 
pyramidal neurons in CA1 are normally less exuberant than those of CA3, 
they were especially amenable to analysis by Sholl profiling and quantification 
of total dendrite length and branch point number. This analysis was carried 
out separately on the apical and basal parts of the dendritic arbors of large 
numbers of these neurons in all three genotypes. This analysis reveals highly 
significant reductions in total dendrite length and branch point number in both 
components of the dendrite arbors of both heterozygous and homozygous 
mice compared with WT mice (Fig.69.C and D). Accordingly, reductions in the 
sizes of both dendritic compartments are evident in Sholl plot, length and 
branching data and the Sholl profiles for heterozygous mice are intermediate 
between those of WT and homozygous mice.  
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Figure 69: Reduced size and complexity of pyramidal dendrites in Gdf-5
bp
 mice. 
Representative images of Golgi stained preparations of the hippocampi of P10 WT and Gdf-
5
bp
 mice illustrating the typical appearance of pyramidal neurons in (A) CA1 and (B) CA3. 
Scale bar: 50µm. Sholl plots, total length and number of branch points in the (C) apical and 
(D) basal dendrites of the CA1 field of P10 hippocampi of P10 WT, Gdf-5
bp
 and heterozygous 
mice. Data represent the mean and sem of 50 neurons from at least 6 separate mice of each 
of each genotype. **indicates P <0.001 and ***indicates P <0.0001, statistical comparison 
with WT, Mann-Whitney U test). 
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6.4. Discussion 
The data obtained in this chapter provide the first evidence that GDF-5 
is a key regulator of dendritic growth in the developing nervous system and 
suggest that it exerts this effect by a Smad/Notch-dependent signalling 
mechanism. 
 
The expression of both GDF-5 and BMP receptors in developing 
hippocampal pyramidal neurons raises the possibility that GDF-5 acts on 
these neurons by an autocrine and/or paracrine mode of action in vivo. 
Autocrine signalling is well documented in the TGF- superfamily, and has 
been demonstrated for several BMPs245,463,464.  In future work, it will be 
important to ascertain whether GDF-5 is constitutively synthesized and 
secreted by pyramidal neurons or whether its synthesis and/or release are 
regulated, as this has a bearing on understanding how GDF-5 participates in 
the regulation of dendrite growth and elaboration in the developing 
hippocampus.  
 
Hippocampal neurons that have been cultured for 3DIVs in the 
presence of recombinant GDF-5 are morphologically indistinguishable from 
neurons cultured in the absence of GDF-5, demonstrating that GDF-5 does 
not regulate axonal outgrowth from developing hippocampal neurons (Fig.53 
and 54). In contrast, 100ng/ml of recombinant GDF-5 induces significant 
dendrite elongation in 7DIVs cultures of hippocampal neurons, whilst 
simultaneously reducing the number of primary dendrites (Fig.53 and 54). 
Although GDF-5 does not induce changes in the length of hippocampal 
neuron axons, BMP family proteins have been shown to play a role in 
promoting axon elongation from other populations of CNS and PNS neurons. 
For example, BMP-7 can induce the differentiation of dorsal horn projection 
interneurons and initiate axonal growth from them465. BMP-7 can also 
orientate axon growth, directing growing axons away from the dorsal midline, 
and increase the extent of axon growth. High concentrations of BMP-7 are 
required to induce dorsal interneuron specification through Smad-dependent 
transcription. In contrast, lower concentrations of BMP-7 regulate the 
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orientation of growing axons via PI3K dependent signalling465. BMPs also 
promote axonal growth from cultured embryonic, but not adult, mouse DRG 
neurons via a Smad-dependent signalling pathway. Interestingly, reactivation 
of the Smad1 signalling pathway in adult mouse DRG neurons, by virally 
transduced overexpression of BMP-4, promotes the regeneration of 
ascending sensory axons in a mouse model of spinal cord injury466. Although 
recombinant GDF-5 does not promote axon elongation in cultures of 
embryonic mouse hippocampal neurons, it may modulate axonal growth at 
postnatal stages of hippocampal development or in the adult. Since it is very 
difficult to establish cultures from postnatal and adult hippocampus, this would 
need to be investigated by examining efferent and afferent hippocampal 
projections in transgenic mouse models, such as Gdf-5bp and Alk6-/- mice. In 
addition, it will be interesting to determine whether GDF-5 has neurotrophic 
effects on spinal cord interneurons and DRG sensory neurons.  
GDF-5 resembles NGF in its ability to promote dendrite growth and 
reduce the number of primary dendrites in cultures of embryonic hippocampal 
neurons110. BMP-7 has also been reported to enhance the growth of identified 
dendrites from cultured sympathetic330, cortical331 and hippocampal332 
neurons, although the physiological significance of these in vitro observations 
have not been addressed or confirmed in vivo. Like GDF-5, BMP-7 selectively 
promotes the growth of dendrites from cultured hippocampal pyramidal 
neurons without affecting axonal growth332. 
 
Having established that GDF-5 promotes the growth of hippocampal 
neuron dendrites, the project focused on identifying the BMP receptors that 
mediate this effect. In particular, the roles of the BMP receptors, BMPR-
Ib/Alk6 and BMPR-II were examined. As mentioned previously, GDF-5 binds 
preferentially to BMPR-Ib compared to other type I BMP receptors455,457. 
However, GDF-5 can also signal via a BMPR-II/BMPR-Ia receptor complex457 
and a receptor complex consisting of BMPR-Ib and Ror2458.  BMPR-Ib has 
previously been established as a regulator of nervous system development. 
For example, double-transgenic mice, that have a germ line null mutation in 
Bmpr-Ib together with a telencephalon specific conditional Bmpr-Ia null 
mutation, have shown that BMPR-Ib signalling is important for the generation 
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of the neuronal lineage within the telencephalon that gives rise to both DG 
granule neurons during development and stem cells that continue to generate 
neurons in the adult hippocampus467. Interestingly, adult double-transgenic 
mice are significantly less responsive to fear or anxiety-provoking stimuli than 
wild type mice467. Moreover, BMPR-Ib is expressed by postmitotic neurons in 
the E11.5 mouse dorsal spinal cord and, in-ovo electroporation of expression 
constructs encoding constitutively active forms of BMPR-Ia and BMPR-Ib has 
shown that BMPR-Ib mediates commissural axon outgrowth and guidance in 
the chicken embryo. In accordance with this, many commissural axons 
display an aberrant trajectory in Bmpr-Ib deficient mice468. In this chapter, 
transfection of cultured hippocampal neurons with expression constructs 
encoding either a CA or a DN forms of BMPR-Ib had identified BMPR-Ib as an 
essential mediator of GDF-5 promoted dendrite growth from hippocampal 
neurons. The expression of CA BMPR-Ib mimics the effects of adding 
recombinant GDF-5 to cultures by increasing the length of dendrites, whereas 
the expression of DN BMPR-Ib prevents GDF-5 from promoting dendrite 
growth and reducing the number of primary dendrites (Fig.57). The essential 
role of BMPR-Ib in mediating the effects of GDF-5 was confirmed by using 
hippocampal cultures established from Alk6+/+ and Alk6-/- mouse embryos. 
Whilst GDF-5 increases the length of dendrites in cultures of Alk6+/+ and 
Alk6+/- hippocampal neurons, it does not affect dendrite length in cultures of 
Alk6-/- hippocampal neurons. The number of primary dendrites is reduced by 
GDF-5 in cultures established from Alk6+/+ and Alk6+/- embryos. Curiously, the 
number of primary dendrites is reduced in the absence of GDF-5 in cultures of 
Alk6-/- hippocampal neurons and the addition of recombinant GDF-5 does not 
reduce the number of primary dendrites further (Fig.58). This may suggest 
that the loss of functional BMPR-Ib induces compensatory alterations in the 
expression levels of other type I BMP receptors that in turn alters the 
response of hippocampal neurons to autocrine/paracrine GDF-5 and/or other 
BMPs.  
 
Hippocampal neurons overexpressing the BMPR-II receptor display an 
increase in dendrite length in the absence of recombinant GDF-5, whereas 
neurons transfected with an expression construct encoding a DN form of 
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BMPR-II are unable respond to recombinant GDF-5 by increasing the length 
of their dendrites (Fig.59). These data clearly show that BMPR-II plays an 
important role in mediating GDF-5 promoted dendrite growth. The 
overexpression of BMPR-II or the expression of DN BMPR-II both reduce the 
number of primary dendrites compared to control neurons in the absence of 
recombinant GDF-5. This reduction in the number of primary dendrites is of a 
similar magnitude to that produced when control transfected neurons are 
cultured with 100ng/ml GDF-5. Whilst this data is counter intuitive, it may 
reflect that GDF-5 can signal through other type II BMP receptors, in a 
redundant manner, to regulate the number of primary dendrites. Although the 
primary role of type II BMP receptors is thought to be to phosphorylate and 
activate type I BMP receptors upon ligand binding, thereby initiating Smad-
dependent signalling273,274, some studies suggest that BMPR-II can signal 
autonomously. A link has previously been made between BMPR-II dependent 
signalling and the regulation of actin dynamics in non-neuronal cell lines469. In 
the absence of ligand binding, the cytoplasmic domain of BMPR-II associates 
with LIM Kinase 1 (LIMK1), thereby inactivating it. LIMK1 is a kinase that 
phosphorylates and inactivates cofilin, preventing cofilin from promoting actin 
depolymerisation. Upon BMP-4 stimulation, LIMK1 dissociates from the 
cytoplasmic tail of BMPR-II resulting in cofilin phosphorylation and an 
increase in actin stability469. Evidence from a motor neuron like cell line, NSC-
34, suggests that BMPR-II dependent signalling may also play a role in 
regulating motor neuron differentiation. BMPR-II is upregulated and 
accumulates in the soma and growth cones of NSC-34 cells when they are 
stimulated to differentiate into neuronal type cells by culture in minimal media 
without serum470. Interestingly, the addition of BMP-2 to differentiating 
cultures increases the expression of BMPR-II whilst concomitantly inhibiting 
NSC-34 cell differentiation.  
 
Having identified BMPR-Ib/BMPR-II as the receptor complex that can 
mediate GDF-5 promoted dendrite growth; the next step of the project was to 
determine the intracellular signalling pathways that are activated following the 
binding of GDF-5 to its receptors. It is well established that Smad transcription 
factors comprise an important signalling pathway downstream of activated 
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BMPR complexes274,293. Ligand/receptor binding induces serine 
phosphorylation of receptor-regulated Smads, allowing them to form 
complexes with Smad4 that translocate to the nucleus where they regulate 
the transcription of a wide variety of target genes by binding to the respective 
promoter elements of these genes471. The first indication that GDF-5 
promotes dendrite growth from hippocampal neurons by a Smad-dependent 
signalling cascade came from the observation that the addition of GDF-5 to 
hippocampal cultures induces a rapid and sustained phosphorylation of 
Smad1, Smad5 and Smad8 (Fig.60). Moreover, the expression of DN Smad4 
completely eliminates GDF-5-promoted dendrite growth and reduces the 
length of hippocampal neuron dendrites compared to control transfected 
neurons in the absence of GDF-5 (Fig.61). Since Smad4 is a common link in 
Smad-dependent signalling, this latter observation may indicate that Smad-
dependent signalling mediates dendrite elongation from hippocampal neurons 
by other endogenously synthesized and secreted trophic factors or that 
autocrine/paracrine GDF-5 signalling promotes dendrite growth in the 
absence of exogenous recombinant GDF-5. Additional evidence that Smads 
mediate GDF-5 promoted dendrite growth comes from the observation that 
overexpression of the inhibitory Smads, Smad6 and Smad7, in cultured 
hippocampal neurons abolishes GDF-5 promoted dendrite growth (Fig.62). 
Finally, the addition of GDF-5 to hippocampal neurons transfected with a 
luciferase reporter construct containing a BMP response element increases 
luciferase activity and this affect can be blocked by co-expression of either 
Smad6 or Smad7 (Fig.63). Taken together, these results strongly suggest that 
Smad signalling plays a crucial role in mediating the striking effects of GDF-5 
on pyramidal neuron dendrite growth in the developing hippocampus.  
 
Whilst the link between Smad signalling and the regulation of neurite 
growth is not well established in the literature, some examples have emerged. 
In cultured sympathetic neurons, BMP-7 treatment leads to phosphorylation 
and nuclear translocation of Smad1 and expression of DN Smad1 inhibits 
BMP-7 induced dendritic growth472. Conversely, BMP-2 activates Smads1, 5 
and 8 and inhibits neurite growth in cultured cerebellar neurons473. The role 
that Smad-independent signalling pathways play in mediating GDF-5 
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promoted dendrite growth from hippocampal neurons is certainly worth 
investigating in future studies. From previously published literature, one 
pathway that will be worth investigating is the activation of the JNKs; JNK1, 
JNK2, and JNK3. Following the addition of BMP-7 to cortical neuron cultures, 
JNKs have been shown to rapidly associate with the C-terminal of BMPR-II 
where they become activated and promote local microtubule stabilization and 
dendrite formation474.  
 
The Hes5 transcription factor gene is among the many genes that 
possess a Smad binding motif in its promoter346, and together with its 
homologue Hes1, Hes5 has been linked to the regulation of dendrite growth 
by both Notch-delta signalling and NGF induced, p75 mediated, NF-B 
signalling in cultured hippocampal neurons110.  All four neurotrophins NGF, 
BDNF, NT3 and NT4, increase the levels of Hes1 and Hes5 mRNAs when 
added to 7DIVs hippocampal cultures. High levels of these transcription 
factors decrease dendrite initiation, reducing the number of primary dendrites, 
and allow NGF to stimulate dendrite elongation110. Similar results are 
observed in hippocampal pyramidal neurons cultured in the presence of GDF-
5. GDF-5 enhances Hes1 and Hes5 mRNA expression in hippocampal 
neurons in a similar manner to neurotrophins (Fig.64). GDF-5 also enhances 
transcriptional activity from an intact Hes5 promoter, but not one that has a 
disrupted Smad binding motif, suggesting that Hes5 is a direct transcriptional 
target of GDF-5-activated Smad signalling in hippocampal neurons (Fig.65). 
The bHLH gene Hes6 is known to inhibit the ability of Hes1 to regulate 
transcription475 and, in the chicken embryo, overexpression of cHES6-2 can 
represses the expression of cHes5476. In accordance with this, overexpression 
of Hes6 prevents GDF-5 from promoting dendrite elongation from 
hippocampal neurons (Fig.66). A requirement for an increase in the 
expression of functional Hes5 for GDF-5 promoted dendrite growth was 
demonstrated by two separate approaches: shRNA knockdown of Hes5 and 
the expression of a truncated, non-functional Hes5 protein (Fig.67 and 
Fig.68). In both cases, compromising the function of Hes5 completely 
eliminates the ability of GDF-5 to enhance dendrite elongation from cultured 
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hippocampal neurons. Finally, Hes5 overexpression in cultured hippocampal 
neurons promotes dendritic growth in the absence of GDF-5 and the addition 
of recombinant GDF-5 does not further enhance dendrite length. Together, 
this data demonstrate that Smad-dependent upregulation of Hes5 is an 
essential part of the signalling mechanism that GDF-5 uses to increase 
dendrite length. 
 The bHLH proteins, Hes1 and Hes5 are essential effectors for Notch 
signalling and regulate the maintenance of undifferentiated cells, such as 
neuronal stem cells. Hes1 and Hes5 repress the expression of genes that 
promote neuronal differentiation and Hes1/5 deficient mice display premature 
neuronal differentiation477. However, the roles that these two transcription 
factors play in postmitotic neurons during development and in the adult are 
still largely unknown478. How Hes5 regulates the molecular machinery that 
modulates dendrite growth is not understood. In future work it will be 
important to determine the genes that are subject to Hes5-dependent 
transcriptional activation and repression and ascertain how they regulate the 
cytoskelatal changes that lead to dendrite elongation. 
   
To validate the physiological relevance of GDF-5 promoted dendrite 
growth in cultures of embryonic hippocampal neurons, dendrites from P10 
WT, Het and Gdf-5bp mice were subject to Sholl analysis in Golgi stained 
preparations. The dendrites of P10 hippocampal pyramidal neurons in mice 
lacking GDF-5 are markedly stunted compared with those of WT mice. The 
intermediate, though highly significant, reduction in the size and complexity of 
pyramidal neuron dendrites in mice that are heterozygous for the Gdf-5bp null 
mutation clearly demonstrates a gene dosage effect, implying that dendrite 
size and complexity are exquisitely sensitive to the levels of endogenous 
GDF-5 in the hippocampus. Quantitative analysis of the CA1 region from Gdf-
5bp mice indicates that both the apical and basal components of the dendritic 
arbors of pyramidal neurons are very significantly smaller and less branched 
than those of age-matched WT mice (Fig.69).  Although both components of 
the dendritic arbors of these neurons are very significantly stunted in Gdf-5bp, 
they are nonetheless morphologically discernible.  This suggests that the 
early differentiation of the dendritic arbors of pyramidal neurons into apical 
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and basal components is unaffected in Gdf-5bp mice, but that the subsequent 
growth and elaboration of both components is impaired. These analyses were 
carried out at P10, when the dendritic arbors of hippocampal pyramidal 
neurons are normally well developed in vivo, and are some 10 days after the 
peak of GDF-5 mRNA expression in the developing hippocampus.  In future 
work, it will be informative to determine exactly when in development the 
abnormal pyramidal neuron phenotype first becomes apparent in Gdf-5bp mice 
and whether further changes occur in these dendrites as the mice age, which 
might indicate an ongoing role for GDF-5 in dendrite maintenance and/or 
plasticity.   
 
Since the in vitro data clearly shows that GDF-5 promoted dendrite 
growth can be mediated by a BMPR-Ib/BMPR-II receptor complex, it will be 
valuable to analyse dendrite morphology in Bmpr-Ib429 and Bmpr-II301 null-
mutant mice in future work. Given that there is a degree of functional 
redundancy between type I and type II BMPR, and BMPR-Ib and BMPR-II are 
receptors for other members of the BMP family, it seems unlikely that the 
hippocampal phenotype of Bmpr-Ib and Bmpr-II deficient mice will be a copy 
of Gdf-5bp mice. For example, the phenotype may be less severe if there is a 
compensatory upregulation of other type I or type II BMPR. Alternatively, the 
phenotype may be more severe in Bmpr deficient mice compared to Gdf-5bp 
mice if the functions of other BMP family members that may regulate 
hippocampal neuron morphology are disrupted.  It would also be informative 
to quantify to the levels of Hes5 transcripts and protein in the hippocampi of 
Gdf-5bp, Bmpr-Ib and Bmpr-II mutant mice at different developmental time 
points and compare them to the levels in wild type mice. As a first step to 
gaining an insight into the functional consequences of shortened dendritic 
arbors in Gdf-5bp mice, hippocampal slices prepared from P10 WT, Het and 
Gdf-5bp mice should be subject to investigation by electrophysiological 
recording. If Bmpr-Ib and Bmpr-II deficient mice prove to have abnormal 
dendritic arbors, hippocampal slices should also be prepared from them and 
age matched WT mice for investigation by electrophysiology.  
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To better understand the functional consequences of the lack of GDF-
5/BMP receptor signalling in the developing hippocampus, adult Gdf-5bp mice 
need to be subjected to a battery of behavioral tests and their performance in 
these tests compared to adult wild type mice. Appropriate behavioural tests 
include T-maze continuous alternation task (T-CAT), context dependent fear 
conditioning (CDFC), and MWM479. Since homozygous Gdf-5bp mice have 
shortened limbs and impaired movement compared to WT mice, they cannot 
be used for behavioural testing. However, heterozygous Gdf-5bp mice are 
physically indistinguishable from WT mice and have significantly smaller 
dendrites than their WT counterparts at P10. Therefore, comparative 
behavioural testing between heterozygous Gdf-5bp and WT mice may yield 
valuable data on the functional consequences of shortened hippocampal 
neuron dendrites. A more satisfactory approach to determining the functional 
consequences of a lack of functional GDF-5/BMP signalling during 
hippocampal development, would be to use a conditional loxP/Cre transgenic 
approach to ablate functional GDF-5/BMP receptor signalling specifically in 
the nervous system or, even better, specifically in the CA regions of the 
hippocampus. Such an approach would circumvent the problems with limb 
development and allow in depth behavioural testing of mice totally lacking 
GDF-5 expression in the developing hippocampus in comparison to WT mice. 
At present, mice containing floxed exons within either the Gdf-5 or Bmpr-Ib 
gene have not been generated. However, it may be worth the time and 
financial investment to generate these mice. Moreover, the use of transgenic 
mice carrying a neuron specific creERT2 transgene that allows temporally 
controlled, tamoxifen inducible deletion of floxed exons480 would allow an 
investigation of the roles of GDF-5/BMP receptor signalling specifically in the 
adult hippocampus, especially with regards to potential roles for GDF-5 in LTP 
in learning and memory. 
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Taken together, this work demonstrates a novel physiological role for 
GDF-5 in the developing mouse hippocampus. GDF-5 regulates the 
developmental elongation of hippocampal pyramidal neuronal dendrites. This 
finding needs to be further explored in subsequent studies, so that the 
functional consequences of a lack of GDF-5/BMP receptor signalling in the 
developing and adult hippocampus can be determined and other potential 
roles for GDF-5 in the developing and adult hippocampus can be identified. 
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7. General Discussion, Conclusions and Future Work 
 The overall aim of this study was to identify novel neurotrophic factors for 
developing mouse hippocampal neurons. In particular, to identify proteins that 
could promote the growth and elaboration of neuritic processes from 
hippocampal neurons and characterise the signalling pathways that these 
proteins use to promote growth. The two candidate proteins selected for 
investigation were the TNF superfamily member, APRIL and the TGF-β family 
member, GDF-5. To provide evidence that these proteins could potentially be 
neurotrophic factors for developing hippocampal neurons, first, the expression 
of APRIL, GDF-5 and their cognate receptors was analysed in dissociated 
hippocampal cultures established from E18 mouse embryos and sections of the 
hippocampus from embryonic and postnatal mice. Expression was analysed at 
both the mRNA and protein level using a wide range of techniques. Having 
established that both ligands and their receptors are expressed by developing 
hippocampal neurons, it was investigated whether APRIL and GDF-5 could 
modulate process outgrowth from cultured hippocampal neurons. Both proteins 
regulated the morphology of hippocampal neurons, with APRIL and GDF-5 
promoting the growth of axons and dendrites, respectively. Next, the receptors 
and intracellular signalling pathways that mediate enhanced process outgrowth 
by both factors were characterised. Finally, the physiological relevance of 
APRIL and GDF-5 promoted process outgrowth in hippocampal cultures, was 
assessed using transgenic mouse models.  
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Reverse transcriptase real-time PCR, Western blotting, 
immunocytochemistry and immunohistochemistry were used to demonstrate 
that APRIL and its receptor, BCMA are expressed by developing hippocampal 
neurons. In contrast, the alternative APRIL receptor, TACI was barely 
detectable by real-time PCR and Western Blotting and not detectable by 
immunocytochemistry or immunohistochemistry. APRIL and BCMA are both 
present in the soma and axons of cultured hippocampal neurons and expressed 
at increasingly high levels in the stratum pyramidale of the CA region of the 
hippocampus as development proceeds from E18 to P10. Moreover, APRIL is 
secreted from cultured hippocampal neurons into the culture medium. Together, 
the expression data suggested that APRIL-BCMA autocrine/paracrine signalling 
might regulate some aspect of hippocampus development (Chapter 3). 
 
 The addition of recombinant APRIL to cultures of E18 hippocampal 
neurons was shown to significantly increase axon length, but have no effect on 
dendrite morphology. A combination of cell culture, together with the 
transfection of expression vectors encoding full length and truncated BCMA, 
pharmacological inhibition of signalling molecules and Western blotting, was 
used to characterise the signalling pathways that APRIL uses to promote axon 
growth. BCMA mediates the axon growth enhancing effects of APRIL and 
HSPGs are not required for effective APRIL signalling. The binding of APRIL to 
BCMA leads to the activation of ERK1/2 and PI3K/Akt signalling pathways and 
inhibition of either pathway prevents axon growth promoted by APRIL. 
Activation of GSK-3β, by supplementation of cultures with LPA, also prevents 
APRIL promoted axon growth and APRIL induces the phosphorylation of GSK-
3β, and hence its inhibition (Chapter 4). The inhibition of GSK-3β activity has 
previously been shown to enhance axonal elongation416,417,482. It is currently not 
clear what the interaction between ERK1/2 and PI3K/Akt signalling is, nor is it 
clear whether activated Akt and/or ERK1/2 mediates the phosphorylation of 
GSK-3β. The signalling pathways that mediate APRIL promoted growth of 
hippocampal neuron axons are summarised in figure 74.  
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Figure 74: APRIL promotes hippocampal axonal growth by binding to BCMA and 
inducing the activation of ERK1/2 and PI3K/Akt signalling. The phosphorylation of GSK-3β 
is downstream of PI3K/Akt and/or ERK1/2 signalling. Question marks denote signalling steps 
that have yet to be characterised and/or validated. 
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  Although a role for APRIL in the nervous system is described for the first 
time in this thesis, other members of the TNFSF have previously been 
investigated as possible extracellular cues for the survival and morphogenesis 
of neurons. For example, TWEAK, which is located in the same chromosome as 
APRIL allowing the formation of a splicing-derived fusion ligand, TWE-PRIL, 
has been studied in the nervous system, particularly in a neuropathological 
context483-485. TWEAK and its receptor, Fn14 are upregulated in rodent models 
of stroke and contribute to ischemic cell death483,485. Interestingly, TWEAK-Fn14 
signalling appears to contribute to the protection from stroke damage that is 
afforded by a preconditioning injury484. Fn14 is induced in mouse DRG neurons 
following sciatic nerve damage238. Overexpression of Fn14 in PC12 cells 
promotes neurite outgrowth by a TWEAK independent mechanism that is 
dependent upon activation of the small GTPase, Rac1 suggesting that the 
upregulation of Fn14 by DRG neurons following sciatic nerve damage may 
contribute to nerve regeneration238. Preliminary experiments have shown that 
TWEAK and Fn14 mRNA are expressed in developing hippocampal neurons 
(data not shown). Recombinant TWEAK significantly increases the extent of 
axonal and dendritic outgrowth in E18 mouse hippocampal cultures (data not 
shown). Whilst these results need additional confirmation, they suggest a 
possible role for TWEAK-Fn14 signalling in modulating neurite development in 
the hippocampus. It will be interesting to further explore the role of TWEAK in 
the developing hippocampus and examine TWEAK-Fn14 mediated signal 
transduction.  
 
The extension of an axon is a highly regulated process that comprises 
extracellular signals, gene expression in the nucleus, anterograde transport of 
proteins and their incorporation into the cytoskeleton482. Intracellular processes 
can limit axon extension in the absence of stimulation by extracellular factors; 
therefore, signalling initiated by extracellular factors facilitates long distance 
axon extension. Neurotrophins are the most extensively characterized group of 
extracellular factors that induce axon growth by binding to and activating their 
corresponding receptors482. The identification of APRIL as an extracellular 
signal that regulates axon elongation raises several important questions. One of 
these questions concerns the identity of the intracellular signalling processes 
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that result in axon growth and their similarity to the signalling pathways used by 
neurotrophins to regulate process outgrowth. The data in Chapter 4 have 
revealed that APRIL-BCMA signalling promotes the activation of ERK1/2 and 
PI3K in cultured hippocampal neurons. PI3K has previously been shown to play 
an important role in controlling axonal elongation and specification. PI3K 
regulates localized axonal growth at the growth cone by regulating GSK-3 
activity and consequently microtubule polymerization486. GSK-3β has multiple 
substrates including proteins that bind to the plus ends of the microtubules 
stabilizing their growing ends such as: adenomatous polyposis coli (APC)416, 
CLIP-associated proteins (CLASP)487 and CRMP-2417. Other GSK-3β 
substrates include the microtubule associated proteins, MAP1B and tau486,488. 
Inactivation of GSK-3β prevents the phosphorylation of APC, thereby allowing it 
to bind to the microtubule plus ends and promote microtubule assembly416. 
Likewise, non-phosphorylated, active CRMP-2 interacts with tubulin 
heterodimers and promotes microtubule assembly417. Assessing the level of 
phosphorylation of GSK-3β substrates in hippocampal neurons that have been 
treated with APRIL, compared to non-treated neurons, would facilitate an 
understanding of the mechanisms by which APRIL regulates axon elongation. 
Furthermore, as mentioned previously, during neuronal morphogenesis 
axonal growth cone is modulated by molecular interactions between 
microtubules and actin filaments38. Local inactivation of GSK-3β at the growth 
cone has been shown to promote growth cone extension. This might occur 
through increasing microtubule stability with the consequent accumulation of 
material within the growth cone. Moreover, inactivation of GSK-3β also leads to 
a reduction of both extension and retraction of filopodia in the growth cone489. 
Others studies have demonstrated that inactive phosphorylated GSK-3β 
colocalises with F-actin in neuronal cells and Sema3 activates GSK-3β leading 
to growth cone collapse490. Additionally, GSK-3β can influence filopodial 
dynamics in growth cones through some of its substrates. For instance, CLASP 
has been shown to bind to actin filaments in the growth cones491 or to actin-
binding proteins492. Also, it has been suggested that MAP1b phosphorylation 
modules filopodia dynamics. In fact, DRG neurons from a Map1b deficient 
mutant mouse show a reduction in axon elongation and an increase in growth 
cone area493. 
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Although, cultures treated with APRIL at 7DIVs show no differences in 
the development and morphology of primary dendrites, it is still unclear whether 
APRIL could affect dendrite development at other developmental stages. The 
data have shown no immunostaining of APRIL or BCMA on hippocampal 
dendrites at 7DIVs. In fact, the staining profile of both proteins was localised in 
the soma and axons. Furthermore, early PI3K-Akt-GSK-3β signalling is often 
associated with early stages of axonal growth, which may partly explain the lack 
of effect of extracellular APRIL on early dendrite development.  
  
Axon specification and the acquisition of polarity are closely linked with 
axon elongation and share some of the same signalling molecules and 
pathways. PI3K-dependent activation of the Rho GTPase, Rac1, which is 
enriched in the axons of developing hippocampal neurons494, has been shown 
to inhibit the activity of RhoA, a negative regulator of actin polymerization, 
thereby inducing axon specification495. The mPar3-mPar6-aPKC complex also 
plays a role in regulating hippocampal neuron polarity. PI3K activity is 
necessary for the correct localisation and activation of the mPar3-mPar6-aPKC 
complex and the Rho GTPase, Cdc42 at the tip of future axons. Since Cdc42 
increases the activity of the mPar3-mPar6-aPKC complex and PI3K increases 
the activity of Cdc42, PI3K activity ensures a positive feedback loop that acts to 
reorganize the cytoskeleton and modulate intracellular trafficking to allow the 
rapid axon extension42,496. It will certainly be interesting to determine in the 
future whether the mPar3-mPar6-aPKC complex, Cdc42 and Rac1 are targets 
of activated PI3K following the addition of APRIL to cultured hippocampal 
neurons. 
 
In addition to further clarifying the signalling mechanisms that lead to 
APRIL promoted axon elongation in developing hippocampal neurons, it will be 
important to explore whether APRIL-BCMA signalling has a role in the adult 
hippocampus, either with regard to the aetiology of neuropathologies associated 
with the hippocampus, such as Alzheimer´s disease, or in modulating plasticity, 
learning and memory. There is a significant body of evidence suggesting that 
aberrant GSK-3β signalling may contribute to the development of Alzheimer´s 
disease. Tau is a neuronal microtubule-associated protein that is important for 
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establishing neuronal polarity and plays a role in regulating axonal transport497. 
Whilst Tau can be phosphorylated by a number of different kinases, it is a major 
target of GSK-3β. GSK-3β phosphorylates sites in Tau that are important for 
microtubule binding, thereby preventing Tau from interacting with microtubules 
with the result that microtubule stability and dynamics are altered. In the brain of 
patients with Alzheimer´s disease, Tau protein becomes abnormally hyper-
phosphorylated changing from 2-5 phosphate groups per molecule to up to 
10498. The resulting enhanced Tau detachment from microtubules is likely to 
favour Tau aggregation into paired helical filaments and neurofibrillary tangles 
and lead to microtubule disruption, pathological phenomena frequently 
observed in Alzheimer´s disease499.  Transgenic mice overexpressing Gsk-3β 
display Tau hyperphosphorylation, disrupted microtubules and increased cell 
death within their hippocampi500. Moreover, lithium chloride induced inhibition of 
GSK-3β in transgenic mice expressing a mutant form of Tau (that leads to the 
production of neurofibrillary tangles, axonal degeneration and behavioural 
deficits) significantly reduces the levels of Tau phosphorylation and reduces 
axonal degeneration501. One of the hallmarks of Alzheimer´s disease is the 
accumulation of Aβ peptides. Curiously, GSK-3α, but not GSK-3β, is required 
for processing the APP leading to an increased production of Aβ502. In 
hippocampal neuron cultures, Aβ peptides induce inactivation of PI3K. Reduced 
PI3K activity results in increased GSK-3β activity, enhanced Tau 
phosphorylation and neuronal death503. Although aberrant GSK-3β activity is 
unlikely to be the sole underlying cause of Alzheimer´s disease, it may 
potentiate the development of Alzheimer´s disease by augmenting Aβ 
production and Tau hyper-phosphorylation. Since APRIL-BCMA signalling 
appears to reduce GSK-3β activity within hippocampal neurons, it may have a 
neuroprotective effect on these neurons as they age and could delay the onset 
of Alzheimer´s disease pathology and symptoms. In accordance with this, April 
and/or Bcma null mutant mice may be more likely to display Aβ accumulation 
and Tau hyperphosphorylation as they age and this is something that should be 
investigated. In addition, it will be interesting to determine whether crossing 
April and/or Bcma null mice with some of the many Alzheimer´s disease mouse 
models that express mutant APP and tau isoforms504 accelerates the 
development of Alzheimer´s disease pathology and behavioural deficits. 
Chapter 7                                                General Discussion, Conclusions and Future Work  
 
 224 
In Chapter 5, the expression of GDF-5 and its receptors, BMPR-Ib and 
BMPR-II, were characterised in the developing hippocampus by reverse 
transcriptase real-time PCR, Western blotting, immunocytochemistry and 
immunohistochemistry. Whilst GDF-5 is mainly detected in the nucleus and 
cytoplasm of pyramidal neurons, its receptors are predominantly expressed in 
the cytoplasm and dendrites of these neurons. The expression pattern of both 
ligand and receptors suggested a possible role for GDF-5 in regulating some 
aspect of hippocampal neuron development. In addition, the expression of 
GDF-5, BMPR-Ib and BMPR-II within individual hippocampal neurons raised the 
possibility that GDF-5 may act in an autocrine and/or paracrine way to exert 
potential trophic effects. Further work will be needed to clarify whether GDF-5 is 
constitutively synthesised and secreted by pyramidal neurons or whether its 
synthesis and/or release are regulated. 
 
 In Chapter 6, potential roles for GDF-5 in the developing hippocampus 
were explored by culturing E18 hippocampal neurons in the presence or 
absence of GDF-5 and measuring axonal and dendritic lengths. This revealed 
that GDF-5 substantially increases dendrite, but not axon, elongation from 
cultured hippocampal neurons. Further investigation identified BMPR-Ib and 
BMPR-II as receptors that mediate the growth promoting effect of GDF-5 on 
dendrites and revealed that the signalling mechanism downstream of BMPR 
involves activation of Smads 1/5/8 and upregulation of the Hes5 transcription 
factor. In vivo, the apical and basal dendritic arbors of pyramidal neurons 
throughout the hippocampus are markedly stunted in homozygous and 
heterozygous Gdf-5bp mutants at P10, in comparison to WT mice, indicating that 
dendrite size and complexity are exquisitely sensitive to the level of GDF-5 in 
the developing hippocampus. The signalling pathway that mediates GDF-5 
promoted dendrite growth is summarised in figure 75. 
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Figure 75:  GDF-5 promotes hippocampal dendrite elongation by binding to a receptor 
complex consisting of BMPR-Ib and BMPR-II. Ligand binding leads to activation and nuclear 
translocation of Smads 1/5/8 and induction of Hes1/Hes5 transcription factors expression.  
  
 Although the results do not reveal any effect of GDF-5 on axonal growth at 
3DIVs, a possible role for GDF-5 in regulating axon growth could be further 
investigated. The expression of BMPR-Ib mRNA increases with development 
(Fig.46) and at 7DIVs it is possible to distinguish expression of both BMPR-Ib 
and BMPR-II proteins (Fig.47). Hence, although technically more challenging, 
axonal extension should be analysed at later stages. 
 Whilst the data in this thesis has identified that GDF-5 is a novel, key 
regulator of the growth and elaboration of pyramidal dendrites in the developing 
hippocampus, further investigation is needed to determine the functional 
consequences of reduced GDF-5/BMP receptor signalling for hippocampal 
function in adult mice (discussed in Chapter 6). Furthermore, the potential roles 
that compromised GDF-5/BMP receptor signalling may play in both age related 
cognitive decline and the aetiology of Alzheimer´s disease need to be explored. 
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Perturbed TGF-β/TGF-βR signalling has previously been implicated in the 
development of Alzheimer´s disease. For example, expression of the TGF-β 
receptor, TGF-β RII is reduced early in the course of Alzheimer´s disease in 
human patients and expression levels are inversely correlated with the number 
of amyloid plaques and neurofibrillary tangles in patients’ brains505. Moreover, 
transgenic mice expressing signalling deficient TGF-β RII show increased Aβ 
deposition and significant dendritic loss compared to their wild type 
counterparts505. In cultures of embryonic mouse hippocampal neurons, 
oligomeric Aβ decreases the length and increases the number of primary 
dendrites, reduces GABAergic connectivity and inhibits neuronal survival175. 
The addition of soluble TGF-β1 to cultures ameliorates the detrimental effects of 
Aβ by a signalling mechanism that involves activation of NF-B and the 
upregulation of Hes1 expression175. Since GDF-5 is a member of the TGF-β 
superfamily and, like TGF-β1, GDF-5 promotes dendrite elongation and reduces 
the number of primary dendrites in hippocampal cultures, GDF-5 may also 
promote neuronal survival in cultures of hippocampal neurons exposed to 
oligomeric Aβ.  
 
 Adult neurogenesis in the DG can be positively or negatively modulated by 
members of the TGF-β superfamily506,507. In Alzheimer´s disease brains, adult 
neurogenesis in the DG becomes deregulated. For example, BMP-6 mRNA and 
protein levels are increased compared with controls in the hippocampi of human 
patients with Alzheimer´s disease and in mouse models. Increased levels of 
BMP-6 result in compromised neurogenesis in both Alzheimer´s disease 
patients and transgenic mice506. In contrast, Noggin can block the action of 
endogenous BMP-4 leading to an increase of the number of proliferating cells in 
the DG in an Alzheimer´s disease mouse model507. In Chapter 5, GDF-5, 
BMPR-Ib and BMPR-II were detected by immunohistochemistry in the outer 
layer of the DG of P10 mice, suggesting a possible role for GDF-5/BMP 
receptor signalling in the modulation of adult neurogenesis in the hippocampus. 
Although there are no obvious differences in the DG area between Gdf-5bp and 
WT mice at P10, this does not rule out the possibility that some aspect of adult 
neurogenesis is regulated by GDF-5 and this should be explored in the future.  
 
Chapter 7                                                General Discussion, Conclusions and Future Work  
 
 227 
 Some members of the TGF-β superfamily have also been implicated in 
modulating synapse formation. For example, the homologue of the vertebrate 
BMP type II receptor, wishful thinking (Wit) is expressed in Drosophila motor 
neurons. Wit mutant larvae have small synapses, alterations in the structure of 
active synaptic zones and a lower frequency of spontaneous vesicle release at 
neuromuscular junctions, thereby demonstrating that Wit plays a role in synaptic 
growth and the assembly of the Drosophila neuromuscular junction508-510. 
Recently, BMP signalling has been implicated in specifying synapses in the 
auditory system of rodents. In particular, conditional deletion of Bmp receptors 
leads to aberrations of synapse morphology and function and, impairment of 
nerve terminal growth511. Interestingly, astrocyte-derived TGF-β induces the 
formation of functional synapses in the cerebral cortex of humans and mice512. 
In addition, BMP-4 has been shown to increase the expression of the pre-
synaptic membrane associated proteins, synaptotagmin I and neurexin I in 
sympathetic neurons513. Moreover, Tgf-β2 null-mutant mice display impaired 
GABAergic and glutamatergic synaptic transmission514, whilst soluble TGF-β2 
modulates synaptic plasticity in cultures of embryonic hippocampal neurons 
through phosphorylation of cAMP response element-binding protein (CREB)515. 
Finally, activin is upregulated during hippocampal LTP and increases the 
number of pre-synaptic contacts made on dendritic spines by modulating spinal 
F-actin morphology and increasing the length of spinal necks516,517. 
 
 With increasing evidence that TGF-β superfamily members play important 
roles in regulating synapse assembly and function, it will be informative to 
investigate whether GDF-5 regulates dendritic spine formation and/or changes 
in spine morphology or modulates any other aspects of functional synapse 
formation. A high magnification analyses of Golgi stained preparations from 
Gdf-5bp and WT adult mice will hopefully clarify how important this protein is for 
the modulation of spine formation and spine shape. Further 
immunohistochemical studies should also be performed to determine the 
expression of pre-synaptic and post-synaptic proteins in the hippocampi of Gdf-
5bp mice compared to wild type mice. Ideally, immunohistochemistry data will be 
complemented by electrophysiological recording from hippocampal slices to 
determine whether the lack of functional GDF-5 interferes with the induction of 
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LTP and/or LTD. 
 
In conclusion, the results described in this thesis contribute to the 
increasingly large body of knowledge on the mechanisms that modulate axonal 
and dendritic growth in the developing mouse hippocampus. Understanding the 
extracellular signals and intracellular signalling pathways that regulate the 
specification and length of hippocampal neuron axons and dendrites during 
development may provide clues about the mechanisms that lead to age related 
degeneration of hippocampal function and cognitive decline. Moreover, this 
knowledge may provide a potentially important insight into the aetiology of 
Alzheimer’s disease in which the pyramidal neurons of the hippocampus 
become damaged and hippocampal circuitry and function is compromised. 
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Appendix I 
Publications 
Osório C., Chacón PJ., White M., Kisiswa L, Wyatt S., Rodríguez-Tébar A. 
and Davies AM. Selective regulation of axonal growth from developing 
hippocampal neurons by tumour necrosis factor superfamily member APRIL. 
Molecular and Cellular Neuroscience (MCN-13-139 manuscript under review). 
 
Osório C., Chacón PJ., Kisiswa L, White M., Wyatt S., Rodríguez-Tébar A. 
and Davies AM. Growth differentiation factor-5 is a major regulator of dendrite 
growth during development. Development. 2013 Dec;140(23):4751-4762 
 
Kisiswa L, Osório C., Erice C, Vizard T, Wyatt S, Davies AM. TNF-α reverse 
signaling promotes sympathetic axon growth and target innervation.  
Nat Neurosci. 2013 Jul;16(7):865-73. 
 
Oral presentations 
“miRNAs in sympathetic neuron development”, MolPark – Santorini, Greece, 
November 1st, 2011 
 
Poster presentations 
Osório C., et al “Role of GDF-5 in regulating dendritic morphology in 
developing hippocampal neurons” Gordon Research conference: 
Neurotrophic Factors. Salve Regina University, June 1-7, 2013, Newport, RI, 
USA  
 
Osório C., et al “Role of APRIL in regulating axon growth from developing 
hippocampal neurons” Neuroscience 2012, Society for Neuroscience's 42nd 
annual meeting. New Orleans, October 13-17, 2012. New Orleans, LA, USA. 
 
Osório C., “Role of microRNAs in sympathetic axon growth”, September 8-9, 
2011. Munich, Germany. 
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Osório C. “Role of microRNAs in sympathetic axon growth” 2nd year Poster 
Session, School of Biosciences, Cardiff University, March, 2011. Cardiff, 
Wales, UK.  
 
Osório C., “Role of the tumour necrosis factor superfamily in regulating 
dendritic growth and morphology in the developing central nervous system” 
1st year Poster Session, School of Biosciences, Cardiff University, February 
10th, 2010. Cardiff, Wales, UK.  
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Appendix II 
Transgenic mice genotyping 
Alk-6 mice genotyping  
 
Primers: 
Alk6-I:  5’- TGG TGA GTG GTT ACA ACA AGA TCA GCA -3’ 
Alk6-E: 5’- CTC GGC CCA AGA TCC TAC GTT G -3’ 
Neo-Al2:  5’- GAA AGA ACC AGC TGG GGC TCG AG -3’ 
 
Estimated band size: WT=350bp 
               KO=300bp 
 
PCR reaction (Paq5000 Hotstart DNA Polymerase, Agilent Technologies): 
Buffer 10x                    2.5l 
dNTPs                         0.25l 
Alk6-I                           1l   
Alk6-E                          0.5l 
Neo-Al2                       0.5l  
Herculase                    0.25l 
Nuclease free water    18l 
 
Reaction mix: 2l of DNA + 23l of PCR mix 
 
PCR Program:  
 
Step 1: 95C 2min 
Step 2: 95C 30secs 
Step 3: 63C 30secs 
Step 4: 72C 50secs 
Step 5: 72C 3min 
Cycle 2 to 4: 40x 
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Solutions for cell culture 
Poly-L-lysine (0.5mg/ml)  
 50mg of poly-L-lysine was dissolved in 100ml of autoclaved milli-Q 
water, in a plastic beaker. The final solution was filtered using a 0.2m filter. 
The solution was then stored at -20C in 10ml aliquots.  
 
Trypsin (10mg/ml)  
10mg of trypsin was dissolved in 1ml of HBSS 1x without Ca2+ and 
Mg2+. The final solution was filtered using a 0.2m filter. This solution was 
freshly made on the dissection day. 
 
Trypsin inhibitor (10mg/ml)  
10mg of trypsin inhibitor was dissolved in 1ml of HBSS 1x without Ca2+ 
and Mg2+. The final solution was filtered using a 0.2m filter. This solution was 
freshly made on the dissection day. 
 
DNase I (1mg/ml)  
100mg of DNase I was dissolved in 100ml of autoclaved milli-Q water. 
The final solution was filtered using a 0.2m filter. The solution was then 
stored at -20C in 100l aliquots.  
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Transfection vectors 
pCDH-CMV-MCS-EF1-copGFP 
 
 
 
 
 
 
 
 
 
 
 
 
RSV:  Hybrid RSV promoter-R; required for viral packaging and transcription 
5’LTR: U5 long terminal repeat; required for viral packaging and transcription 
Gag: Packaging signal 
RRE: Rev response element binds gag and it is involved in packaging of viral 
transcripts 
Env: Packaging signal 
cPPT: Central polypurine tract (includes DNA Flap region) involved in nuclear 
translocation and integration of transduced viral genome  
CMV: Constitutive Human cytomegalovirus (CMV) promoter for transcription 
of cloned cDNA insert 
EF1: Constitutive Elongation factor 1α promoter for transcription of reporter  
copGFP: Copepod green fluorescent protein (similar to regular EGFP, but 
with brighter color) as a reporter for the transfected/transduced cells 
WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element—
enhances the stability of the viral transcripts 
3’LTR: Required for viral reverse transcription; self-inactivating 3' LTR with 
deletion in U3 region prevents formation of replication-competent viral 
particles after integration into genomic DNA 
SV40polyA: Transcription termination and polyadenylation 
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SV40 ORI: Allows for episomal replication of plasmid in eukaryotic cells 
pUC ORI: Allows for high-copy replication in E. coli 
AmpR: Ampicillin resistant gene for selection of the plasmid in E. coli  
 
Solutions for Immunohistochemistry 
4% PFA (paraformaldehyde) (100ml) 
 80ml of PBS was heated up to 60C in a ventilated hood. Then 4mg of 
PFA powder were added to the heated PBS solution. The pH was raised by 
adding 1N NaOH dropwise until the solution was clear. Once the PFA was 
dissolved, the solution was cooled, aliquoted and frozen at -20°C. 
  
Solutions for western blot  
RIPA lysis buffer (Radio Immuno Precipitation Assay buffer) 
150 mM sodium chloride 
1.0% Triton X-100 
0.5% sodium deoxycholate 
0.1% SDS (sodium dodecyl sulphate) 
50 mM Tris, pH 8.0 
 Store at -20C in 1ml aliquots. 
 
5x Laemmli sample buffer 
 0.05% bromophenol blue 
300 mM Tris–HCl 2M pH 6.8  
50% glycerol 
 10% SDS 
25% β-mercaptoethanol 
Store at -20C in 1ml aliquots. 
 
10% running gel (5 ml) 
 2.01 ml distilled water 
 1.25 ml Tris–HCl 1.5M pH 8.8  
50 l SDS 10% 
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 1.67 ml 30% acrylamide/bis solution 29:1 
 25 l ammonium persulfate 10% 
 5 l TEMED 
 
5% stacking gel (3 ml) 
 1.7 ml distilled water 
 750 l Tris–HCl 0.5M pH 6.8  
30 l SDS 10% 
 500 l acrylamide/bis solution 29:1  
15 l ammonium persulfate 10% 
 5 l TEMED 
 
1x Running buffer  
 25 mM Tris  
192 mM Glycine 
0.1% SDS 
Dissolve in water. 
 
1x Transfer buffer  
 48 mM Tris  
39 mM Glycine 
5% methanol 
Dissolve in water. 
 
Ponceau S staining solution 
0.1% (w/v) Ponceau S  
5% (v/v) acetic acid 
Dissolve in water. 
